Page last updated: 2024-10-20

pyrazinamide and Pulmonary Consumption

pyrazinamide has been researched along with Pulmonary Consumption in 1055 studies

pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.

Research Excerpts

ExcerptRelevanceReference
" The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status."9.15Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011)
"To study intralesional concentrations of isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA) in tuberculous pleural effusions and psoas abscesses, and to compare these to reference serum values and minimal inhibitory concentration (MIC)."9.11Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess. ( Jutte, PC; Rutgers, SR; Uges, DR; Van Altena, R; Van Horn, JR, 2004)
"A case of isoniazid induced gynecomastia is being reported in an 18-year old male, who received a re-treatment regimen for the relapse of pulmonary tuberculosis (TB)."8.87Unilateral and painless development of isoniazid induced gynecomastia during re-treatment of pulmonary tuberculosis. ( Behera, D; Gupta, R; Jaiswal, A; Kumar, L; Murar, A; Puri, MM, 2011)
"Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children."7.88Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018)
"We report the case of a 35-year-old man treated by RHEZ for a first episode of a smear positive pulmonary tuberculosis and who developed a DRESS syndrome due to pyrazinamide after twenty days of treatment, associated with a viral reactivation to Human Herpes Virus 6 (HHV6)."7.88[DRESS syndrome secondary to pyrazinamide: An uncommon complication of tuberculosis treatment]. ( Dia Kane, Y; Diouf, NF; Fall, L; Ka, W; Kombila, UD; Koutonin, ANE; Mbaye, FBR; Ouedraogo, P; Oumar Toure Badiane, N, 2018)
"Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease."7.85Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017)
"Pyrazinamide (PZA) has been in use for almost 50 years as a first-line drug for short-course chemotherapy against Mycobacterium tuberculosis."7.76Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India. ( Ayalusamy, N; Jagadeesan, S; Muthaiah, M; Muthuraj, U; Prabhu, SS; Senthilkumar, K; Sreenivasan, M; Veerappan, S, 2010)
"In this study we investigated whether leptin and TNFalpha levels change with improvement in body weight with antituberculotic therapy in active tuberculosis patients."7.70Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis. ( Aral, Y; Cakir, B; Demirbaş, B; Güler, S; Gürsoy, G; Odabaşi, E; Yönem, A, 1999)
"We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents."7.69Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994)
"Noncaseating granulomatous hepatitis may be caused by a variety of drugs, but we have not found, by computer search of the literature, a previous describe of granulomatous hepatitis associated with pyrazinamide."7.69Pyrazinamide-induced granulomatous hepatitis. ( Buyanowsky, G; Dan, M; Knobel, B; Zaidel, L, 1997)
"A case of thrombocytopenia caused by pyrazinamide is reported in a patient receiving chemotherapy for pulmonary tuberculosis."7.67Pyrazinamide induced thrombocytopenia. ( Jain, VK; Prakash, OM; Vardhan, H, 1988)
"Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide."7.67Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986)
" PZA dosage was less than 1."6.69[Hyperuricemia and arthralgia during pyrazinamide treatment]. ( Ikeda, N; Ikeda, T; Inoue, T; Kurasawa, T; Nakatani, K; Sato, A; Yoshimatsu, H, 1999)
" One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands."5.43HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016)
"Rosacea is a common chronic inflammatory cutaneous disease of unknown etiology, characterized by remissions and exacerbations, presenting with centrofacial erythema and telangiectasias."5.42Pyridoxine induced rosacea-like dermatitis. ( Mokos, ZB; Paštar, Z; Rezaković, S, 2015)
"Pyrazinamide is an antituberculous drug that is administered as a two-month course during treatment of pulmonary tuberculosis."5.35Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide. ( Murakami, T; Nikai, T; Ogawa, K; Taki, H, 2008)
"The isoniazid was discontinued, and the gynecomastia was partially resolved by the end of treatment."5.35Gynecomastia: a rare adverse effect of isoniazid. ( Braz, AG; Maia, JA; Morrone Junior, N; Morrone, N, 2008)
"Pyrazinamide therapy has been associated with dose-dependent hepatotoxicity, hyperuricaemia, arthralgia and arthritis."5.28Tubulointerstitial nephritis associated with pyrazinamide. ( Kauffmann, RH; Sanwikarja, S; Serlie, J; te Velde, J, 1989)
" The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status."5.15Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011)
"To study intralesional concentrations of isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA) in tuberculous pleural effusions and psoas abscesses, and to compare these to reference serum values and minimal inhibitory concentration (MIC)."5.11Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess. ( Jutte, PC; Rutgers, SR; Uges, DR; Van Altena, R; Van Horn, JR, 2004)
"A case of isoniazid induced gynecomastia is being reported in an 18-year old male, who received a re-treatment regimen for the relapse of pulmonary tuberculosis (TB)."4.87Unilateral and painless development of isoniazid induced gynecomastia during re-treatment of pulmonary tuberculosis. ( Behera, D; Gupta, R; Jaiswal, A; Kumar, L; Murar, A; Puri, MM, 2011)
"Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children."3.88Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018)
"We report the case of a 35-year-old man treated by RHEZ for a first episode of a smear positive pulmonary tuberculosis and who developed a DRESS syndrome due to pyrazinamide after twenty days of treatment, associated with a viral reactivation to Human Herpes Virus 6 (HHV6)."3.88[DRESS syndrome secondary to pyrazinamide: An uncommon complication of tuberculosis treatment]. ( Dia Kane, Y; Diouf, NF; Fall, L; Ka, W; Kombila, UD; Koutonin, ANE; Mbaye, FBR; Ouedraogo, P; Oumar Toure Badiane, N, 2018)
"Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease."3.85Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017)
"A 26-year-old man, who had started treatment for pulmonary tuberculosis, developed polyarthralgia, generalised myalgia, weakness, and elevated uric acid and creatine kinase levels."3.81Drug-induced myopathy in a patient with pulmonary tuberculosis. ( Shah, R; Venkatesan, P, 2015)
" The objectives of this investigation were to evaluate the impact of body weight on the overall systemic exposure to pyrazinamide (PZA) and to assess whether the use of one fixed dose, without adjustment according to weight, would ensure target exposure and safety requirements across the overall patient population."3.78Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis. ( Della Pasqua, O; Sahota, T, 2012)
"Pyrazinamide (PZA) has been in use for almost 50 years as a first-line drug for short-course chemotherapy against Mycobacterium tuberculosis."3.76Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India. ( Ayalusamy, N; Jagadeesan, S; Muthaiah, M; Muthuraj, U; Prabhu, SS; Senthilkumar, K; Sreenivasan, M; Veerappan, S, 2010)
"We present the case of an elderly patient who died of fulminant hepatic failure in the course of receiving 2 months of treatment with pyrazinamide and rifampin for his latent tuberculosis."3.71Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis. ( Medinger, A, 2002)
"In this study we investigated whether leptin and TNFalpha levels change with improvement in body weight with antituberculotic therapy in active tuberculosis patients."3.70Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis. ( Aral, Y; Cakir, B; Demirbaş, B; Güler, S; Gürsoy, G; Odabaşi, E; Yönem, A, 1999)
"We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents."3.69Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994)
"To test the efficacy of a short-course regimen of 6 months rifampicin and isoniazid supplemented by 2 months initial pyrazinamide (2HRZ-4HR), in the treatment of smear and culture-negative pulmonary tuberculosis and tuberculous pleural effusion in routine clinical practice."3.69Short-course chemotherapy for tuberculous pleural effusion and culture-negative pulmonary tuberculosis. ( Horsfield, N; McCarthy, OR; Ormerod, LP; Rudd, RM, 1995)
"Noncaseating granulomatous hepatitis may be caused by a variety of drugs, but we have not found, by computer search of the literature, a previous describe of granulomatous hepatitis associated with pyrazinamide."3.69Pyrazinamide-induced granulomatous hepatitis. ( Buyanowsky, G; Dan, M; Knobel, B; Zaidel, L, 1997)
"A case of thrombocytopenia caused by pyrazinamide is reported in a patient receiving chemotherapy for pulmonary tuberculosis."3.67Pyrazinamide induced thrombocytopenia. ( Jain, VK; Prakash, OM; Vardhan, H, 1988)
"Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide."3.67Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986)
"An analysis carried out on the dosage schemes adopted in several controlled clinical trials in tuberculosis has indicated that preestablishing the daily doses of isoniazid, rifampicin, and pyrazinamide in the initial intensive phase results in large deviations of the doses administered from those considered appropriate in mg/kg body weight."3.67Short-course chemotherapy of pulmonary tuberculosis: a new approach to drug dosage in the initial intensive phase. ( Acocella, G; Angel, JH, 1986)
" Secondary outcomes were clinical signs and symptoms of pulmonary TB and adverse drug reactions (ADRs) related to anti-TB agents."3.01Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial. ( Kawkitinarong, K; Laohapojanart, N; Ratanajamit, C; Srichana, T, 2021)
"Linezolid is increasingly used for the treatment of tuberculosis resistant to first-line agents, but the most effective dosing strategy is yet unknown."2.94Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis. ( Burger, DA; Dawson, R; De Jager, VR; Diacon, AH; Everitt, D; Mendel, CM; Narunsky, K; Nedelman, J; Pappas, F; Vanker, N, 2020)
" We investigated the incidence of adverse events and cure rates according to HIV status for patients receiving standard TB therapy in the trial."2.90Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. ( Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; McHugh, TD; Mendel, CM; Meredith, SK; Mohapi, L; Murphy, ME; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD, 2019)
"Linezolid improves the treatment outcomes of multidrug-resistant tuberculosis substantially."2.90Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. ( Ahn, H; Cho, YJ; Choi, HS; Choi, SM; Hahn, S; Han, J; Heo, EY; Hwang, YR; Jeong, I; Jo, YS; Joh, JS; Ki, J; Kim, DK; Kim, H; Kim, HS; Kim, J; Kim, SJ; Kwak, N; Lee, CH; Lee, J; Lee, JH; Lee, JK; Lee, JY; Lee, M; Lee, SH; Lee, SM; Lee, YJ; Lim, JN; Park, JH; Park, JS; Park, SS; Park, YS; Song, T; Yim, JJ; Yoon, HI, 2019)
"Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) remain unsatisfactory, and long-term use of second-line anti-TB drugs is accompanied by the frequent occurrence of adverse events, low treatment compliance, and high costs."2.90Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m ( Ahn, H; Ahn, JH; Cho, SN; Hahn, S; Jang, JY; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, CK; Kim, DK; Kim, JS; Kim, SY; Kim, YR; Koh, WJ; Lee, JH; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Shim, TS; Shin, S; Shin, SJ; Song, T; Won, HJ; Yim, JJ, 2019)
" Incidence rate of adverse effects was 19."2.90Efficacy and safety of cholecalciferol-augmented anti-tuberculosis therapy for treatment of naïve patients with pulmonary tuberculosis: A randomized, controlled, clinical study. ( Abd-Ellatief, RB; Hasanain, AFA; Nafee, AMA; Zayed, AAH, 2019)
" In conclusion, regimen including PZA seems to be safe for late elderly patients with pulmonary TB."2.90Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study. ( Asaoka, M; Baba, T; Hagiwara, E; Katano, T; Kitamura, H; Komatsu, S; Ogura, T; Okuda, R; Sekine, A; Suido, Y, 2019)
" Intensive pharmacokinetic sampling occurred in 63 patients after 6 weeks of treatment, and safety/tolerability was assessed."2.84Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. ( Aarnoutse, RE; Boeree, MJ; Colbers, A; Gillespie, SH; Haraka, F; Hoelscher, M; Kibiki, GS; Logger, JGM; Magis-Escurra, C; Mpagama, SG; Mtabho, CM; Phillips, PPJ; Plemper van Balen, G; Reither, K; Semvua, HH; Sumari-de Boer, IM; Te Brake, LHM; van den Boogaard, J; Wattenberg, M, 2017)
" Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among heterozygous carriers of SLCO1B1 rs1104581 (previously associated with low rifampin concentrations)."2.82Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. ( Egan, D; Hennig, S; Kellerman, T; McIlleron, H; Naiker, S; Owen, A; Pym, A; Reddy, T; Wiesner, L, 2016)
"There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when drug disposition may differ."2.82Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ( Bekker, A; Donald, PR; Draper, HR; Hesseling, AC; McIlleron, HM; Murray, S; Schaaf, HS; van der Laan, L; Wiesner, L, 2016)
"To assess whether increasing the dose of rifampicin (RMP) from 10 mg/kg to 15 or 20 mg/kg results in an increase in grade 3 or 4 hepatic adverse events and/or serious adverse events (SAE)."2.82A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. ( Atwine, D; Bonnet, M; Borgulya, G; Burgos, M; Checkley, AM; de Fernandes, RA; de Patiño, IW; Dubash, F; Gonzales, T; Harrison, TS; Jindani, A; Mitchison, D; Patel, N; Shrestha, B, 2016)
" Median rifapentine area under the concentration-time curve (AUC0-24) was 313 mcg*h/mL, similar to recent studies of rifapentine dosed at 450-600 mg daily."2.82A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. ( Armstrong, DT; Barnes, GL; Cavalcante, SC; Chaisson, RE; Cohn, S; Conde, MB; Dalcolmo, M; Dooley, KE; Dorman, SE; Duarte, RS; Durovni, B; Efron, A; Loredo, C; Marzinke, MA; Mello, FC; Moulton, LH; Rolla, V; Savic, RM, 2016)
" There was a nonlinear increase in exposure to rifampin without an apparent ceiling effect and a greater estimated fall in bacterial load in the higher dosing groups."2.80A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. ( Aarnoutse, RE; Boeree, MJ; Burger, D; Dawson, R; Diacon, AH; du Bois, J; Gillespie, SH; Heinrich, N; Hoelscher, M; Magis-Escurra, C; McHugh, TD; Narunsky, K; Phillips, PP; Plemper van Balen, G; Rehal, S; van Ingen, J; van Soolingen, D; Venter, A, 2015)
" We also assessed safety and tolerability by monitoring adverse events."2.80Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul ( Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F, 2015)
"3%] in the RPT 450 mg, RPT 600 mg and RMP groups), as were ⩾grade 3 adverse events (0/54 [0%], 1/51 [2."2.80Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis. ( Barnes, GL; Carman, D; Chaisson, RE; Dawson, R; Dorman, SE; Efron, A; Gupte, N; Hoffman, J; McIlleron, H; Narunsky, K; Whitelaw, A, 2015)
"To observe the clinical effect on type 2 diabetes mellitus (T2DM) complicated with pulmonary tuberculosis (TB) of insulin, isoniazid, rifampicin, pyrazinamide and ethambutol (conventional medication) administered together with Qi-boosting and Yin-nourishing decoction derived from Traditional Chinese Medicine (TCM)."2.80Effects on type 2 diabetes complicated with pulmonary tuberculosis: regiment of insulin, isoniazid, rifampicin, pyrazinamide and ethambutol versus the regiment plus Qi-boosting and Yin-nourishing decoction of Traditional Chinese Medicine. ( Shi, G; Zhang, L, 2015)
" Data was analysed using population pharmacokinetic modelling."2.80Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. ( Andersen, AB; Castel, S; Changalucha, J; Chigutsa, E; Christiansen, M; Denti, P; Faurholt-Jepsen, D; Friis, H; Hagen, CM; Jeremiah, K; McIlleron, H; PrayGod, G; Range, N; Wiesner, L, 2015)
"The pyrazinamide MIC range was 12."2.79The pyrazinamide susceptibility breakpoint above which combination therapy fails. ( Chigutsa, E; Gumbo, T; McIlleron, H; Pasipanodya, J; Sirgel, FA; van Helden, PD; Visser, M, 2014)
" Adverse events were mostly mild and no serious adverse events or drug discontinuations were reported."2.78Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. ( Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013)
" Noninferiority was dependent on consistent results from a per-protocol and modified intention-to-treat analysis, using 2 different models for the latter, classifying all changes of treatment or refusal to continue treatment (eg, bacteriological failure/relapse, adverse event, default, drug resistance) as unfavorable (model 1) and classifying changes of treatment for reasons other than therapeutic outcomes according to their 18-month bacteriological outcome if available (post hoc model 2)."2.76Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. ( Anyo, G; Burgos, M; Cook, SV; Enarson, DA; Jindani, A; Kim, SJ; Lienhardt, C; Nunn, AJ; Rigouts, L; Yorke-Edwards, V, 2011)
"Rifampin is a key drug for tuberculosis (TB) treatment."2.73Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. ( Aarnoutse, RE; Alisjahbana, B; Nijland, HM; Parwati, I; Ruslami, R; van Crevel, R, 2007)
"The patients with drug susceptible pulmonary tuberculosis treated with 2HRZE/4H2R2 under the supervision by the pharmacists or the patients treated with 2HRZE/4HR by self-administration were followed-up for two years after completion of chemotherapy."2.73[Relapse rate of pulmonary tuberculosis within two years following completion of twice weekly intermittent chemotherapy]. ( Hoshino, H; Mitarai, S; Ogata, H; Ohmori, M; Okumura, M; Uchimura, K; Wada, M; Yoshiyama, T, 2008)
" With a dosage of 30 mg/kg PZA, efficient serum levels were reached."2.73Pyrazinamide serum levels in childhood tuberculosis. ( Detjen, A; Magdorf, K; Thee, S; Wahn, U, 2008)
"Patients were treated in a controlled clinical trial with 2HRZE3/6HE with thrice-weekly direct dosing in the intensive phase and once-weekly with six doses self-administered in the continuation phase."2.73Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis. ( , 2007)
" The occurrence of adverse effects was also monitored."2.73Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients. ( Chaudhry, A; Jamshaid, M; Zaka-Ur-Rehman, Z, 2008)
"The concentration and half-life of theophylline was decreased and its clearance was increased significantly at days 5-7 after administration of antituberculosis agents compared to before the therapy was started."2.71The clearance of theophylline is increased during the initial period of tuberculosis treatment. ( Ahn, HC; Lee, YC, 2003)
"Thirty-one patients with documented pulmonary tuberculosis were treated with rifampin/isoniazid for six months, plus pyrazinamide for the first two months."2.71Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial. ( Badaró, R; Bandeira, AC; Barberin, MG; Brites, C; Guerra, C; Netto, EM; Pedral-Sampaio, DB, 2003)
" There was no significant difference in the pharmacokinetic parameters of rifampicin as a component of Mairin-P and in combination with antitubercuous agents as free dosage forms."2.71[Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis]. ( Semenova, OV, 2003)
"Fifty patients with drug-resistant pulmonary tuberculosis were managed by withdrawing all anti-tuberculosis drugs until the results of a drug sensitivity test were obtained (approximately 3 months), and then a 12-month self-administered regimen with four to six anti-tuberculosis drugs at full daily doses was initiated, based primarily on the sensitivity test and secondarily on the history of previous treatment."2.70Results of a 12-month regimen for drug-resistant pulmonary tuberculosis. ( Martínez-Rossier, LA; Pérez-Guzmán, C; Torres-Cruz, A; Vargas, MH; Villarreal-Velarde, H, 2002)
" Group II also registered; the maximum cost and highest incidence of adverse effects."2.70Comparative evaluation of efficacy and safety profile of three anti-tuberculous regimens in Mangalore. ( Beena, S; Pai, MR; Rao, KN, 2002)
" Further studies with increased rifapentine dosage are necessary."2.70Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. ( Chan, SL; Goodall, RL; Kam, KM; Mitchison, DA; Tam, CM, 2002)
" Because of poor bioavailability of the rifapentine used (produced in China), its dose size was increased from 600 mg initially to about 750 mg in the last third of patients to obtain serum concentrations similar to those with rifapentine of Western origin; all doses were given after a meal promoting absorption."2.69Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. ( Chan, SL; Kam, KM; Lam, CW; Leung, CC; Mitchison, DA; Morris, JS; Tam, CM, 1998)
" PZA dosage was less than 1."2.69[Hyperuricemia and arthralgia during pyrazinamide treatment]. ( Ikeda, N; Ikeda, T; Inoue, T; Kurasawa, T; Nakatani, K; Sato, A; Yoshimatsu, H, 1999)
"Ethambutol (E) was sometimes substituted for streptomycin."2.69Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report. ( Bakare, NA; Ige, OM; Onadeko, BO, 2000)
"Three hundred eight new smear positive pulmonary tuberculosis patients were randomly allocated with a ratio of 2 to 1 into treatment group (227 cases, receiving 2RIFATER/4RIFINAH regimen) and controls (81 cases, 2HRZ/4HR) for observation."2.69[Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy]. ( Ma, W; Yan, B; Zhu, L, 1998)
"The triple combination studied could replace the separate drugs in the initial treatment phase in countries where the bioavailability of the drugs used has been proven."2.68[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose]. ( Boulahbal, F; Chaulet, P, 1995)
" Food may however decrease the oral bioavailability of rifampicin and isoniazid."2.68Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. ( Smith, P; Zent, C, 1995)
"To compare the pharmacokinetic parameters and the clinical efficacy of isoniazid, administered in 10 mg/kg or 5 mg/kg to children suffering from pulmonary tuberculosis."2.68Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels. ( Chopra, K; Roy, V; Tekur, U, 1996)
"310 patients with pulmonary tuberculosis disseminating bacteria received isoniazid, rifampicin, streptomycin (ethambutol) and pirazinamid in different regimens and dosage forms."2.67[Combined chemotherapy of patients with tuberculosis - new regimens and dosage forms]. ( Elistratova, NA; Khalbaeva, IV; Koriakin, VA; Sokolova, GB; Ziia, AV, 1993)
" The formulation employed contained 125 mg of isoniazid (H), 100 mg of rifampicin (R) and 375 mg of pyrazinamide (Z) per tablet; six tablets were administered to every subject, giving a total dosage of 750 mg of isoniazid, 600 mg of rifampicin and 2,250 mg of pyrazinamide."2.67Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy. ( Acocella, G; Grassi, C; Grassi, GG; Luisetti, M; Peona, V; Pozzi, E, 1993)
"250 patients suffering from pulmonary tuberculosis who were smear positive received a chemotherapy regime for 6 months combining Rifampicin and Isoniazid every day with a daily supplement of Pyrazinamide for the first 8 weeks."2.67[A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment]. ( Agounitestane, D; Ait Khaled, N; Boulahbal, F; Chaulet, P; Chiheb, M; Khaled, S, 1990)
"7%]); had similar rates of adverse drug reactions (7."2.67USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. ( Combs, DL; Geiter, LJ; O'Brien, RJ, 1990)
" New data on optimal drug selection and dosing are emerging with the inclusion of children in clinical trials and ongoing research on age-related pharmacokinetics and pharmacodynamics."2.66Tuberculosis treatment in children: The changing landscape. ( Huynh, J; Marais, BJ; Schaaf, HS; Thwaites, G, 2020)
"Intracranial tuberculomas are rare yet lethal forms of tuberculosis."2.66Multiple tuberculomas in an immunocompetent patient and their diagnostic challenge in a high prevalence country: Case report and literature review. ( Alva-Diaz, C; Esteban-Arias, D; López-Saavedra, A; Metcalf, T; Orellana-Tovar, I; Pacheco-Barrios, K; Rodriguez-López, E; Velásquez-Rimachi, V, 2020)
" The dosage of each drug was very similar whether it was given combined or separately."2.66Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. ( , 1989)
"Patients with pulmonary tuberculosis who were failures of primary chemotherapy with strains resistant to isoniazid or to isoniazid and streptomycin were allocated at random to receive a regimen of rifampicin and ethambutol for 6 (4RE) or 9 months (7RE), supplemented in both treatment series by streptomycin plus pyrazinamide for the first 2 months."2.66Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. ( Aluoch, JA; Babu Swai, O; Darbyshire, JH; Edwards, EA; Githui, WA; Nunn, AJ; Thiong'o, R, 1988)
"To measure the effectiveness of treatment for pulmonary tuberculosis in Peru we evaluated the fate of 2,669 patients who had tuberculosis diagnosed in 1981."2.66Operational evaluation of treatment for tuberculosis. Results of 8- and 12-month regimens in Peru. ( Baron, RB; Ganter, B; Hopewell, PC; Sanchez-Hernandez, M, 1985)
" tuberculosis were treated in the initial phase as inpatients for 2-3 months at random with either pyrazinamide (Z) or ethambutol (E) in combination with isoniazid (H) and rifampicin (R)."2.66[Which is the best drug combination for the short-term therapy of tuberculosis? A prospective randomized study with 190 patients]. ( Bezel, R; Brändli, O; Häcki, M; Karrer, W; Röthlisberger, K; Rubin, S, 1985)
"When pyrazinamide was omitted in the first 2 months the relapse rates were 18% for the 6-month and 6% for the 8-month series."2.65Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study. ( , 1980)
"A cooperative french trial in the treatment of pulmonary tuberculosis has compared the efficacy and the tolerance of daily antituberculous regimes, one of short duration of 18 weeks (HRSZ/HRZ), the other of standard duration of 9 months (HRE)."2.65[Short-term chemotherapy of tuberculosis. Cooperative French trial]. ( Pretet, S, 1983)
"Relapses have occurred in two of 119 SHRZ6 patients, four of 127 EHRZ6 patients and two of 127 EHR9 patients."2.65A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society. ( , 1984)
" In a controlled study of culture-positive advanced pulmonary tuberculosis we have compared treatment regimens with PZA in a dosage of less than 2 g and with ethambutol (EMB)."2.65[Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study]. ( Brändli, O; Fiala, W; Häcki, MA, 1983)
"Relapse has occurred in 1 of 125 SHRZ6 patients, 3 of 132 EHRZ6, and 2 of 136 EHR9 patients."2.65A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association. ( , 1982)
" It is concluded that the arthralgia was often self-limiting, that aspirin had a small beneficial effect, that allopurinol, in the dosage studied, may have had a slightly deleterious effect, but that it would be worth studying larger dosages of allopurinol because the dosage studied did not affect the serum uric acid concentration."2.65Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration. ( Allan, WG; Fox, W; Girling, DJ; Horsfall, PA; Nunn, AJ; Plummer, J, 1979)
"All 33 relapses were with strains sensitive to isoniazid and streptomycin, and 76 per cent of them occurred in the first 3 months after the end of chemotherapy."2.64Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. ( , 1975)
" The results confirm that the twice-weekly regimen is highly effective and demonstrate that its efficacy is not influenced by the rate of inactivation of isoniazid or by a reduction (by one-fourth) in the dosage of streptomycin."2.63A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. ( , 1970)
"To supplement previous state-of-art reviews on anti-tuberculosis treatment and to pave the way forward with reference to the current status, we systematically reviewed published literature on clinical research on tuberculosis (TB) over the past decade in the treatment of drug-susceptible and multidrug-resistant TB (MDR-TB), with a focus on drugs, dosing factors and regimens."2.52Clinical research in the treatment of tuberculosis: current status and future prospects. ( Chang, KC; Sotgiu, G; Yew, WW, 2015)
"This review will introduce pharmacokinetic parameters for key anti-TB drugs, as well as the indications and limitations of measuring these parameters in clinical practice."2.50Understanding pharmacokinetics to improve tuberculosis treatment outcome. ( Heysell, SK; Reynolds, J, 2014)
"Pyrazinamide (PZA) is an essential sterilizing drug and with rifampicin enables six-month short-course antituberculosis chemotherapy."2.48Pyrazinamide pharmacokinetics and efficacy in adults and children. ( Diacon, AH; Donald, PR; Maritz, JS, 2012)
" The rifamycin activity could be improved by increasing the dose size of rifampicin or by daily dosing with long acting rifapentine."2.46The near future: improving the activity of rifamycins and pyrazinamide. ( Fourie, PB; Mitchison, DA, 2010)
"About 97% of patients with pulmonary tuberculosis became bacteriologically quiescent by the 12 months of streptomycin, para-aminosalicylate and isoniazid."2.41[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients]. ( Wada, M, 2001)
"Treatment of tuberculosis has three major goals: healing the patient, preventing selection of resistant strains and control transmission of tuberculosis."2.40[Antitubercular chemotherapy]. ( Dautzenberg, B; Jouveshomme, S, 1997)
"appearance of a bilateral bacillary pulmonary tuberculosis with a severe involvement of the right lung."2.40[Sharp syndrome complicating pulmonary tuberculosis: apropos of a case]. ( Ba, O; Cissokho, S; Diatta, A; Dieng, MT; Hane, AA; Kandji, M; Ndiaye, B; Ndiaye, M; Ndir, M; Niang, A, 1999)
"The here described investigations show correspondingly that the administration of isoniazid, rifampicin and pyrazinamide in a fixed combination of the administration of the individual substances is bioequivalent under pharmacokinetic aspects."2.38[Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide]. ( Lode, H; Schaberg, T, 1991)
"Pyrazinamide is an antituberculosis drug synthesized in the 1950s and formerly used only as salvage therapy."2.37The role of pyrazinamide in tuberculosis chemotherapy. ( Des Prez, RM; Steele, MA, 1988)
" Population pharmacokinetic models used plasma and intrapulmonary drug levels at 8 and 16 weeks."1.72High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis. ( Chasweka, M; Chirambo, AP; Chitani, A; Corbett, EL; Davies, GR; Ghany, JF; Gordon, SB; Khoo, SH; Malamba, R; Mallewa, JE; McCallum, AD; Meghji, JZ; Mwandumba, HC; Pertinez, HE; Shani, D; Sheha, I; Sloan, DJ, 2022)
" The effect of CART-derived thresholds for individualized dosing on treatment outcome should be studied in a randomized controlled trial."1.62Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response. ( Alffenaar, JW; Bao, Z; Bruchfeld, J; Forsman, LD; Gao, Y; Hoffner, S; Hu, Y; Li, X; Ren, W; Zheng, X, 2021)
"This features mimic Gitelman's syndrome which is an autosomal recessive disorder affecting kidneys causing electrolyte disturbances."1.56Gitelman-like syndrome: A rare complication of using aminoglycosides in tuberculosis - A case report. ( E R, V; Keny, S; Lawande, D; Parrikar, A, 2020)
" Blood sampling was also performed 120  minutes after dosing for the detection of Cmax purpose."1.56Effect of interval between food intake and drug administration at fasting condition on the plasma concentrations of first-line anti-tuberculosis drugs in Chinese population. ( Chu, N; Du, Y; Guo, R; Han, X; Pang, Y; Wang, J; Wang, Q, 2020)
"There is a need for individualized dosing of isoniazid and rifampicin based on plasma concentration measurements (therapeutic drug monitoring) and for clinical trials on higher doses of these TB drugs in patients with TB and DM."1.51Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. ( Aarnoutse, RE; Boeree, MJ; Burger, DM; Colbers, A; Irongo, CF; Kibiki, GS; Mtabho, CM; Semvua, HH; Tostmann, A; van Crevel, R; van den Boogaard, J; van der Ven, AJAM, 2019)
" Stochastic PK/pharmacodynamic (PD) simulations were carried out to evaluate current regimen combinations and dosing guidelines in distinct patient strata."1.51Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. ( Bang, H; Barry, CE; Dartois, V; Eum, S; Fox, WS; Gupta, SV; Lee, M; Savic, RM; Shim, T; Strydom, N; Via, LE; Zimmerman, M, 2019)
"Treatment of isoniazid, rifampicin, pyrazinamide with the diagnosis of epituberculosis was started by taking a sample of gastric aspirate culture sample."1.48[Management and treatment difficulties of multi-drug resistant pulmonary tuberculosis in a pediatric case]. ( Acar, EM; Bayramoğlu, Z; Çalışkan, E; Erköse, G; Hançerli Törün, S; Kılıçaslan, Z; Şatana, D; Somer, A, 2018)
"Ulcerative skin tuberculosis (TB) is a rare form of extrapulmonary TB."1.48Perianal ulcerative skin tuberculosis: A case report. ( Chen, H; Song, X; Wang, W; Wu, S; Xiong, W; Yu, X, 2018)
"Pyrazinamide (PZA) is a critical component of current first-line TB therapy."1.48Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis. ( Braunstein, M; Durham, PG; Hayden, JD; Hickey, AJ; Lin, FC; Miller, BK; Montgomery, SA; Rank, L; Welch, JT; Young, EF; Zulauf, KE, 2018)
" Pyrazinamide pharmacokinetic (PK) data from 61 HIV/TB-coinfected patients in South Africa were used in the analysis."1.46Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. ( Chirehwa, MT; Denti, P; McIlleron, H; Mthiyane, T; Onyebujoh, P; Rustomjee, R; Smith, P, 2017)
"Upon diagnosis, Pulmonary Tuberculosis patients are treated for TB for a period of 6-9 months."1.46Serum levels of soluble urokinase plasminogen activator receptor (suPAR) as a marker of tuberculosis treatment efficacy. ( Indumati, V; Krishnaswamy, D; Rajeshwari, V; Ramesh, A; Shantala, D; Shilpa, A; Vijay, V, 2017)
" As irrational use and inadequate dosing of anti-TB drugs may contribute to the epidemic of drug-resistant TB, we assessed the drug types and dosages prescribed in the treatment of TB cases in a representative sample of health care facilities in Yunnan."1.46Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit. ( Chen, J; Chiang, CY; Innes, AL; Li, L; Xu, L, 2017)
"The currently preferred regimen for treatment of pulmonary tuberculosis (PTB) is isoniazid, rifampin, pyrazinamide, and ethambutol, which has been used either as separate tablets (ST) or as fixed-dose combination (FDC)."1.46Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. ( Al-Shaer, MH; Elewa, H; Iqbal, F; Mansour, H; Salameh, P, 2017)
"If isoniazid Cmax was <4."1.46Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. ( Denti, P; Gumbo, T; Lesosky, M; McIlleron, H; Meintjes, G; Pasipanodya, JG; Rockwood, N; Sirgel, F; Wilkinson, RJ, 2017)
"Seventeen (4."1.43Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. ( Cho, YJ; Kim, SJ; Lee, CT; Lee, JH; Lee, JY; Lee, YJ; Park, JS; Song, J; Yoon, HI, 2016)
"Pyrazinamide (PZA) is a key sterilizing drug in first-line tuberculosis (TB) regimens and exerts its activity entirely during the first 2 months in human infections."1.43Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis. ( Betoudji, F; Lanoix, JP; Nuermberger, E, 2016)
"Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug, however, there are relatively few available data on PZA resistant (PZA-R) rate in China."1.43Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China. ( Gao, Q; Gicquel, B; Luo, T; Nsofor, CA; Shen, X; Wu, J; Xu, P; Yang, C; Zhang, Y; Zhu, G, 2016)
"A population-based multicenter study of pulmonary tuberculosis (TB) cases was carried out from 2011 to 2013 in four Chinese districts/counties with different geographic and socioeconomic features."1.43Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China. ( Drobniewski, F; Hoffner, S; Hu, Y; Li, D; Mansjö, M; Werngren, J; Xu, B; Zheng, X, 2016)
"Pyrazinamide resistance was assessed in 4972 patients."1.43Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. ( Alikhanova, N; Andres, S; Cabibbe, AM; Cirillo, DM; Dadu, A; Dean, AS; Dreyer, A; Driesen, M; Floyd, K; Gilpin, C; Hasan, R; Hasan, Z; Hoffner, S; Husain, A; Hussain, A; Ismail, N; Kamal, M; Kimerling, M; Mansjö, M; Mukadi, YD; Mvusi, L; Niemann, S; Omar, SV; Qadeer, E; Raviglione, MC; Rigouts, L; Ruesch-Gerdes, S; Schito, M; Seyfaddinova, M; Skrahina, A; Tahseen, S; Wells, WA; Weyer, K; Zignol, M, 2016)
" One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands."1.43HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016)
"Pirfenidone is a recently approved antifibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF)."1.43The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis. ( Ahidjo, BA; Andrade, BB; Beck, S; Bishai, WR; Cheung, LS; Ihms, EA; Jain, S; Maiga, M; Maiga, MC; Ordonez, AA, 2016)
"Anti-tuberculosis drug-induced hepatotoxicity (ATDH) is a serious adverse reaction to anti-tuberculosis (TB) treatment."1.43Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study. ( He, JQ; Ji, GY; Liu, QQ; Sandford, AJ; Wang, Y; Wu, JC; Wu, SQ; Zhang, MM, 2016)
"33 patients with pulmonary tuberculosis were treated with one Risorine kit, daily consisting of one capsule of Risorine, one tablet of ethambutol (800 mg) and two tablets of Pyrazinamide 750 mg each, for first two months of therapy."1.43Role of Risorine in the Treatment of Drug - Susceptible Pulmonary Tuberculosis: A Pilot Study. ( Patel, K; Patel, S; Vora, A, 2016)
"The available pharmacokinetic data on anti-tubercular drugs in children raises the concern of suboptimal plasma concentrations attained when doses extrapolated from adult studies are used."1.42Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. ( Kabra, SK; Kanhiya, K; Lodha, R; Mukherjee, A; Singla, M; Velpandian, T, 2015)
"Rosacea is a common chronic inflammatory cutaneous disease of unknown etiology, characterized by remissions and exacerbations, presenting with centrofacial erythema and telangiectasias."1.42Pyridoxine induced rosacea-like dermatitis. ( Mokos, ZB; Paštar, Z; Rezaković, S, 2015)
"Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug that is generally administered with isoniazid, rifampicin, ethambutol and streptomycin."1.40Characterisation of pyrazinamide-resistant Mycobacterium tuberculosis strains isolated in Poland and Germany. ( Augustynowicz-Kopeć, E; Hillemann, D; Napiórkowska, A; Richter, E; Rüsch-Gerdes, S, 2014)
" In this study, we sought to investigate the sterilizing activity of human-equivalent doses of thioridazine when given in combination with the "Denver regimen" against acute murine tuberculosis."1.40Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis. ( Dutta, NK; Karakousis, PC; Pinn, ML, 2014)
"Seventy-five male patients with pulmonary tuberculosis (mean age, 40."1.40Association of serum levels of iron, copper, and zinc, and inflammatory markers with bacteriological sputum conversion during tuberculosis treatment. ( de Melo Guedes de Oliveira, HM; de Oliveira, MM; Delogo, KN; Dos Anjos, MJ; Kritski, AL; Mesquita, ED; Miranda, PF; Moraes, ML; Netto, AR; Ramalho, DM, 2014)
"Gastrointestinal events, hepatitis, hearing impairment, arthralgia, psychosis, hypothyroidism, visual disturbances, giddiness, peripheral neuropathy, skin reactions, swelling or pain at injection site, anorexia and sleep disturbances were important amongst these."1.40Profile of adverse drug reactions in drug resistant tuberculosis from Punjab. ( Bharti, H; Bhushan, B; Chander, R; Gupta, A; Kajal, NC; Ranga, V, 2014)
" We therefore determined the pharmacokinetic characteristics of first-line TB drugs in Tanzanian patients using intensive pharmacokinetic sampling."1.39Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. ( Aarnoutse, RE; Boeree, MJ; Kibiki, GS; Mtabho, CM; Semvua, HH; Tostmann, A; van den Boogaard, J, 2013)
"[Methods] Thirty-six patients with pulmonary tuberculosis, who were admitted to Yokohama City University Hospital between June 2011 and March 2012 were included."1.39[Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide]. ( Horita, N; Ishigatsubo, Y; Miyazawa, N; Sasaki, M; Takahashi, R; Tomaru, K; Tsukahara, T, 2013)
"The isoniazid C2 h was noticeably lower in fast versus slow acetylators (0."1.39Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. ( Aarnoutse, R; Ascobat, P; Burhan, E; Donders, R; Ginanjar, A; Mangunnegoro, H; Ruesen, C; Ruslami, R; van Crevel, R, 2013)
" Serum concentration-time profiles, maximum serum concentrations, time to achieve maximum serum concentrations, the half-life and the areas under the serum concentration-time curve for each of the four drugs were determined."1.39Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients. ( Arpag, H; Babalık, A; Bakirci, N; Çarpaner, E; Dagyildiz, L; Kuyucu, T; Ulus, IH, 2013)
"The study was performed among 60 pulmonary tuberculosis (TB) in-patients at a tertiary care university-affiliated hospital in Tehran, Iran."1.39Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. ( Bozorg, BD; Dastan, F; Emami, S; Fahimi, F; Goodarzi, A; Habibi, M; Kobarfard, F; Salamzadeh, J; Shahsavari, N; Tabarsi, P, 2013)
" This is despite the availability of antibiotics that have good activity against Mycobacterium tuberculosis in vitro and favorable pharmacokinetic profiles in plasma."1.38Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. ( Barry, CE; Dartois, V; Goh, A; Kern, S; Kjellsson, MC; Low, KM; Pillai, G; Via, LE; Weiner, D, 2012)
"Pyrazinamide (PZA) is an important drug in the treatment of tuberculosis."1.38A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis. ( Cotrina, M; Fuentes, P; Gilman, RH; Gutierrez, A; Kirwan, D; Loli, S; Sheen, P; Zimic, M, 2012)
"Pyrazinamide was omitted in 15 cases while rifampicin only in one patient."1.38Management of and risk factors related to hepatotoxicity during tuberculosis treatment. ( Ağca, S; Arda, H; Babalık, A; Bakırcı, N; Calışır, HC; Cetintaş, G; Kızıltaş, S; Oruç, K, 2012)
"Rifampin-treated BALB/c mice remained culture positive at 3 months."1.37Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. ( Ahmad, Z; Almeida, DV; Converse, PJ; Grosset, JH; Li, SY; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Zhang, M, 2011)
"Paragonimiasis is a food-borne zoonosis caused by a trematode of the genus Paragonimus(1,2)."1.37[Pulmonary paragonimiasis]. ( Fortes-Alen, J; Gómez-Escolar, PF; Gómez-Seco, J; Presa-Abos, T; Rodríguez-Guzmán, MJ; Rodríguez-Nieto, MJ, 2011)
"Thirteen patients with pulmonary tuberculosis detected."1.37Pulmonary tuberculosis in infants less than one year old: implications for early diagnosis. ( Bayhan, GI; Ekşioğlu, AS; Kitiş Çelik, B; Tanır, G, 2011)
"The frequency of late recurrences following treatment completion has not been well-studied."1.37When tuberculosis comes back: who develops recurrent tuberculosis in california? ( Deriemer, K; Flood, JM; Pascopella, L; Watt, JP, 2011)
" Intensive pharmacokinetic sampling was performed for rifampin, pyrazinamide, and ethambutol at steady state."1.36Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. ( Aarnoutse, RE; Adhiarta, IG; Alisjahbana, B; Kariadi, SH; Nijland, HM; Ruslami, R; van Crevel, R, 2010)
"Pyrazinamide sensitivity was carried out using the BACTEC 7H12 medium."1.36Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients. ( Irfan, M; Mehfooz, Z; Rao, NA; Soomro, MM, 2010)
"Pyrazinamide (PZA) is an important first-line antituberculous drug, which is applied together with INH, RMP, EMB and SM."1.36[Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland]. ( Augustynowicz-Kopeć, E; Napiórkowska, A; Zwolska, Z, 2010)
"Metronidazole treatment (for 6 weeks at 100 mg/kg of body weight) resulted in no reduction in the bacillary burden and significantly worsened lesion inflammation."1.35Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. ( Basaraba, RJ; Brooks, EJ; Caraway, ML; Driver, ER; Hoff, DR; Lenaerts, AJ; Orme, IM; Peloquin, CA; Ryan, GJ, 2008)
"Pyrazinamide was the most sensitive drug i."1.35Primary drug resistance against Mycobacterium tuberculosis in Karachi. ( Hussain, SJ; Irfan, M; Rao, NA, 2008)
"Treatment with rifampin and pyrazinamide was more effective than treatment with rifampin, isoniazid, and pyrazinamide at reducing the lung CFU count, consistent with past evidence of isoniazid's antagonism in this model."1.35Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. ( Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K, 2008)
"Pyrazinamide is an antituberculous drug that is administered as a two-month course during treatment of pulmonary tuberculosis."1.35Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide. ( Murakami, T; Nikai, T; Ogawa, K; Taki, H, 2008)
"tuberculosis isolates from pulmonary tuberculosis patients."1.35Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. ( Fourie, PB; Grewal, HM; Mannsåker, T; Mphahlele, M; Muthivhi, T; Stavrum, R; Syre, H; Valvatne, H; Weyer, K, 2008)
"Temozolomide (TMZ) is a cytotoxic agent of the imidazotetrazine class, chemically related to dacarbazine."1.35Tuberculosis in a patient on temozolomide: a case report. ( de Barros e Silva, MJ; de Paiva, TF; Fanelli, MF; Gimenes, DL; Rinck, JA, 2009)
"The isoniazid was discontinued, and the gynecomastia was partially resolved by the end of treatment."1.35Gynecomastia: a rare adverse effect of isoniazid. ( Braz, AG; Maia, JA; Morrone Junior, N; Morrone, N, 2008)
" Therefore, lowering of pyrazinamide dosage is suggested in children for better patient compliance along with reduction in cost, side-effects and toxicity without compromising its efficacy."1.35Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs. ( Arya, DS; Nandave, M; Ojha, SK; Semwal, OP, 2008)
" Therapy was performed according to regimens 3 and 1, by using individual dosage regimens depending on the extent and severity of a specific process, the presence of complications, and age-related features."1.35[Optimization of chemotherapy regimens in children with primary pulmonary tuberculosis]. ( Dovgaliuk, IF; Ovchinnikova, IuE; Starshinova, AA, 2009)
"Isoniazid was stopped and patient was continued on R & E till completion of the treatment up to nine months."1.35Isoniazid induced gynaecomastia: a case report. ( Garg, R; Mehra, S; Prasad, R, 2009)
"In previous studies, the diarylquinoline R207910 (also known as TMC207) was demonstrated to have high bactericidal activity when combined with first- or second-line antituberculous drugs."1.34Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. ( Andries, K; Chauffour, A; Ibrahim, M; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N, 2007)
"He was diagnosed as pulmonary tuberculosis, and started treatment with INH, RFP, EB, and PZA."1.34[A case of tuberculosis showing immune reconstitution syndrome after the initiation of antiretroviral therapy for HIV infection]. ( Izumi, S; Taniguchi, H, 2007)
"A 65-year-old woman developed a confusional syndrome one week after starting treatment for pulmonary military tuberculosis."1.34[Aseptic cerebral venous thrombosis and multiple cerebral tuberculomas associated with pulmonary miliary tuberculosis]. ( Amara, B; Belahsen, MF; Benjelloun, FZ; Benjelloun, MC; Messouak, O; Tizniti, S, 2007)
"Types and frequency of drug-related adverse events and outcomes of treatment."1.33Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. ( Bock, NN; Grabau, JC; Jasmer, RM; Lobato, MN; Reves, RR; Shang, N, 2005)
"89 microg/mL) and area under concentration curve (AUC) was 30% of the values observed under fasting conditions."1.33Population pharmacokinetics of pyrazinamide in elephants. ( Dunker, F; Isaza, R; Maslow, JN; Mikota, SK; Peloquin, CA; Riddle, H; Zhu, M, 2005)
"MDR-TB can be successfully treated during pregnancy by using a regimen including effective second-line anti-tuberculosis drugs."1.33[Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy]. ( Ano, H; Danno, K; Han, Y; Kawahara, K; Matsumoto, T; Nagai, T; Takashima, T; Tamura, Y; Tsuyuguchi, I; Yoshida, H, 2006)
"All cases had evidence of pulmonary tuberculosis."1.33Ocular tuberculosis in acquired immunodeficiency syndrome. ( Babu, RB; Biswas, J; Kumarasamy, N; Sudharshan, S; Therese, L, 2006)
"Major adverse reactions to antituberculosis drugs can cause significant morbidity, and compromise treatment regimens for tuberculosis (TB)."1.32Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. ( Menzies, D; Parisien, I; Pelletier, M; Rocher, I; Valiquette, C; Yee, D, 2003)
"A healthy 57 year-old woman with past untreated pulmonary tuberculosis, disclosed a bilateral uveitic syndrome characte rized by iritis, vitreitis, multiple peripheral retinal punched-out lesions, and cystoid macular edema."1.32[Tuberculous peripheral multifocal choroiditis]. ( González Guijarro, J; Pérez Alvarez, MJ; Santos Gil, I, 2003)
"In total, 45 children with pulmonary tuberculosis participated."1.32Follow-up of compliance with tuberculosis treatment in children: monitoring by urine tests. ( Gultekin, D; Kayaalp, N; Palanduz, A, 2003)
" Relative bioavailability of encapsulated drugs was greater than that of free drugs."1.32Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis. ( Khuller, GK; Sharma, S; Ul-Ain, Q, 2003)
"All 44 non-private hospitals in Malawi treating pulmonary tuberculosis (PTB) patients with an oral regimen (0."1.32Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi. ( Gausi, F; Harries, AD; Salaniponi, FM, 2004)
"A hundred new cases of active pulmonary tuberculosis whose age was 60 to 87 years were treated by the intensive chemotherapy regimen recommended by the WHO."1.32[Efficiency of an intensive stage of chemotherapy for tuberculosis in elderly and senile patients]. ( Karachunskiĭ, MA; Uvarova, TE, 2004)
" Severe adverse reactions included rash (two), toxic hepatitis (six), Immune Reconstitution Syndrome (seven), and four deaths."1.32Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis. ( Alves, CR; Badaro, R; Brites, C; Netto, EM; Oliveira, AS; Pedral-Sampaio, DB, 2004)
"A case of Pulmonary Alveolar Proteinosis (PAP), in association with tuberculosis, is described in a 35-year-old diabetic patient."1.31Pulmonary alveolar proteinosis and tuberculosis in a diabetic patient: a rare or a seldom diagnosed association? ( Coelho JC, JC; Marinho, MM; Pereira-Silva, JL; Veloso, TV, 2002)
"Lupus vulgaris is the most common cutaneous manifestation of tuberculosis in industrialised countries, but nevertheless it remains rare and it is a very unusual presenting feature of underlying pulmonary tuberculosis."1.31[Pulmonary tuberculosis presenting as tubercular lupus]. ( Barbaud, A; Fays, S; Martin, S; Schmutz, JL, 2002)
"Intracranial tuberculomas are a rare manifestation of neurotuberculosis and are due to hematogenous dissemination of distant focuses of Mycobacterium tuberculosis infection."1.31[Intracranial tuberculomas developing during treatment of pulmonary tuberculosis: case report]. ( Alves, SM; Belo Neto, E; Brandão, RZ; Novis, SA; Pimentel, ML, 2000)
"Hyponatremia is seen in 40% to 60% of hospitalized acquired immune deficiency syndrome (AIDS) patients."1.31Normouricemia in the syndrome of inappropriate antidiuretic hormone secretion. ( Akalin, E; Chandrakantan, A; Hamburger, RJ; Keane, J, 2001)
"Pyrazinamide was not used in the intensive phase in the control group (n = 73)."1.31[Effectiveness of chemotherapy of intrathoracic tuberculosis in children: late follow-up data]. ( Iukhimenko, NV, 2001)
"Pericardial effusion was shown by echocardiography and subsequently removed by pericardiocentesis."1.31Tuberculous pericarditis in an infant evolving during triple chemotherapy. ( Bettendorf, M; Meyburg, J; Nützenadel, W; Schmidt, KG, 2002)
"Pyrazinamide (PZA) is a first-line drug for short-course tuberculosis therapy."1.30Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. ( Cynamon, M; Gilman, R; Heifets, L; Lindholm-Levy, P; Scorpio, A; Siddiqi, S; Zhang, Y, 1997)
"The re-treatment pulmonary tuberculosis with positive spits represent 13."1.30[The results of retreatment of pulmonary tuberculosis using a short 6-month protocol 1985-1991 in the pneumo-phthisiology department of the Point G hospital in Bamako]. ( Kayantao, D; Keïta, B; Sangaré, S, 1997)
"Two patients with multidrug-resistant pulmonary tuberculosis were surgically treated after 3 and 7 years of unsuccessful chemotherapy."1.30[Surgical treatment of patients with multi-resistant pulmonary tuberculosis--case reports]. ( Kuś, J; Michałowska-Mitczuk, D, 1997)
"Although relapse was more frequent in patients with positive smears than those with negative smears (9."1.30Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? ( Bechan, S; Connolly, C; Short, GM; Standing, E; Wilkinson, D, 1998)
"Pyrazinamide, which was readministered last (at the full dose in one case and at progressive doses in the two others), induced a recurrence in two of them."1.30[Eruption after the 1st dose of standard antitubercular chemotherapy. Thoughts on pyrazinamide]. ( Autret, E; Carré, P; Jonville-Bera, AP; Lemarié, E; Radal, M; Van-Egroo, C, 1998)
"The management of pulmonary tuberculosis (TB) in Scotland in 1993 was studied by asking the physicians responsible for all 321 adult cases of the disease notified that year to complete a standardized questionnaire relating to drug treatment and bacteriology."1.30The management of pulmonary tuberculosis in adults notified in Scotland in 1993. ( Heald, SH; Leitch, AG; Simpson, AJ; Sudlow, MF; Watt, B, 1998)
"Pyrazinamide, which was re-administered last, induced a recurrence."1.30-Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-. ( Autret, E; Jonville-Béra, AP; Martel, C; Mazaud, S; Olivier, C; Radal, M, 1998)
"Out of 1128 new pulmonary tuberculosis patients, six-hundred twenty started treatment with six-month (2HRZS or E/4HRE) in Fukujuji Hospital, JATA, in Tokyo from January 1991 to December 1996."1.30[Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability]. ( Ito, K; Mizutani, S; Ogata, H; Sugita, H; Wada, M; Yoshiyama, T, 1999)
"Seventy-seven patients had pulmonary tuberculosis, 23 extrapulmonary and three had both."1.30The spectrum of mycobacterial disease in a Dublin teaching hospital. ( McDonnell, T; O'Reilly, P, 1999)
"Isoniazid resistance was more likely in HIV seronegative patients with M."1.30Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda. ( Borgdorff, MW; Bretzel, G; Bwire, R; Kawuma, HJ; Rieder, HL; Rüsch-Gerdes, S; Sticht-Groh, V, 1999)
"The frequency of chromosomal aberrations and sister-chromatid exchanges (SCEs) did not show any statistically significant differences in the patients before treatment and after exposure to combined HRZ therapy as compared to controls (p > 0."1.29Cytogenetic study of tuberculosis patients before and after tuberculostatic drug treatment. ( Ekmekçi, A; Sayli, A, 1995)
"Fourteen (30%) infants had extrapulmonary tuberculosis (11 central nervous system disease, 2 disseminated disease, and 1 cervical adenitis)."1.29Clinical features, diagnosis, and treatment of tuberculosis in infants. ( Ong, LT; Starke, JR; Vallejo, JG, 1994)
"There are few reports of children with AIDS and TB."1.29Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome. ( Birnbaum, J; Chan, SP; Rao, M; Steiner, P, 1996)
"Patients with cavitating pulmonary tuberculosis continue to excrete viable tubercle bacilli for approximately 6 weeks despite supervised treatment."1.29The duration of excretion of viable bacilli in elderly patients on treatment for cavitating pulmonary tuberculosis. ( Morris, CD, 1996)
"They are enlarged in acute pulmonary tuberculosis."1.29Changes in the size of adrenal glands in acute pulmonary tuberculosis with therapy. ( Durak, AC; Gülmez, I; Keleştimur, F; Ozesmi, M, 1996)
"1,350 smear positive pulmonary tuberculosis cases in the ten research pilot counties of Liaoning province from 1992 to 1993 were selected to receive short-course intermittent chemotherapies under full-course supervision."1.29[Analysis of short-term effects of short-course intermittent chemotherapies of the World Bank Loaned Project]. ( Su, Y; Wen, S; Zhang, F, 1996)
"Twenty-nine patients with extensive pulmonary tuberculosis and drug-induced hepatitis were treated with ofloxacin along with other relatively non-hepatotoxic drugs, either during the interim phase to await recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others."1.28Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. ( Kwan, SY; Lee, J; Wong, PC; Yew, WW, 1992)
"Patients with direct smear positive pulmonary tuberculosis were admitted to hospital during the initial phase of treatment for two months."1.28Fixed dose combination short course chemotherapy in the treatment of pulmonary tuberculosis. ( Abdi, A; Lema, E; Roscigno, G; Wolde, K, 1992)
"Pyrazinamide (PZN) was administered to 10 patients of pulmonary tuberculosis (for 7 consecutive days) each day after an overnight fast."1.28Effect of simultaneous isoniazid administration on pharmacokinetic parameters of pyrazinamide. ( Singhal, KC; Varshney, MK, 1991)
"Forty-one of our patients had pulmonary tuberculosis, 38 had extra pulmonary and in 61 it was disseminated."1.28AIDS and tuberculosis in Spain. A report of 140 cases. ( Adrados, M; Díaz, F; García Aguado, C; González Lahoz, JM; Laguna, F; Martínez, R; Puente, S, 1991)
"Seven patients received no treatment because tuberculosis was first diagnosed after death."1.28Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. ( Chaisson, RE; Goodman, PC; Hopewell, PC; Sande, MA; Schecter, GF; Small, PM, 1991)
"Pyrazinamide was prescribed to 80%, which represents a substantial increase on the 19% recorded in a similar survey of patients notified in 1983."1.28The management of pulmonary tuberculosis in adults notified in England and Wales in 1988. The British Thoracic Society Research Committee and the Medical Research Council Cardiothoracic Epidemiology Group. ( , 1991)
"0, 12 experimental groups, each containing 10 mice, were treated for 8 weeks with pyrazinamide (PZA) given in mean daily dosages of 100, 200 or 400 mg/kg/day, with the interval between the doses within each dosage group being 1, 2, 4 or 8 days."1.28Efficacy of intermittent pyrazinamide in experimental murine tuberculosis. ( Dickinson, JM; Mitchison, DA, 1991)
" Elderly patients are more sensitive to antituberculous (anti-TB) drugs; therefore, a modification in the dosage for this patient group should be considered."1.28The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide. ( Chan, HS; Chan, K; Walubo, A; Wong, CL; Woo, J, 1991)
"In Zimbabwe patients with pulmonary tuberculosis who are acid-fast bacilli (AFB) negative in the sputum are treated in the two month intensive phase with isoniazid, thiacetazone pyrazinamide and streptomycin (regimen A)."1.28Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population. ( Kusema, T; Mhonda, M; Neill, P; Nhachi, CF; Pringle, D, 1990)
"No relapse was noted among patients with extrapulmonary tuberculosis."1.28[Treatment of tuberculosis. Drug combinations, therapeutic problems and results in a 10-year case load]. ( Morland, L, 1990)
"We investigated the pharmacokinetic interaction of RMP (administered from the first day of treatment onwards), PZA (given from the second day onwards), and INH (day 17 onwards) in ten, previously untreated patients with pulmonary tuberculosis (five slow acetylators and five fast acetylators)."1.28[Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide]. ( Loos, U; Musch, E; Schwabe, HK, 1990)
"Pyrazinamide therapy has been associated with dose-dependent hepatotoxicity, hyperuricaemia, arthralgia and arthritis."1.28Tubulointerstitial nephritis associated with pyrazinamide. ( Kauffmann, RH; Sanwikarja, S; Serlie, J; te Velde, J, 1989)
"The good results gotten employing short-term (6 months) medication regimes with rifampin, isoniazid and an initial supplement (2 months) of streptomycin and pyrazinamide, gave an impulse to pharmacodynamic research."1.27[Pharmacokinetics of antitubercular agents in man]. ( Acocella, G, 1984)
" The therapeutic advantage of using these two drugs in combination should be more readily appreciated."1.27A comparative evaluation of drug combinations used in the treatment of pulmonary tuberculosis. ( Miller, SD, 1983)
" Bioavailability of pyrazinamide was only slightly increased in patients, its dialysis extraction coefficient being 55."1.27Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure. ( Farinotti, R; Fessi, H; Kenouch, S; Méry, JP; Montes, C; Stamatakis, G; Trouvin, JH, 1988)
"Due to these findings systemic lupus erythematosus (SLE) was suspected."1.27[Tuberculostatics-induced systemic lupus erythematosus]. ( Engelhard, M; Layer, P, 1986)
" Minor adverse reactions occurred with similar frequencies during daily (5%) and intermittent (5%) treatment but in no case was modification of rifampicin dosage required."1.27Safety of thrice-weekly rifampicin for tuberculosis in South-East Asian refugees. ( McKenzie, DK; Mukerjee, CM, 1985)
"The adverse effects of drugs which caused changes in therapeutic regimens have been studied in 511 patients with pulmonary tuberculosis, at the Pavilion Koch of Buenos Aires University."1.26Adverse effects of antituberculosis drugs causing changes in treatment. ( Dambrosi, A; Dambrosi, VM; Gonzalez Montaner, LJ; Manassero, M, 1982)
"Pyrazinamide was found to be capable of significantly inducing amino-levulinic acid synthetase activity; the other antituberculous drugs caused either slight or no induction of amino-levulinic acid synthetase."1.26Exacerbation of porphyria during treatment of pulmonary tuberculosis. ( Magnussen, CR; Patterson, JR; Treece, GL; Tschudy, DP, 1976)

Research

Studies (1,055)

TimeframeStudies, this research(%)All Research%
pre-1990481 (45.59)18.7374
1990's168 (15.92)18.2507
2000's165 (15.64)29.6817
2010's208 (19.72)24.3611
2020's33 (3.13)2.80

Authors

AuthorsStudies
Ibrahim, M2
Andries, K3
Lounis, N2
Chauffour, A1
Truffot-Pernot, C3
Jarlier, V2
Veziris, N2
Ruslami, R5
Nijland, HM2
Alisjahbana, B2
Parwati, I1
van Crevel, R5
Aarnoutse, RE7
Hoff, DR1
Caraway, ML2
Brooks, EJ1
Driver, ER1
Ryan, GJ1
Peloquin, CA13
Orme, IM3
Basaraba, RJ2
Lenaerts, AJ3
Adhiarta, IG1
Kariadi, SH1
Rullas, J1
García, JI1
Beltrán, M1
Cardona, PJ1
Cáceres, N1
García-Bustos, JF1
Angulo-Barturen, I1
Shaikh, A1
Sriraman, K1
Vaswani, S1
Oswal, V1
Rao, S1
Mistry, N1
Kim, JS2
Kim, YH3
Lee, SH4
Kim, JW1
Kang, JY1
Kim, SK1
Kim, SJ7
Kang, YS1
Kim, TH1
Mok, J3
Byun, MK1
Park, HJ1
Joh, JS2
Park, YB1
Lim, HS1
Choi, H1
Kim, H4
Yang, J1
Shen, X2
Alsultan, A2
Cho, I1
Geiter, L2
Shim, TS3
Carr, W1
Kurbatova, E1
Starks, A1
Goswami, N1
Allen, L1
Winston, C1
McCallum, AD1
Pertinez, HE1
Chirambo, AP1
Sheha, I1
Chasweka, M1
Malamba, R1
Shani, D1
Chitani, A1
Mallewa, JE1
Meghji, JZ1
Ghany, JF1
Corbett, EL1
Gordon, SB1
Davies, GR3
Khoo, SH2
Sloan, DJ1
Mwandumba, HC1
Lopez-Varela, E1
Abulfathi, AA1
Strydom, N2
Goussard, P1
van Wyk, AC1
Demers, AM1
Deventer, AV1
Garcia-Prats, AJ2
van der Merwe, J1
Zimmerman, M2
Carter, CL1
Janson, J1
Morrison, J1
Reuter, H1
Decloedt, EH1
Seddon, JA2
Svensson, EM1
Warren, R1
Savic, RM3
Dartois, V5
Hesseling, AC4
Heysell, SK3
Mpagama, SG4
Ogarkov, OB1
Conaway, M1
Ahmed, S1
Zhdanova, S1
Pholwat, S1
Alshaer, MH1
Chongolo, AM1
Mujaga, B1
Sariko, M1
Saba, S1
Rahman, SMM1
Uddin, MKM1
Suzdalnitsky, A1
Moiseeva, E1
Zorkaltseva, E1
Koshcheyev, M1
Vitko, S1
Mmbaga, BT1
Kibiki, GS8
Pasipanodya, JG4
Banu, S1
Houpt, ER2
Kwak, N2
Jeon, D2
Park, Y1
Kang, YA2
Kim, KJ1
Kim, YR2
Kwon, BS1
Kwon, YS1
Kim, HJ2
Lee, JH5
Lee, JY4
Lee, JK3
Cheon, M1
Park, J1
Hahn, S3
Yim, JJ3
Lyons, MA1
Dooley, KE5
Hendricks, B3
Gupte, N5
Barnes, G3
Narunsky, K8
Whitelaw, C3
Smit, T3
Ignatius, EH4
Friedman, A3
Dorman, SE5
Dawson, R13
Paton, NI1
Cousins, C1
Suresh, C1
Burhan, E3
Chew, KL1
Dalay, VB1
Lu, Q1
Kusmiati, T1
Balanag, VM1
Lee, SL1
Pokharkar, Y1
Djaharuddin, I1
Sugiri, JJR1
Veto, RS1
Sekaggya-Wiltshire, C2
Avihingsanon, A1
Sarin, R1
Papineni, P1
Nunn, AJ13
Crook, AM3
Tweed, CD1
Diacon, AH9
McHugh, TD6
Mendel, CM6
Meredith, SK3
Mohapi, L1
Murphy, ME1
Phillips, PPJ3
Singh, KP1
Spigelman, M2
Gillespie, SH9
Esmail, H1
Lipman, MC2
Nunn, A2
Walker, TM1
Mtabho, CM4
Semvua, HH5
van den Boogaard, J4
Irongo, CF1
Boeree, MJ6
Colbers, A3
Burger, DM2
van der Ven, AJAM1
Tostmann, A2
Peetluk, LS1
Rebeiro, PF1
Cordeiro-Santos, M1
Kritski, A1
Andrade, BB2
Durovni, B2
Calvacante, S1
Arriaga, MB1
Turner, MM1
Figueiredo, MC1
Rolla, VC1
Sterling, TR1
McKenna, L1
Furin, J1
Filipenko, ML1
Dymova, MA1
Cherednichenko, AG1
Khrapov, EA1
Mishukova, OV1
Schwartz, YS1
De Jager, VR2
Vanker, N2
Burger, DA2
Everitt, D3
Pappas, F2
Nedelman, J1
Genestet, C1
Hodille, E1
Berland, JL1
Ginevra, C1
Bryant, JE1
Ader, F1
Lina, G1
Dumitrescu, O1
Cho, HJ1
Lim, YJ1
Kim, J3
Koh, WJ3
Song, CH1
Kang, MW1
Decroo, T1
de Jong, BC5
Piubello, A1
Lynen, L1
Van Deun, A2
Rahimi, BA1
Rahimy, N1
Ahmadi, Q1
Hayat, MS1
Wasiq, AW1
van Niekerk, C4
Hutchings, J1
van der Merwe, L1
Choi, J1
Nam, K1
Huynh, J1
Thwaites, G1
Marais, BJ1
Schaaf, HS5
Manyazewal, T1
Woldeamanuel, Y1
Holland, DP1
Fekadu, A1
Blumberg, HM1
Marconi, VC1
Naluyange, R1
Mboowa, G1
Komakech, K1
Semugenze, D1
Kateete, DP1
Ssengooba, W1
Dean, P1
Berger, T1
Matt, M1
Schlaudecker, E1
Riney, L1
Velásquez-Rimachi, V1
Orellana-Tovar, I1
Rodriguez-López, E1
López-Saavedra, A1
Esteban-Arias, D1
Pacheco-Barrios, K1
Metcalf, T1
Alva-Diaz, C1
Saroha, D1
Garg, D1
Singh, AK1
Dhamija, RK1
E R, V1
Parrikar, A1
Keny, S1
Lawande, D1
Swindells, S1
Zheng, X3
Bao, Z1
Forsman, LD2
Hu, Y4
Ren, W1
Gao, Y1
Li, X3
Hoffner, S4
Bruchfeld, J1
Alffenaar, JW2
Wang, J4
Du, Y1
Guo, R1
Han, X1
Wang, Q4
Pang, Y1
Chu, N2
Fernandez Do Porto, DA1
Monteserin, J1
Campos, J1
Sosa, EJ1
Matteo, M1
Serral, F1
Yokobori, N1
Benevento, AF1
Poklepovich, T1
Pardo, A1
Wainmayer, I1
Simboli, N1
Castello, F1
Paul, R2
Martí, M1
López, B1
Turjanski, A1
Ritacco, V1
Xu, X1
Hu, X1
Hase, I1
Toren, KG1
Hirano, H1
Sakurai, K1
Horne, DJ2
Saito, T1
Narita, M3
Laohapojanart, N1
Ratanajamit, C1
Kawkitinarong, K1
Srichana, T1
Chiwala, G1
Liu, Z1
Mugweru, JN1
Wang, B1
Khan, SA1
Bate, PNN1
Yusuf, B1
Hameed, HMA1
Fang, C1
Tan, Y1
Guan, P1
Hu, J1
Tan, S2
Liu, J1
Zhong, N1
Zhang, T1
Wang, Y4
Xiang, X1
Wu, SQ3
Chen, G2
Zhang, MM3
Wang, MG1
Wang, FJ1
Sandford, AJ2
He, JQ3
Dutta, NK3
Pinn, ML4
Karakousis, PC5
Driesen, M2
Kondo, Y1
Torrea, G2
Asnong, S1
Desmaretz, C1
Mostofa, KSM1
Tahseen, S2
Whitfield, MG1
Cirillo, DM2
Miotto, P1
Cabibbe, AM2
Rigouts, L5
Omonge, E1
Otieno, F1
Kubo, M1
Shiruli, B1
Chirehwa, MT1
McIlleron, H13
Rustomjee, R4
Mthiyane, T3
Onyebujoh, P1
Smith, P4
Denti, P7
de Knegt, GJ2
Dickinson, L1
Pertinez, H2
Evangelopoulos, D2
Bakker-Woudenberg, IAJM1
de Steenwinkel, JEM2
Li, SY3
Tasneen, R6
Tyagi, S7
Soni, H1
Converse, PJ3
Mdluli, K1
Nuermberger, EL6
Namasivayam, S1
Maiga, M2
Yuan, W1
Thovarai, V1
Costa, DL1
Mittereder, LR1
Wipperman, MF1
Glickman, MS1
Dzutsev, A1
Trinchieri, G1
Sher, A1
Goel, N1
Kumar, V1
Arora, S1
Ghosh, B1
Indumati, V1
Vijay, V1
Krishnaswamy, D1
Rajeshwari, V1
Ramesh, A1
Shantala, D1
Shilpa, A1
Mourik, BC1
Verbon, A1
Mouton, JW1
Bax, HI1
Calderón, RI1
Velásquez, GE1
Becerra, MC2
Zhang, Z3
Contreras, CC1
Yataco, RM1
Galea, JT1
Lecca, LW1
Kritski, AL3
Murray, MB1
Mitnick, CD3
Reither, K3
Haraka, F1
Sumari-de Boer, IM1
Magis-Escurra, C2
Wattenberg, M1
Logger, JGM1
Te Brake, LHM1
Hoelscher, M3
Plemper van Balen, G2
Díaz, A1
Bongiovanni, B1
D'Attilio, L1
Santucci, N1
Dídoli, G1
Fernández, RDV1
Kovalevski, L1
Lioi, S1
Gardeñez, W1
Brandan, N1
Nannini, LJ1
Besedovsky, H1
Del Rey, A1
Bottasso, O1
Bay, ML1
Castelnuovo, B1
von Braun, A1
Musaazi, J1
Muller, D1
Buzibye, A1
Gutteck, U1
Henning, L1
Ledergerber, B1
Corti, N1
Lamorde, M1
Fehr, J1
Kambugu, A1
Feng, M1
Wu, JC2
Ji, GY2
Liu, QQ2
Park, S1
Jo, KW2
Lee, SD1
Kim, WS1
Xu, L1
Chen, J2
Innes, AL1
Li, L2
Chiang, CY3
Ngabonziza, JCS1
Diallo, AB1
Tagliani, E1
Diarra, B1
Kadanga, AE1
Togo, ACG1
Thiam, A1
de Rijk, WB1
Alagna, R1
Houeto, S1
Ba, F1
Dagnra, AY1
Ivan, E1
Affolabi, D1
Schwoebel, V1
Trebucq, A3
Daneau, G1
Sigal, GB1
Segal, MR1
Mathew, A1
Jarlsberg, L1
Wang, M2
Barbero, S1
Small, N1
Haynesworth, K1
Davis, JL1
Weiner, M1
Whitworth, WC1
Jacobs, J1
Schorey, J1
Lewinsohn, DM1
Nahid, P1
Yeboah-Manu, D1
Gehre, F1
van der Laan, LE1
Tikiso, T1
Wiesner, L5
de Kock, M1
Winckler, J1
Norman, J1
Kim, S1
Lee, H1
Park, HY1
Jeon, K1
Huh, HJ1
Lee, NY1
Jeong, BH1
Wondale, B1
Medihn, G1
Teklu, T1
Mersha, W1
Tamirat, M1
Ameni, G1
Hsia, YC1
Naseri, A1
Schallhorn, JM1
Nansumba, M1
Kumbakumba, E1
Orikiriza, P1
Bastard, M1
Mwanga, JA1
Boum, Y1
de Beaudrap, P1
Bonnet, M2
Cerezo Lajas, A1
Caminero Luna, JA1
Rodríguez Guzmán, MDC1
de Miguel Díez, J1
Kombila, UD1
Ka, W1
Mbaye, FBR1
Diouf, NF1
Fall, L1
Ouedraogo, P1
Koutonin, ANE1
Dia Kane, Y1
Oumar Toure Badiane, N1
Adane, K1
Spigt, M1
Dinant, GJ1
Bwalya, P1
Yamaguchi, T1
Mulundu, G1
Nakajima, C1
Mbulo, G1
Solo, ES1
Fukushima, Y1
Kasakwa, K1
Suzuki, Y2
Eedara, BB1
Rangnekar, B1
Sinha, S1
Doyle, C1
Cavallaro, A1
Das, SC1
Hançerli Törün, S1
Acar, EM1
Somer, A1
Erköse, G1
Şatana, D1
Bayramoğlu, Z1
Çalışkan, E1
Kılıçaslan, Z1
Wu, S1
Wang, W2
Chen, H1
Xiong, W1
Song, X1
Yu, X1
Alfarisi, O1
Mave, V1
Gaikwad, S1
Sahasrabudhe, T1
Ramachandran, G2
Kumar, H2
Kulkarni, V1
Deshmukh, S1
Atre, S1
Raskar, S1
Lokhande, R1
Barthwal, M1
Kakrani, A1
Chon, S1
Gupta, A2
Golub, JE2
Yates, WB1
Nothling, S1
Lawlor, M1
Montgomery, SA1
Young, EF1
Durham, PG1
Zulauf, KE1
Rank, L1
Miller, BK1
Hayden, JD1
Lin, FC1
Welch, JT2
Hickey, AJ1
Braunstein, M1
McAulay, K1
Saito, K1
Warrier, T1
Walsh, KF1
Mathurin, LD1
Royal-Mardi, G1
Lee, MH1
Ocheretina, O1
Pape, JW1
Fitzgerald, DW1
Nathan, CF1
Kim, DK2
Yoon, HI3
Jeong, I2
Heo, EY1
Park, YS1
Jo, YS1
Park, SS1
Park, JS4
Lee, SM1
Lee, CH1
Lee, J2
Choi, SM1
Park, JH1
Cho, YJ3
Lee, YJ2
Hwang, YR1
Ki, J1
Lim, JN1
Choi, HS1
Lee, M3
Song, T2
Kim, HS1
Han, J1
Ahn, H2
Smythe, W2
Merle, CS3
Olliaro, PL3
Deshpande, D1
Magombedze, G1
Gumbo, T4
Lee, T1
Kim, SY1
Jhun, BW1
Ahn, JH1
Kim, CK1
Shin, S1
Shin, SJ1
Won, HJ1
Jang, JY1
Cho, SN1
Khan, N1
Mendonca, L1
Dhariwal, A1
Fontes, G1
Menzies, D4
Xia, J1
Divangahi, M1
King, IL1
Hasanain, AFA1
Zayed, AAH1
Abd-Ellatief, RB1
Nafee, AMA1
Padmapriyadarsini, C2
Bhavani, PK1
Natrajan, M1
Ponnuraja, C1
Gomathy, SN1
Guleria, R1
Jawahar, SM1
Singh, M2
Balganesh, T1
Swaminathan, S4
Gupta, SV1
Fox, WS1
Via, LE3
Bang, H1
Eum, S1
Shim, T1
Barry, CE4
Gardner Toren, K1
Spitters, C1
Pecha, M1
Bhattarai, S1
Lucena, SMA1
Alberio, CAA1
Pinto, ACG1
Vieira, JLF1
Suárez, I1
Maria Fünger, S1
Jung, N1
Lehmann, C1
Reimer, RP1
Mehrkens, D1
Bunte, A1
Plum, G1
Jaspers, N1
Schmidt, M2
Fätkenheuer, G1
Rybniker, J1
Hagiwara, E1
Suido, Y1
Asaoka, M1
Katano, T1
Okuda, R1
Sekine, A1
Kitamura, H1
Baba, T1
Komatsu, S1
Ogura, T1
Muntean, PE1
Svensson, RJ1
Sabiiti, W1
Ntinginya, NE3
Bhatt, N1
Davies, G2
Simonsson, USH1
Ishiwada, N1
Tokunaga, O1
Nagasawa, K1
Ichimoto, K1
Kinoshita, K2
Hishiki, H1
Kohno, Y1
O'Donnell, MR1
Padayatchi, N1
Kvasnovsky, C1
Werner, L1
Master, I1
Horsburgh, CR1
Miyazawa, N1
Horita, N1
Tomaru, K1
Tsukahara, T1
Takahashi, R1
Sasaki, M1
Ishigatsubo, Y1
Diacon, A1
Ruesen, C2
Ginanjar, A1
Mangunnegoro, H1
Ascobat, P1
Donders, R1
Aarnoutse, R3
Gniadek, TJ1
Belchis, DA1
Mdluli, KE3
Gninafon, M2
Lo, MB2
Bah-Sow, O1
Lienhardt, C4
Horton, J2
Simonsson, US1
Wejse, C1
Furtado, A1
Camara, C1
Lüneborg-Nielsen, M1
Sodemann, M1
Gerstoft, J1
Katzenstein, TL1
Burger, A1
Wash, PA1
Pérez-Guzmán, C2
Vargas, MH2
Pérez-Arellano, CP1
García-Toledo, D1
Wallis, RS3
Wang, C1
Meyer, D1
Thomas, N1
Babalik, A3
Ulus, IH2
Bakirci, N3
Kuyucu, T2
Arpag, H2
Dagyildizi, L1
Capaner, E1
Colasanti, P1
Cardone, M1
Zanchini, R1
Cordedda, M1
Grande, A1
Mozzillo, R1
Manca, C1
Koo, MS1
Peixoto, B1
Fallows, D1
Kaplan, G1
Subbian, S1
Tsou, CC1
Chien, JY1
Dagyildiz, L1
Çarpaner, E1
Bark, CM1
Gitta, P2
Ogwang, S1
Nsereko, M1
Thiel, BA1
Boom, WH2
Eisenach, KD2
Joloba, ML1
Johnson, JL4
Hung, NV1
Ando, H1
Thuy, TT1
Kuwahara, T1
Hang, NT1
Sakurada, S1
Thuong, PH1
Lien, LT1
Keicho, N1
Fahimi, F2
Tabarsi, P2
Kobarfard, F1
Bozorg, BD1
Goodarzi, A1
Dastan, F1
Shahsavari, N1
Emami, S1
Habibi, M1
Salamzadeh, J1
Li, H1
Zhou, M1
Geng, X1
Yu, J1
Zhang, XE1
Wei, H1
Ndusilo, N1
Stroup, S1
Kumburu, H1
Gratz, J1
Neino Mourtala Mohamed, A1
Tummino, C1
Gouitaa, M1
Chanez, P1
Nomi, F1
Hosaka, K1
Kurosawa, T1
Akkerman, OW1
van Altena, R2
Bolhuis, MS1
van der Werf, TS1
Gutiérrez-Aroca, JB1
Ruiz, P1
Casal, M1
Xiang, Y1
Ma, L2
Wu, W1
Liu, W1
Li, Y1
Zhu, X1
Ma, J1
Cao, M1
Yao, X1
Yang, L1
Wubuli, A1
Merle, C1
Milligan, P1
Mao, Y1
Gu, J1
Xin, X1
Reynolds, J1
Oualil, H1
Nejjari, S1
Bourkadi, JE1
Iraqi, G1
Napiórkowska, A2
Rüsch-Gerdes, S2
Hillemann, D1
Richter, E1
Augustynowicz-Kopeć, E2
Chigutsa, E3
Pasipanodya, J1
Visser, M2
van Helden, PD1
Sirgel, FA2
Xia, Y2
Goel, S1
Harries, AD3
Gao, T1
Wang, L1
Cheng, S1
Lin, Y1
Du, X1
Moraes, ML1
Ramalho, DM1
Delogo, KN1
Miranda, PF1
Mesquita, ED1
de Melo Guedes de Oliveira, HM1
Netto, AR1
Dos Anjos, MJ1
de Oliveira, MM1
Fu, EQ1
Jin, FG1
Pouplin, T1
Phuong, PN1
Toi, PV1
Nguyen Pouplin, J1
Farrar, J1
Saitou, Y1
Hatazi, O1
Aonuma, H1
Ogura, S1
Yamamoto, N1
Kobayashi, T1
Murray, SR1
Phillips, PP4
Rusen, ID1
Squire, SB1
Madan, J1
Cook, SV2
Burgos, M3
Yorke-Edwards, V2
Anyo, G2
Enarson, DA4
Jindani, A9
Mathys, V1
van de Vyvere, M1
de Droogh, E1
Soetaert, K1
Groenen, G1
Fielding, K1
Sow, OB1
Odhiambo, J1
Amukoye, E1
Bah, B1
Kassa, F1
N'Diaye, A1
Perronne, C1
Sismanidis, C1
Lapujade, O1
Harrison, TS2
Churchyard, GJ1
Charalambous, S2
Hatherill, M1
Geldenhuys, H1
McIlleron, HM2
Zvada, SP1
Mungofa, S1
Shah, NA1
Zizhou, S1
Magweta, L1
Shepherd, J1
Nyirenda, S1
van Dijk, JH1
Clouting, HE1
Coleman, D1
Bateson, AL1
Butcher, PD1
Mitchison, DA21
Oshi, SN2
Alobu, I2
Ukwaja, KN2
Oshi, DC2
Yamana, H1
Matsui, H1
Fushimi, K1
Yasunaga, H1
Song, J2
Lee, CT2
du Bois, J2
Venter, A5
Heinrich, N2
Rehal, S2
van Soolingen, D1
van Ingen, J1
Burger, D1
Franke, MF1
Tierney, DB1
Rich, ML1
Bonilla, C1
Bayona, J1
McLaughlin, MM1
Bhushan, B1
Chander, R1
Kajal, NC1
Ranga, V1
Bharti, H1
Honeyborne, I1
Eckold, C1
Pym, A4
Stehr, M1
Elamin, AA1
Mayor, S1
Sotgiu, G2
Migliori, GB1
Donald, PR8
Schall, R1
Conradie, A1
Eisenach, K1
Ive, P1
Page-Shipp, L1
Variava, E1
von Groote-Bidlingmaier, F2
Braga, JU1
Trajman, A1
Mukherjee, A1
Velpandian, T1
Singla, M1
Kanhiya, K1
Kabra, SK1
Lodha, R1
Peppard, T2
Hermann, D1
Igari, H1
Imasawa, T1
Noguchi, N1
Nagayoshi, M1
Mizuno, S1
Ishikawa, S1
Kadomura, M1
Nishimura, M1
Yamagishi, F3
Carman, D1
Whitelaw, A1
Efron, A4
Barnes, GL3
Hoffman, J1
Chaisson, RE7
Rezaković, S1
Mokos, ZB1
Paštar, Z1
Huang, Z1
Gao, C1
Chi, X1
Hu, YW1
Zheng, L1
Zeng, T1
Shah, R1
Venkatesan, P1
Shi, G1
Zhang, L2
Chen, M1
Deng, J1
Li, W1
Su, C1
Abuaku, BK1
Tan, H1
Wen, SW1
Fan, L1
Zhang, Y8
Yang, X1
Bai, D1
Yao, J1
Yi, L1
Hennig, S1
Naiker, S1
Reddy, T1
Egan, D1
Kellerman, T1
Owen, A1
Jeremiah, K1
Faurholt-Jepsen, D1
PrayGod, G1
Range, N1
Castel, S1
Hagen, CM1
Christiansen, M1
Changalucha, J1
Friis, H1
Andersen, AB1
Betoudji, F2
Williams, K4
Yang, T1
Lanoix, JP2
Ioerger, T1
Ormond, A1
Kaya, F1
Sacchettini, J1
Nuermberger, E7
Chang, KC3
Yew, WW7
Bekker, A1
Draper, HR1
van der Laan, L1
Murray, S1
Dobler, CC1
Chidiac, R1
Williamson, JP1
Jelfs, PJ1
Das, MK1
Arya, R1
Debnath, S1
Debnath, R1
Lodh, A1
Bishwal, SC1
Das, A1
Nanda, RK1
Gao, J1
Ma, Y1
Du, J1
Zhu, G2
Fu, Y2
Liu, F1
Hu, D1
Li, Q1
Borgulya, G1
de Patiño, IW1
Gonzales, T1
de Fernandes, RA1
Shrestha, B1
Atwine, D1
Dubash, F1
Patel, N1
Checkley, AM1
Mitchison, D1
Xu, P1
Wu, J1
Yang, C1
Luo, T1
Nsofor, CA1
Gicquel, B2
Gao, Q1
Conde, MB3
Mello, FC1
Duarte, RS1
Cavalcante, SC1
Rolla, V1
Dalcolmo, M1
Loredo, C2
Armstrong, DT1
Marzinke, MA1
Cohn, S1
Moulton, LH2
Ortega-Muro, F1
Alameda-Martin, L1
Liu, Y1
Schipani, A1
Coates, A1
Zheng, R1
Werngren, J2
Mansjö, M3
Xu, B2
Li, D1
Drobniewski, F1
Aseffa, A1
Chukwu, JN1
Vahedi, M2
Aguwa, EN1
Bedru, A1
Mebrahtu, T1
Ezechi, OC1
Yimer, G1
Yamuah, LK1
Medhin, G1
Connolly, C3
Rida, W2
Aderaye, G1
Zumla, AI1
Onyebujoh, PC2
Zignol, M1
Dean, AS1
Alikhanova, N1
Andres, S1
Dadu, A1
Dreyer, A1
Gilpin, C1
Hasan, R1
Hasan, Z1
Husain, A1
Hussain, A1
Ismail, N1
Kamal, M1
Mvusi, L1
Niemann, S1
Omar, SV1
Qadeer, E1
Ruesch-Gerdes, S1
Schito, M1
Seyfaddinova, M1
Skrahina, A1
Wells, WA1
Mukadi, YD1
Kimerling, M1
Floyd, K1
Weyer, K2
Raviglione, MC1
Meinzen, C1
Proaño, A1
Gilman, RH2
Caviedes, L1
Coronel, J1
Zimic, M2
Sheen, P2
Rockwood, N2
Meintjes, G2
Chirehwa, M1
Wilkinson, RJ2
Shenai, S1
Ronacher, K1
Malherbe, S1
Stanley, K1
Kriel, M1
Winter, J1
Dodd, LE1
Walzl, G1
Alland, D1
McNaughton, A1
Blackmore, T1
McNaughton, H1
Ahidjo, BA1
Maiga, MC1
Ihms, EA1
Ordonez, AA2
Cheung, LS1
Beck, S1
Jain, S1
Bishai, WR4
Santra, G1
Karak, A1
Mukhopadhay, S1
Vora, A1
Patel, S1
Patel, K2
Fofana, MO1
Shrestha, S1
Knight, GM1
Cohen, T1
White, RG1
Cobelens, F1
Dowdy, DW1
Churchyard, G1
Sanne, I1
Minja, LT1
Hunt, RD1
Hanekom, M1
Manyama, C1
Mtafya, B1
Mekota, A1
Henne, S1
van Balen, GP1
Smith-Jones, P1
Wang, H1
Gogarty, KR1
Daryaee, F1
Bambarger, LE1
Chang, YS1
Jain, SK1
Tonge, PJ1
Al-Shaer, MH1
Mansour, H1
Elewa, H1
Salameh, P1
Iqbal, F1
Sirgel, F1
Lesosky, M1
Agibothu Kupparam, HK1
Vedhachalam, C1
Thiruvengadam, K1
Rajagandhi, V1
Dusthackeer, A1
Karunaianantham, R1
Jayapal, L1
Wada, M7
Okumura, M1
Hoshino, H1
Mitarai, S1
Ohmori, M1
Uchimura, K1
Yoshiyama, T2
Ogata, H4
Rao, NA3
Irfan, M2
Hussain, SJ1
Gevers, T1
Van Den Berg, J1
Grosset, J6
Taki, H1
Ogawa, K1
Murakami, T1
Nikai, T1
Thee, S2
Detjen, A1
Wahn, U2
Magdorf, K3
Mphahlele, M1
Syre, H1
Valvatne, H1
Stavrum, R1
Mannsåker, T1
Muthivhi, T1
Fourie, PB2
Grewal, HM2
Acharya, PR1
Sahoo, R1
Baliga, P1
de Paiva, TF1
de Barros e Silva, MJ1
Rinck, JA1
Fanelli, MF1
Gimenes, DL1
Barboza, CE1
Winter, DH1
Seiscento, M1
Santos, Ude P1
Terra Filho, M1
Morrone, N1
Morrone Junior, N1
Braz, AG1
Maia, JA1
Cailleaux-Cezar, M1
de A Melo, D1
Xavier, GM1
de Salles, CL1
de Mello, FC1
Ruffino-Netto, A1
Arya, DS1
Ojha, SK1
Semwal, OP2
Nandave, M1
Kamal, A1
Azeeza, S1
Malik, MS1
Shaik, AA1
Rao, MV1
Skvortsova, LA1
Pavlova, MV1
Kondakova, MN1
Vinogradova, TI1
Kovaleva, RG1
Archakova, LI1
Wikman, PE1
Jover, F1
Peris, J1
Cuadrado, JM1
Ovchinnikova, IuE1
Starshinova, AA1
Dovgaliuk, IF1
Naidu, VG1
Tammineni, AK1
Biscopink, RJ1
Davis, TL1
Veerabagu, MP1
De Souza, GR1
Graça, NP1
Cezar, MC1
Ram, M1
Chaudhary, MA1
Garg, R1
Mehra, S1
Prasad, R1
Ramos, A1
Daza, R2
Alvarez-Espejo, T1
Guzmán, MF1
Chideya, S1
Winston, CA1
Bradford, WZ2
Hopewell, PC4
Wells, CD1
Reingold, AL3
Kenyon, TA2
Moeti, TL2
Tappero, JW2
Bartacek, A1
Schütt, D1
Panosch, B1
Borek, M1
Hadad, DJ1
Dietze, R1
Maciel, EL1
Sewali, B1
Okwera, A4
Mugerwa, RD3
Alcaneses, MR1
Quelapio, MI1
Tupasi, TE1
Horter, L1
Debanne, SM1
Yüksel, P1
Tansel, O1
Lancioni, C1
LaBeaud, AD1
Esper, F1
Abughali, N1
Auletta, J1
Almeida, D4
Rosenthal, I3
Peloquin, C1
Wang, JY1
Lee, LN1
Yu, CJ1
Chien, YJ1
Yang, PC1
Albini, TA1
Kumaradas, M1
Fraig, MM1
Kuaban, C2
Bame, R1
Mouangue, L1
Djella, S1
Yomgni, C1
Ordway, DJ1
Shanley, CA1
Orme, EA1
Bucy, DS1
Hascall-Dove, L1
Henao-Tamayo, M1
Harton, MR1
Shang, S1
Ackart, D1
Kraft, SL1
Façanha, MC1
Gondim, AM1
Pinheiro, VG1
Barroso, EC1
Guerrant, RL1
Lima, AA1
Soomro, MM1
Mehfooz, Z1
Baniasadi, S1
Eftekhari, P1
Raoufy, MR1
Masjedi, MR1
Velayati, AA1
Jesinger, RA1
Ballard, EA1
Allton, DR1
Lane, JW1
Folio, L1
Su, WJ2
Feng, JY1
Chiu, YC1
Huang, SF1
Lee, YC2
Tutor-Ureta, P1
Martín-Jiménez, ML1
Vargas, JA1
Guo, N1
Marra, F2
Fitzgerald, JM3
Elwood, RK3
Marra, CA1
Cheigh, CI1
Senaratne, R1
Uchida, Y1
Casali, N1
Kendall, LV1
Riley, LW1
Zwolska, Z1
Muthaiah, M1
Jagadeesan, S1
Ayalusamy, N1
Sreenivasan, M1
Prabhu, SS1
Muthuraj, U1
Senthilkumar, K1
Veerappan, S1
Morais, P1
Ferreira, O1
Nogueira, A1
Bettencourt, H1
Azevedo, F1
Gulati, K1
Ray, A1
Vijayan, VK2
Wateba, MI1
Diop, SA1
Salou, M1
Womitso, K1
Nichols, S1
Tidjani, O1
Zhang, M2
Rosenthal, IM3
Almeida, DV1
Ahmad, Z1
Grosset, JH6
Leung, CC5
Khajotia, R1
Manthari, K1
Gómez-Seco, J1
Rodríguez-Guzmán, MJ1
Rodríguez-Nieto, MJ1
Gómez-Escolar, PF1
Presa-Abos, T1
Fortes-Alen, J1
Mulliez, P1
Mbassi Fouda, FL1
Roy Saint-Georges, F1
Bayhan, GI1
Ekşioğlu, AS1
Kitiş Çelik, B1
Tanır, G1
Tripathy, S1
Anand, A1
Inamdar, V1
Manoj, MM1
Khillare, KM1
Datye, AS1
Iyer, R1
Kanoj, DM1
Thakar, M1
Kale, V1
Pereira, M1
Risbud, AR1
Baek, SH1
Li, AH1
Sassetti, CM1
Bounouar, M1
Baybay, H1
Gallouj, S1
Meziane, M1
Mikou, O1
Mernissi, F1
Chraibi, M1
Harmouch, T1
Amarti, A1
Maritz, JS1
Consunji-Araneta, R1
Higgins, R1
Qing, G1
Bouhasan, L1
Seifart, HI1
Werely, CJ1
Rosenkranz, B1
Roll, S1
Kjellsson, MC1
Goh, A1
Weiner, D1
Low, KM1
Kern, S1
Pillai, G1
Pascopella, L1
Deriemer, K1
Watt, JP1
Flood, JM1
Losada, I1
Cifuentes, C1
Martín, C1
García, M1
De Groote, MA1
Gruppo, V1
Woolhiser, LK1
Gilliland, JC1
Loli, S1
Gutierrez, A1
Fuentes, P1
Cotrina, M1
Kirwan, D1
Smith, PJ2
Erondu, N1
Ginsberg, AM1
Becker, P2
Spigelman, MK2
Kumar, L3
Gupta, R2
Puri, MM1
Jaiswal, A1
Murar, A1
Behera, D1
Gönlügür, U1
Koşar, S1
Mirici, A1
Chu, NH1
Wang, QF1
Sahota, T1
Della Pasqua, O1
Arda, H1
Ağca, S1
Oruç, K1
Kızıltaş, S1
Cetintaş, G1
Calışır, HC1
Symons, G1
Winter, H1
Leung, EC2
Leung, WM2
Tam, CM5
Bhardwaj, A1
Narang, RK3
Murthy, RS1
Fillekes, Q1
Kisonga, RM1
Mleoh, L1
Ndaro, A1
Kisanga, ER1
van der Ven, A1
González, C1
Sáenz, C1
Herrmann, E1
Jajati, M1
Kaplan, P1
Monzón, D1
Smith, T1
Wolff, KA1
Nguyen, L1
Maartens, G2
Kirkpatrick, CM1
Karlsson, MO1
Trindade, MÂ1
Miyamoto, D1
Benard, G1
Sakai-Valente, NY1
Vasconcelos, Dde M1
Naafs, B1
Shaweno, D1
Worku, A1
Teleman, MD1
Chee, CB1
Earnest, A1
Wang, YT1
Yamazaki, Y1
Matsumoto, H1
Fujiuchi, S1
Pereira-Silva, JL1
Marinho, MM1
Veloso, TV1
Coelho JC, JC1
Kawakami, K2
Turner, DJ1
Hoyle, SL1
Snewin, VA1
Gares, MP1
Brown, IN1
Young, DB1
Kellman, M1
Franchini, DL1
McMillan, ME1
Hollender, ES1
Ashkin, D1
Chakaya, JM1
Kibuga, D1
Ng'ang'a, L1
Githui, WA2
Mansoer, JR1
Gakiria, G1
Kwamanga, D1
Maende, J1
Fays, S1
Martin, S1
Barbaud, A1
Schmutz, JL1
Sokolova, GB4
Semenova, OV2
Bogadel'nikova, IV1
Kunichan, AD2
Zeliger, LR1
Elistratova, NA3
Nolan, CM3
Goldberg, SV2
Lee, AM1
Mennone, JZ1
Jones, RC1
Paul, WS1
Perng, RP1
Gierek, T1
Markowski, J1
Kieda-Szurkowska, J1
Paluch, J1
Bielecki, I1
Doré, CJ1
McNeill, L1
Allen, M1
Estrada, C1
Cook, P1
Martínez-Rossier, LA1
Torres-Cruz, A1
Villarreal-Velarde, H1
Yee, D1
Valiquette, C1
Pelletier, M1
Parisien, I1
Rocher, I1
Miteva, L1
Bardarov, E1
Phyu, S1
Ti, T1
Jureen, R1
Hmun, T1
Myint, H1
Htun, A1
Bjorvatn, B1
Lu, PL1
Lee, YW1
Peng, CF1
Tsai, JJ1
Chen, YH1
Hwang, KP1
Chen, TP1
Beena, S1
Rao, KN1
Pai, MR1
Palanduz, A2
Gültekin, D2
Erdem, E1
Kayaalp, N2
Inoue, T2
Tanaka, E1
Oida, K1
Taguchi, Y1
Kato, T1
Sakuramoto, M1
Maeda, Y1
Maniwa, K1
Samman, Y2
Krayem, A1
Haidar, M1
Mimesh, S1
Osoba, A1
Al-Mowaallad, A1
Abdelaziz, M1
Wali, S2
Pérez Alvarez, MJ1
González Guijarro, J1
Santos Gil, I1
Han, JP1
Sun, SL1
Li, RZ1
Zhang, FS1
Wang, SC1
Cheng, J1
Deng, YF1
Yu, CB1
Xu, WG2
Gao, Z1
Fan, BD1
Ahn, HC1
Nguyen, D1
Brassard, P1
Westley, J1
Thibert, L2
Proulx, M1
Henry, K1
Schwartzman, K2
Behr, MA1
Ul-Ain, Q1
Sharma, S1
Khuller, GK1
Irtuganova, OA1
Smirnova, NS1
Slogotskaia, LV1
YEAGER, RL2
MUNROE, WG2
DESSAU, FI2
CAMPAGNA, M2
CALIX, A1
HAUSER, G1
PHILLIPS, S4
LARKIN, JC1
LITZENBERGER, WL1
HORTON, GE2
HAIMSOHN, JS1
SCHWARTZ, WS3
MOYER, RE2
MUSCHENHEIM, C2
McDERMOTT, W4
McCUNE, R1
DEUSCHLE, K2
ORMOND, L1
TOMPSETT, R2
POTTER, BP1
CHANG, SF1
ORGANICK, A1
MCCUNE, RM3
BATTEN, J1
DE SIMONI, G7
SPINA, G4
ZORINI, AO3
DUGGELI, O1
NICK, J1
STEWART, SM3
MURDOCH, JM1
CROFTON, JW1
HAY, D2
GRIVA, L1
MARENGO, G1
RANDONE, M1
SESIA, L1
STORNIELLO, G1
FANTOLI, U2
BISETTI, A2
CATTENEO, C1
FANTILI, U1
CATTANEGO, C1
SACCO, F4
ZUCCHETTI, B3
GUALA, B4
GUERRA, P4
DONNERBERG, RL1
ATWELL, RJ2
BROWNING, RH2
REALE, M1
GARAVENTA, A1
PAOLI, G1
COSTA, G2
MORETTI, E2
DI PORTO, A1
RELLINI, G1
ROCCHI, V1
MAZZINI, C1
SCHWARTZ, JA1
POGGIO, G1
WRUBL, A1
ROTTINI, E2
PICCHIO, E2
FIORENTINI, M2
CROISSANT, J1
GYSELEN, A1
DE BRABANDERE, R1
CALLENS, L2
PECORA, DV1
SISTI, MA1
SCODITTI, G1
SALVETTI, F2
CELLERINO, A3
PIOVANO, V2
EMANUELE, B1
GIOVA, C1
DI RUGGIERO, A1
MARINELLI, N1
CANIGLIA, M1
DE SIMONI, GE1
KAMEYAMA, Y1
WEBB, WR1
SPARKUHL, K1
RITCHIE, JA1
CAMPBELL, AE1
CUTHBERT, J1
BRUCE, LG1
TOGURI, E1
ALLISON, ST1
MACLEOD, HM1
SANTOPADRE, I1
POLIMENI, L1
BUTT, H1
HAAPANEN, J1
GILL, R1
RUSSELL, WF1
KASS, I4
OSEWSKI, T1
SALIBA, A2
BEATTY, OA2
SESSNER, HH1
KIMEL, VM1
JACOBS, S1
van DIJK, B1
KRAAN, JK1
SMALL, MJ1
DE PALMA, M1
MIRABELLI, S1
CINQUEGRANA, A1
FRENKEL, S1
JAWORSKI, J1
LUKIANSKA, D1
SMOL, Z1
STEINBRUECK, P1
ZAUMSEIL, I1
PETTY, TL2
MITCHELL, RS1
PINES, A4
GORGENYI-GOTTCHE, O1
SZOCSKA, M1
HEYMER, A1
RIVERA, E1
SOMNER, AR4
BRACE, AA2
TODOROFF, T1
FRANZOSI, P1
HALL, E1
RIDDELL, RW1
CATTANEO, C1
FOSTER, JH1
KILLEN, DA1
RHEA, WG1
DIVELEY, WL1
MCCRACKEN, RL1
HUBBARD, WW1
KITAMOTO, O1
MIGLIOLI, S1
CALABRESE, L1
WOLINSKY, E1
TANI, P2
POPPIUS, H1
HORNUNG, S1
KRAKOWSKA, M1
GRECO, S1
DUSI, U1
MENOZZI, V1
STUPENENGO, RH1
WENDY, CD1
RUSSO, V1
PFUETZE, KH1
PYLE, MM1
JANCIK, E4
ZELENKA, M3
TOUSEK, J5
MAKOVA, M1
WAGNER, J2
MONDESHKI, M1
PASHMAKOV, I1
MITCHELL, JH1
RUIZ, RC1
OKULICZ JASINKA, H1
ZIERSKI, M16
SNAJDR, V1
KRAKORA, P1
FISER, F1
CHODOUNSKA, V1
LUCCHESI, M1
BANCALE, A1
ROSSI, P1
SABAR, IR1
BAYGIN, R1
DEENSTRA, H1
CORPE, RF4
GOMAA, TM1
BERNARD, E2
PIERON, R1
GROUNDS, JG1
ACEVEDO, RC1
HERRERO, JJ1
PILHEU, J1
RODRIGUEZ, E1
DALRYMPLE, GV1
PEREZ, JA1
FARIAS, CE1
BRONSTEIN, DL1
CONTRERAS, H1
MUNARO, N1
CHAVES, AD1
VELU, S2
DAWSON, JJ1
DEVADATTA, S1
FOX, W10
KULKARNI, KG1
MOHAN, K1
RAMAKRISHNAN, CV3
STOTT, H3
RICHARDSON, RJ1
VILARDO, S1
COTTIN, S1
COZAN, R1
VERAN, P1
LESTON, JM2
FOSTIKOV, B1
DRAGANIC, J1
VRANJESEVIC, G1
SERI, I1
KOLUMBAN, K1
BALOGH, Z1
FILLA, E1
COMENALE, D1
ROSSI, F1
BLALOCK, FA3
ENTZ, A1
LARSON, CL1
WICHT, WC1
VULLIEMOZ, P1
FAVEZ, G1
GIUNIO, N1
GROSS, JH1
GOLDHAMMER, EJ1
SMITH, AE1
ASPEVIK, E1
EVENSTAD, E1
HAUKENES, G1
VERWILGHEN, R1
REYBROUCK, G1
COSEMANS, J1
TANNER, E1
MEDINA, G1
CHAPMAN, PT1
SHENNAN, DH2
VANWYCK, PJ1
SCHLESS, JM1
ALLISON, RF1
INGLIS, RM1
WHITE, EF1
TOPPERMAN, S1
BARRAS, G1
VOIGT, H1
WILLROTH, P1
BOESZOERMENYI, M1
FAUSZT, I1
BARAT, I1
SCHWEIGER, O1
KULKA, F1
SCHERER, E1
POSZLER, L1
ROMEO, G1
SCARPA, A1
ZANELLA, A1
KALLOS, Z1
LACZKO, E1
DUBRA, FA1
PALERMO, FM1
NAITO, M1
ROZEWSKA, M1
Chen, QL1
Chen, L1
Yin, JJ1
Yotsumoto, H2
Yonemaru, M1
Suzuki, K1
Kawabe, Y2
Sasaki, Y1
Toyoda, E1
Kudoh, K1
Kurasawa, T2
Ito, M1
Kawashiro, T1
Sakatani, M1
Mori, M1
Pedral-Sampaio, DB2
Netto, EM2
Brites, C2
Bandeira, AC1
Guerra, C1
Barberin, MG1
Badaró, R2
Saito, W1
Nagayama, N1
Miyamoto, M1
Hara, H1
Suzuki, J1
Masuda, K1
Baba, M1
Tamura, A1
Nagai, H1
Akagawa, S1
Machida, K1
Kurashima, A1
Long, R1
Bochar, K1
Chomyc, S1
Talbot, J1
Barrie, J1
Kunimoto, D1
Tilley, P1
Choudhary, J1
Mubarik, M1
Parvez, A1
Naikoo, MA1
Santha, T3
Rehman, F1
Sarma, GR4
Reetha, AM1
Prabhaker, R1
Chan, CK1
Visser, ME1
Texeira-Swiegelaar, C1
Park, SK1
Lee, WC1
Lee, DH1
Han, L1
Seung, KJ2
Gausi, F2
Chimzizi, R1
Salaniponi, FM2
Stout, JE1
Story, RE1
Ditto, AM1
Cox, VC1
Moadebi, S1
Karachunskiĭ, MA3
Uvarova, TE1
Krasnov, VA2
Ursov, IG1
Yepes, JF1
Sullivan, J1
Pinto, A1
Alves, CR1
Oliveira, AS1
Gelmanova, IE1
Peremitin, GG1
Golubchikova, VT1
Pavlova, VE1
Sirotkina, OB1
Yanova, GV1
Strelis, AK1
Suárez-Méndez, R1
García-García, I1
Fernández-Olivera, N1
Valdés-Quintana, M1
Milanés-Virelles, MT1
Carbonell, D1
Machado-Molina, D1
Valenzuela-Silva, CM1
López-Saura, PA1
Lambert, ML1
Delgado, R1
Michaux, G1
Volz, A1
Van der Stuyft, P1
Jutte, PC1
Rutgers, SR1
Uges, DR1
Van Horn, JR1
Perel'man, MI1
Cokolova, GB1
Mozhokina, GN1
Lazareva, IaV2
Strekchev, AIu1
Nakanishi, N1
Moritaka, T1
Ueda, N1
Farah, MG1
Tverdal, A1
Steen, TW1
Heldal, E1
Brantsaeter, AB1
Bjune, G1
Chernykh, NA1
Kaminskaia, GO2
Kossiĭ, IuE1
Tortajada, C1
Martínez-Lacasa, J1
Sánchez, F1
Jiménez-Fuentes, A1
De Souza, ML1
García, JF1
Martínez, JA1
Caylà, JA1
Ige, OM2
Sogaolu, OM1
Odaibo, GN1
Olaleye, OD1
Lobato, MN1
Reves, RR1
Jasmer, RM1
Grabau, JC1
Bock, NN1
Shang, N1
Toyama, T1
Kato, H1
Kobayashi, E1
Kusakabe, A1
Fuziwara, K1
Nemoto, A1
Hayashi, K1
Ogino, M1
Tsuzuki, T1
Tasduq, SA1
Kaisar, P1
Gupta, DK1
Kapahi, BK1
Maheshwari, HS1
Jyotsna, S1
Johri, RK1
Raghavan, A1
Duraipandian, M1
Kripasankar, AS1
Ramachandran, P2
Agerton, TB1
Hopewell, P1
Lockman, S1
Oyewo, A1
Talbot, EA1
Moffat, HJ1
Lu, W1
He, HJ1
Gu, XR1
Zhu, M1
Maslow, JN1
Mikota, SK1
Isaza, R1
Dunker, F1
Riddle, H1
Yano, S1
Kobayashi, K1
Kato, K1
Ikeda, T2
Currie, GP1
Emmanuel, FX1
Ford, D1
Devereux, G1
Schechter, M1
Zajdenverg, R1
Falco, G1
Faulhaber, JC1
Coberly, JS2
Moore, RD1
Vernon, AA1
Freier, G1
Wright, A1
Nelson, G1
Brenner, E1
Mase, S1
Tasker, S1
Matthews, KL1
Bohnker, BK1
Takashima, T1
Danno, K1
Tamura, Y1
Nagai, T1
Matsumoto, T1
Han, Y1
Ano, H1
Yoshida, H1
Kawahara, K1
Tsuyuguchi, I1
Williams, KN2
Moniruzzaman, A1
Schulzer, M1
Jacquet, V1
Morose, W1
Oxlade, O1
Barr, G1
Grimard, F1
Babu, RB1
Sudharshan, S1
Kumarasamy, N1
Therese, L1
Biswas, J1
Brindle, R1
Aarons, LJ1
Wong, HY1
Chau, CH1
Taniguchi, H1
Izumi, S2
Messouak, O1
Amara, B1
Benjelloun, FZ1
Tizniti, S1
Benjelloun, MC1
Belahsen, MF1
Bai, GH1
Park, YK1
Choi, YW1
Bai, JI1
Chang, CL1
Sirmatel, O1
Yazgan, P1
Gursoy, B1
Sirmatel, F1
Zeyrek, FY1
Ozturk, A1
Byrne, ST1
Denkin, SM1
Gu, P1
Ovsiankina, ES1
Gubkina, MF1
Kuz'mina, IK1
Stakheeva, LB1
Borodina, NN1
Zaletina, EIu1
Harada, Y1
Koyama, K1
Yamaryo, T1
Kimura, Y1
P V, K1
Palaian, S1
Ojha, P1
P R, S1
Ida, N1
Yamamoto, K3
Gonda, H1
Oishi, T1
Suganuma, N1
Yamaguchi, I1
Suzuki, R1
Suh, GY1
Chung, MP1
Kwon, OJ1
Lim, SY2
Kam, KM3
Yip, CW1
Ma, CH1
Law, WS1
Sukumar, B1
Iliayas, S1
Kumar, SR1
Triveni, C1
Gomathy, P1
Thomas, B1
Mathew, M1
Narayanan, PR1
Zaka-Ur-Rehman, Z1
Jamshaid, M1
Chaudhry, A1
Cakir, E1
Gocmen, B1
Uyan, ZS1
Oktem, S1
Kiyan, G1
Karakoc, F1
Ersu, R1
Karadag, B1
Dagli, T1
Dagli, E1
Lachowicz, D1
Siekierzyńska, A1
Styszewska, H2
Ramirez, J1
Danan, G1
Pessayre, D1
Larrey, D1
Benhamou, JP1
Carpenter, JL1
Covelli, HD1
Avant, ME1
McAllister, CK1
Higbee, JW1
Ognibene, AJ1
Pretet, S3
Marsac, J1
Choudat, D1
Bollinelli, R1
Flenley, DC1
Kroening, U1
Acocella, G3
Girling, DJ7
Nagasawa, S1
Valenzuela, P4
Valenzuela, MT4
Farga, V3
Yañez, A2
Scheel, G2
Mendoza, F2
Torres, E2
Icekson, I2
Grinspun, M2
Fernández, M3
Tynystanova, RI1
Kozlova, NV1
Cataldi Amatriain, RM1
Rossi Case, E1
Miles, SH1
Maat, RB1
Snider, DE4
Graczyk, J2
Bek, E6
Rogowski, J2
Pilheu, JA3
de Salvo, MC3
Koch, OR2
Arias, RF2
Sjögren, I1
Boman, G2
Löfdahl, CG1
Skoogh, BE1
Nikodemowicz, E2
Kamińska, M2
Caban, M1
Struzik, T1
Acharyulu, GS1
Kannapiran, M2
Murthy, PV1
Gurumurthy, P2
Tripathy, SP6
Kleeberg, HH3
Swart, DJ1
Carey, SM1
Chaulet, P7
Boulahbal, F6
Ait Khaled, N2
El Awadi, Z2
Tazir, M3
Fiala, W1
Häcki, MA1
Brändli, O3
Suzuki, T1
Shimada, M1
Yamaguchi, W1
Kameda, K1
Okamura, S1
Aizawa, H2
Mehrotra, ML3
Gautam, KD3
Chaube, CK2
Khaled, S3
Aber, VR2
Edwards, EA2
Moulding, TS1
Pivet, HT1
Barrios, J1
Lefrock, JL1
Smith, BR1
Miller, SD1
Cohen, CD1
Sayed, AR1
Kirsch, RE1
Gonzalez Montaner, LJ1
Dambrosi, A1
Manassero, M1
Dambrosi, VM1
Sbarbaro, JA2
Stead, WW3
Dutt, AK3
Krishnamurthy, PV2
Garhupati Sarma, G1
Angel, JH3
Escreet, BC2
Cowie, RL5
Long, MW1
Zabow, M1
Pearson, JO3
Schröder, KH1
Müller, U1
Sighart, H3
Opl, G3
Weirich, H1
Ishiguro, S1
Koch, O1
Jenner, PJ1
Ellard, GA4
Allan, WG4
Singh, D1
Burkhardt, KR1
Nel, EE1
Humber, DP1
Nsanzumuhire, H1
Aluoch, JA2
Webster, AD1
Sandblom, RE1
Thummel, KE1
Slattery, JT1
Nelson, SD1
Whalen, C1
Byekwaso, F1
Vjecha, M1
Johnson, J1
Huebner, R3
Mugerwa, R1
Ellner, J1
Walubo, A3
Folb, PI1
Punnotok, J1
Pumprueg, U1
Chakorn, T1
Sedlaczek, AM1
Serwatowski, P1
Spiewak, W1
de Villiers, CL1
Macnab, MF1
Urban, T1
Maquarre, E1
Housset, C1
Chouaid, C1
Devin, E1
Lebeau, B1
Stevens, JP1
Daniel, TM1
Mitinskaia, LA1
Elufimova, VF1
Iukhimenko, NV3
Pogodaeva, NP1
Iavorskiĭ, KM1
Ormerod, LP3
McCarthy, OR2
Rudd, RM2
Horsfield, N3
Ong, EL1
Schrappe, M1
Wassermann, K1
Kroegel, C1
Zent, C1
al-Majed, SA1
Bourke, SJ1
White, J1
Stenton, SC1
Hendrick, DJ1
Arizzi-Rusche, AF1
Geiter, LJ4
O'Brien, RJ4
Yosiyama, T1
Yosikawa, M1
Sugie, T1
Nakasono, T1
Sugita, H2
Dubus, JC1
Piarroux, R1
Panuel, M1
Garnier, JM1
Faure, F1
Devred, P1
Unal, D1
Ekmekçi, A1
Sayli, A1
van der Kooi, K1
Mottet, JJ1
Regamey, C1
Chan, SL4
Wong, PC2
Jones, BE2
Otaya, M1
Antoniskis, D1
Sian, S1
Wang, F1
Mercado, A1
Davidson, PT1
Barnes, PF1
Yamamoto, S1
Sugita, N1
Kino, T1
Hayashi, A1
Vallejo, JG1
Ong, LT2
Starke, JR2
Luo, C1
Chintu, C1
Bhat, G1
Raviglione, M1
Diwan, V1
DuPont, HL1
Zumla, A1
Levée, G1
Glaziou, P1
Chanteau, S1
Seth, V1
Beotra, A1
Seth, SD1
Kabra, S1
Jain, Y1
Mukhopadhya, S1
Robson, SC1
Pillans, P1
Willcox, PA1
Kennedy, N2
Fox, R2
Kisyombe, GM2
Saruni, AO2
Uiso, LO2
Ramsay, AR2
Ngowi, FI2
Potashova, VA1
Zyrianova, TV1
Naryshkina, SL1
Koriakin, VA3
Khalbaeva, IV1
Ziia, AV1
Jain, A1
Mehta, VL1
Kulshrestha, S1
Kamolratanakul, P1
Chunhaswasdikul, B1
Jittinandana, A3
Tangcharoensathien, V1
Udomrati, N1
Akksilp, S1
Datta, M1
Radhamani, MP1
Selvaraj, R1
Paramasivan, CN3
Gopalan, BN1
Sudeendra, CR1
Prabhakar, R2
Luisetti, M1
Grassi, GG1
Peona, V1
Pozzi, E1
Grassi, C1
Chandrasekaran, V1
Sudarsanam, NM1
Atkin, SL1
Masson, EA1
Bodmer, CW1
Walker, BA1
White, MC1
Kassim, S1
Sassan-Morokro, M1
Ackah, A1
Abouya, LY1
Digbeu, H1
Yesso, G1
Coulibaly, IM1
Coulibaly, D1
Whitaker, PJ1
Doorly, R1
Botha, FJ1
Parkin, DP1
van de Wal, BW1
McColloster, P1
Neff, NE1
Berger, L1
Curram, J1
Gutmann, J1
Sam, N1
Tillotson, G1
Yates, M1
Chan, SP1
Birnbaum, J1
Rao, M1
Steiner, P1
Rothe, TB1
Karrer, W2
Miller, MA1
Desjardins, F1
Siddiqi, SH1
Dascal, A1
Roy, V2
Tekur, U2
Chopra, K2
Morris, CD1
Espinal, MA1
Pérez, G1
Camilo, E1
Soto, S1
Cruz, E1
Matos, N1
Gonzalez, G1
Fisher, M1
Tomlinson, DR1
Coker, RJ1
Nitta, AT1
Burman, WJ1
Brudney, KF1
Miranda-Massari, JR1
McGuinness, ME1
Berning, SE1
Gerena, GT1
Schaberg, T2
Rebhan, K1
Lode, H2
Scriven, JM1
Berry, D1
Escobar, MA1
Saravia, NG1
Weigle, KA1
Barakat, MT1
Scott, J1
Hughes, JM1
Walport, M1
Calam, J1
Friedland, JS1
Ind, PW1
McKenna, C1
Gülmez, I1
Keleştimur, F1
Durak, AC1
Ozesmi, M1
Schütte, W1
Berghaus, A1
Schütte, A1
Scorpio, A1
Lindholm-Levy, P1
Heifets, L2
Gilman, R1
Siddiqi, S1
Cynamon, M1
Sreevatsan, S1
Pan, X1
Kreiswirth, BN1
Musser, JM1
Bozóky, G1
Ruby, E1
Góhér, I1
Tóth, J1
Mohos, A1
Ridzon, R1
Meador, J1
Maxwell, R1
Higgins, K1
Weismuller, P1
Onorato, IM1
Fattinger, K1
Braunschweig, S1
Reichen, J1
Meier-Abt, PJ1
Krähenbühl, S1
Knobel, B1
Buyanowsky, G1
Dan, M1
Zaidel, L1
Sánchez-Albisua, I1
Vidal, ML1
Joya-Verde, G1
del Castillo, F1
de José, MI1
García-Hortelano, J1
Kayantao, D1
Keïta, B1
Sangaré, S1
Whalen, CC2
Hom, DL2
Mugyenyi, P1
Ellner, JJ2
Naqvi, A1
Akhtar, F1
Naqvi, R1
Akhtar, S1
Askari, H1
Lal, M1
Bhatti, S1
Shahzad, A1
Soomro, S1
Rizvi, A1
Blanco Ramos, JR1
Rosel Rioja, L1
Dopereiro Gómez, R1
Oteo Revuelta, JA1
Sybrecht, GW1
Yan, S1
Ye, H1
Lin, S1
Erreimi, N1
Hida, M1
Mouane, N1
Bouchta, F1
Michałowska-Mitczuk, D2
Kuś, J2
Jouveshomme, S1
Dautzenberg, B1
Beji, M1
Louzir, B1
Ben Rhomdane, N1
Zouari, M1
Mtimet, B1
Daghfous, J1
Halsey, NA1
Desormeaux, J1
Losikoff, P1
Atkinson, J1
Contave, M1
Johnson, M1
Davis, H1
Johnson, E1
Boulos, R1
Park, IW1
Choi, BW1
Hue, SH1
Rieder, HL4
Wilkinson, D1
Bechan, S1
Standing, E1
Short, GM1
Bai, KJ1
Yu, MC1
Suo, J2
Chiang, IH1
Lin, TP2
Luh, KT1
Kimerling, ME1
Phillips, P1
Patterson, P1
Hall, M1
Robinson, CA1
Dunlap, NE1
Wen, S1
Su, Y1
Zhang, F1
el-Sadr, WM1
Perlman, DC1
Matts, JP1
Nelson, ET1
Cohn, DL2
Salomon, N1
Olibrice, M1
Medard, F1
Chirgwin, KD1
Mildvan, D1
Telzak, EE1
Klein, O1
Hafner, R1
Lam, CW1
Morris, JS1
Mehta, JB1
Mejia, E1
Gallemore, GH1
Ramsey, GF1
Zeenreich, A1
Gochstein, B1
Grinshpoon, A1
Miron, M1
Rosenman, J1
Ben-Dov, I1
Bercion, R1
Koula-Shiro, S1
Radal, M2
Jonville-Bera, AP2
Van-Egroo, C1
Carré, P1
Lemarié, E1
Autret, E2
de Kantor, IN1
Latini, O1
Barrera, L1
Collazos, J2
España, P1
Mayo, J2
Martínez, E2
Izquierdo, F1
Morgan, JR1
Clarke, KW1
Brear, SG1
Tong, FM1
Chow, SK1
Sethna, KB1
Mistry, NF1
Dholakia, Y1
Antia, NH1
Harboe, M1
Mbaye, PS1
Talarmin, F1
Sane, M1
Eladari, D1
Klotz, F1
Goyal, A1
Nagarkar, NM1
Uppal, KS1
Mohan, H1
Dass, A1
Mwinga, A1
Hosp, M1
Godfrey-Faussett, P1
Quigley, M1
Mwaba, P1
Mugala, BN1
Nyirenda, O1
Luo, N1
Pobee, J1
Elliott, AM1
McAdam, KP1
Porter, JD1
Asai, S1
Futsuki, Y1
Tomari, S1
Araki, J1
Simpson, AJ1
Watt, B1
Heald, SH1
Sudlow, MF1
Leitch, AG1
Kistler, A1
Lappin, DW1
Coward, RA1
Iseman, MD1
Teo, SK1
Ikeda, N1
Sato, A1
Nakatani, K1
Yoshimatsu, H1
Olivier, C1
Mazaud, S1
Martel, C1
Ito, K1
Mizutani, S1
Xiao, C1
Li, Z1
Hoashi, S1
Tai, H1
Tamari, M1
O'Reilly, P1
McDonnell, T1
Duchin, JS1
Shields, T1
Sah, SP1
Raj, GA1
Bahadur, T1
Gach, O1
Corhay, JL1
Lousberg, L1
Bartsch, P1
Barker, J1
Makatini, Z1
Millard, J1
Bwire, R1
Borgdorff, MW1
Sticht-Groh, V1
Kawuma, HJ1
Bretzel, G1
Te Water Naude, JM1
Hussey, GD1
Kibel, MA1
Louw, A1
Perkins, DR1
Rao, GP1
Sousa, AO1
Wargnier, A1
Poinsignon, Y1
Simonney, N1
Gerber, F1
Lavergne, F1
Herrmann, JL1
Lagrange, PH1
Pimentel, ML1
Alves, SM1
Novis, SA1
Brandão, RZ1
Belo Neto, E1
Cakir, B1
Yönem, A1
Güler, S1
Odabaşi, E1
Demirbaş, B1
Gürsoy, G1
Aral, Y1
Draper, P1
Zimhony, O1
Cox, JS1
Vilchèze, C1
Jacobs, WR1
Roosihermiatie, B1
Nishiyama, M1
Nakae, K1
Yang, WC1
Chang, IT1
Tsai, BL1
Sharma, AK1
Tolani, SL1
Rathi, GL1
Gupta, HP1
Asano, T1
Kawamoto, H1
Asakuma, J1
Tanimoto, T1
Kobayashi, H1
Hayakawa, M1
Akalin, E1
Chandrakantan, A1
Keane, J1
Hamburger, RJ1
Arnadottir, T1
Yan, B2
Zhu, L2
Khan, MY1
Kinsara, AJ1
Osoba, AO1
Memish, Z1
Bakare, NA1
Onadeko, BO2
Ma, W1
Mayanja, H1
Mutuluuza Kityo, C1
Nsubuga, P1
Nakibali, JG1
Loughlin, AM1
Yun, H1
Mugyenyi, PN1
Vernon, A1
Maurya, V1
Panjabi, C1
Shah, A1
de Maria, A1
Berardi, M1
Dignetti, P1
Ferrera, L1
Viassolo, L1
Canonica, GW1
Suzuki, A1
Tamaru, A1
Katsukawa, C1
Oda, H1
Al-Dossary, FS1
Correa, AG1
Chierakul, N1
Chaiprasert, A1
Tingtoy, N1
Arjratanakul, W1
Pattanakitsakul, SN1
Goodall, RL1
Dosumu, EA1
Ndiaye, M1
Hane, AA1
Dieng, MT1
Ndir, M1
Ba, O1
Cissokho, S1
Kandji, M1
Diatta, A1
Niang, A1
Ndiaye, B1
Meyburg, J1
Schmidt, KG1
Nützenadel, W1
Bettendorf, M1
Medinger, A1
Gned'ko, NI1
Krüüner, A1
Pehme, L1
Ghebremichael, S1
Koivula, T1
Hoffner, SE1
Mikelsaar, M1
Pregowski, W2
Rossouw, JE1
Saunders, SJ1
Clarke, PD1
Kalich, R1
Gerloff, W1
Neubert, R1
Ulber, H1
Mamolat, AS1
Bialik, IB2
Khutorskaia, VD1
Horsfall, PA3
Plummer, J1
Aquinas, M1
Perdrizet, S1
Eule, H2
Promisloff, RA1
Johnston, RF3
Korotaev, GA2
Kozulitsyna, TM1
Utkin, VV4
Bravo, TC1
Parthasarathy, R2
Sambamoorthy, S2
Somasundaram, PR3
Subbammal, S4
Hinshaw, HC1
Iatsozhinskiĭ, IuD1
Kulik, NM1
Molotkov, VN1
Petrenko, VM1
Shkol'nyi, LK1
Dahlström, G1
Hanngren, A1
Stavenow, S1
Wiman, LG1
Treece, GL1
Magnussen, CR1
Patterson, JR1
Tschudy, DP1
Kislitsyna, NA1
Kotova, NI1
Kwan, SY1
Wolde, K1
Lema, E1
Roscigno, G1
Abdi, A1
Kumaresan, JA1
Maganu, ET1
Abbo, AW1
Kortekaas, JC1
Singhal, KC1
Varshney, MK1
Laguna, F1
Adrados, M1
Díaz, F1
Martínez, R1
García Aguado, C1
Puente, S1
González Lahoz, JM1
Wiesner, B1
Cramer, G1
Hamel, U1
Roth, G1
Small, PM1
Schecter, GF1
Goodman, PC1
Sande, MA1
Dickinson, JM1
del Castillo Martín, F1
Calvo Rey, C1
Vidal López, ML1
del Cerro, MJ1
García Hortelano, J1
Chan, K3
Woo, J3
Chan, HS2
Wong, CL2
Narang, NK1
Meratwal, S1
Jain, D1
Rac, VV1
Gupta, EV1
Thomas, IM1
Catlin, BJ1
Peterson, KL1
Judson, FN1
Agounitestane, D1
Chiheb, M1
Nowak, D2
Radenbach, D2
Magnussen, H2
Balasubramanian, R1
Sivasubramanian, S2
Ramachandran, R1
Jawahar, MS1
Selvakumar, N1
Combs, DL2
Brink, BA1
Campbell, IA1
Neill, P1
Pringle, D1
Mhonda, M1
Kusema, T1
Nhachi, CF1
Onishchenko, VV1
Shapatava, MN1
Iurchenko, LN1
Morland, L1
Dhand, R1
Singhi, PD1
Rao, KL1
Katariya, S1
Savula, MM1
Smolenko, MI1
Romaniuk, MD1
Slivka, IuI1
Musch, E1
Loos, U1
Schwabe, HK1
Roden, S1
Lagneau, M1
Homasson, JP1
Kecharanandana, P1
Payanandana, W1
Daramas, M1
Ladron de Guevara, R1
Bellabas, M1
Khaled, NA1
Haegi, V1
Villiger, B1
Bohn, W1
Baumann, HR1
Zäch, R1
Porokhnia, VV1
Khomenko, VV1
Petrovich, DI1
Iusukhno, EE1
Skvira, VP1
Felten, MK1
Schilling, W1
Schnorr, R1
Landmann, H1
Sanwikarja, S1
Kauffmann, RH1
te Velde, J1
Serlie, J1
le Bourgeois, M1
de Blic, J1
Paupe, J1
Scheinmann, P1
Ellis, ME1
Tayoub, F1
Steele, MA1
Des Prez, RM1
Babu Swai, O1
Thiong'o, R1
Darbyshire, JH2
Hong, YP1
Kim, SC1
Chang, SC1
Jin, BW1
Park, CD1
Zaman, R1
Orakzai, SA1
Yunus, A1
Xu, RX1
Baba, H2
Shinkai, A2
Izuchi, R2
Azuma, Y2
Trivedi, SS1
Desai, SG1
Schwartz, MS1
Kahlstrom, EJ1
Hawkins, DB1
Lecoeur, H1
Stamatakis, G1
Montes, C1
Trouvin, JH1
Farinotti, R1
Fessi, H1
Kenouch, S1
Méry, JP1
Mignot, P1
Dumas, R1
Lavarenne, J1
Molina, C1
Lacroix, C1
Guyonnaud, C1
Chaou, M1
Duwoos, H1
Lafont, O1
Jain, VK1
Vardhan, H1
Prakash, OM1
Goldberger, MJ1
Schell, G1
Lagos, A1
Nuñez, A1
Soto, R1
Araya, D1
Lee, CN1
Lee, JJ1
Yang, SP1
Szymański, A2
Czaplińska-Jóźwiak, E1
Leung, A1
Lai, KN1
Teoh, R1
Spychalski, W1
Grzegorzewska, A1
Westfal, I1
Herlevsen, P1
Nielsen, C1
Pedersen, JT1
Farer, LS1
Beck, H1
Evers, H1
Fischer, P1
Kwiatkowski, H1
Merkel, S1
Reech, R1
Sieler, R1
Thomas, E1
Weinecke, W1
Awotedu, AA1
Ogunbanjo, BO1
Aderinto, EB1
Dong, SQ1
Corsello, BF1
Jonker, R1
Kopeć, H1
Maternowska, W1
Prus, F1
Sembratowicz, L1
Berkani, M1
Summers, RS1
Crewe-Brown, HH1
Glatthaar, E1
McCutcheon, JP1
Layer, P1
Engelhard, M1
Janardhanam, B2
Mukerjee, CM1
McKenzie, DK1
Sandron, D1
Marin, I1
Huchon, G1
Ganter, B1
Baron, RB1
Sanchez-Hernandez, M1
Röthlisberger, K1
Bezel, R1
Häcki, M1
Rubin, S1
Blanco Quirós, A1
Mazouni, L1
Kecharananta, P1
Rattarasarn, S1
Sriyabhaya, N1
Langton, ME2
Krivinka, R1
Wilson, TM1
Schütz, I1
Radenbach, KL1
Bartmann, K1
Virchow, C1
Flemming, J1
De ville de Goyet, CA1
Pätiälä, J1
Trnka, L1
Karuga, WK1
Dingley, HB1
Pande, DC1
Grover, KL1
Wildrick, KH1
Bartal, M1
Nejjar, A1
Laraki, A1
Rushchak, VA1
Gartmann, JC1
Jancikova-Máková, M1
Bayliss, CG1
Steiner, M1
Grumbach, F1
Iaschenko, BP1
Steininger, WJ1
Stýblo, K1
Kubík, A1
Langerová, M1
Matusková, E1
Morávková, K1
Kochnowski, G1
Malinowska, B1
Pawlak, F1
Jesiotr, M1
Crofton, J1
Lester, W2
Mital, OP1
Agarwala, MC1
Singh, SK2
Heise, A1
Blaha, H1
Reimann, B1
Vanasin, B1
Colmer, M1
Davis, PJ1
Neumann, G1
Sirota, DS1
Man'kovetskiĭ, EF1
Koĭfman, SG1
Vatsyk, MZ1
Beckert, W2
Gomi, J1
Aoyagi, T1
Doster, B1
Murray, FJ1
Newman, R1
Woolpert, SF1
Sasaoka, M1
Kawamori, Y1
Kakuno, J1
Whitcomb, ME1
Rocklin, RE1
Stańczuk-Holub, A1
Muranda, M1
Del Solar, JA1
Jorquera, C1
Saavedra, L1
Pemjean, I1
Greene, ME1
Stonehill, RB1
Tauchnitz, C1
Storch, W1
Ellorhaoui, M1
Stradling, P1
Onisk, J1
Radecki, A2
Kanwiszer, H1
Krzanowska, E1
Donderowicz, A1
Zacara, A1
Woźniak, S1
Bignall, JR2
De March Ayuela, P1
Turell Gumá, J1
Böszörményi, M3
Feldmann, FM2
Lambert, HP1
Nair, NG1
Radhakrishna, S1
Rudoĭ, NM1
Fedorova, IE1
Afanas'eva, IuP1
Schaich, W1
Sunahara, S1
Lind, A2
Rist, N2
Stepanenko, VA1
Marr, JJ1
Yamamoto, M1
Isoe, K1
Fuse, M1
Selkon, JB1
Walton, M1
White, AB1
Matzel, W1
Lindemann, I1
Anastasatu, C1
Ulpian, C1
Weiss, P1
Susteric, J1
Vidinel, I1
Ozgen, ZS1
Hokama, S1
Krishnamurthy, DV2
Venkataraman, P1
Dissmann, E1
Foster-Carter, AF1
Rizzo, A1
Magalhães, M1
Moura, N1
Kolosovskaia, VP1
Lees, AW1
Tyrrell, WF1
Smith, J1
Allan, GW1
Grymiński, J1
Lyczewska, J1
Walczak, J1
Mkrtchian, SV1
Egorkina, ND1
Zachara, A3
Lukaszczyk, E1
Ignasiak, J1
Urbancik, B1
Antonijević, A1
Pannain, M1
Tarantino, AB1
Mac Dowell, A1
Costa, JA1
Cunha, JM1
Pantoja, W1
Ivanova, ES1
Komarova, AA1
Vasilik, GV2
Kaminskaia, AA1
Golitsina, LV1
Fegiz, G1
Organick, AB1
Wilson, EM1
Ropek, M1
Chetkowski, A1
Tarocińska, B1
Novák, M1
Jancíková, M1
Krátký, J1
Feitová, S1
Bukalska, Z1
Pickroth, G1
Kataria, YP1
Gajewska, E1
Petera, V1
Klapálek, D1
Paichl, P1
Pecený, A1
Grunert, M1
Reutgen, H1
Iwainsky, H1
McCurdy, PR1
Donohoe, RF1
Magovern, M1

Clinical Trials (47)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.[NCT03988933]Phase 21,368 participants (Actual)Interventional2019-09-20Active, not recruiting
Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.[NCT00760149]Phase 2150 participants (Actual)Interventional2010-07-31Completed
A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis[NCT02836483]Phase 279 participants (Actual)Interventional2016-12-10Completed
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin to 3 Months After Culture Conversion (Hi-DoRi-3): A Phase 3, Multicenter, Randomized, Open-label, Clinical Trial[NCT04485156]Phase 3926 participants (Anticipated)Interventional2020-09-30Not yet recruiting
A Phase 2 Dose-ranging Trial to Evaluate the Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Linezolid in Adult Subjects With Newly Diagnosed Drug-Sensitive, Smear-Positive Pulmonary Tuberculosis.[NCT02279875]Phase 2113 participants (Actual)Interventional2014-11-30Completed
Electronic Pillbox-enabled Self-administered Therapy Versus Standard Directly Observed Therapy for Tuberculosis Medication Adherence and Treatment Outcomes in Ethiopia: a Multicenter Randomized Controlled Trial[NCT04216420]114 participants (Actual)Interventional2020-06-01Completed
Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults[NCT01782950]Phase 4400 participants (Anticipated)Interventional2013-02-28Recruiting
Substitution of Ethambutol With Linezolid During the Intensive Phase of Treatment of Pulmonary Tuberculosis: A Prospective, Multicenter, Randomized, Open-label Phase II Trial[NCT01994460]Phase 2429 participants (Anticipated)Interventional2014-01-31Recruiting
A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis[NCT00216385]Phase 32,070 participants Interventional2005-01-31Recruiting
Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for the Treatment of Patients With Fluoroquinolone-sensitive MDR-TB: A Phase 2/3, Multicenter, Randomized, Open-label, Clinical Trial[NCT02619994]Phase 2238 participants (Anticipated)Interventional2016-01-31Recruiting
A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744]Phase 2112 participants (Anticipated)Interventional2021-08-03Recruiting
Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451]Phase 1/Phase 2120 participants (Actual)Interventional2020-07-27Completed
Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery[NCT00816426]Phase 119 participants (Actual)Interventional2008-12-29Completed
A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678]Phase 240 participants (Anticipated)Interventional2021-12-07Recruiting
A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277]Phase 2130 participants (Actual)Interventional2019-04-30Completed
Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811]625 participants (Anticipated)Observational2020-01-30Recruiting
A Randomized Clinical Trial of Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa[NCT04618198]Phase 3436 participants (Anticipated)Interventional2021-12-10Recruiting
A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening[NCT00864383]Phase 31,931 participants (Actual)Interventional2008-01-31Completed
Using Biomarkers to Predict TB Treatment Duration[NCT02821832]Phase 2946 participants (Actual)Interventional2017-06-21Active, not recruiting
A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis[NCT04187469]286 participants (Anticipated)Interventional2020-03-01Not yet recruiting
Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy: Comparison of 8 Weeks Standard Therapy (Rifampicin Plus Clarithromycin) vs. 4 Weeks Standard Plus Amoxicillin/Clavulanate Therapy [RC8 vs. RCA4][NCT05169554]Phase 2140 participants (Anticipated)Interventional2021-12-01Recruiting
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis[NCT05575518]Phase 3414 participants (Anticipated)Interventional2023-08-11Recruiting
Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Idiopathic Infantile Hypercalcemia[NCT03384121]Phase 15 participants (Anticipated)Interventional2018-02-22Recruiting
A Phase IIA Dose Ranging Trial to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Higher Doses of Rifampicin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis[NCT01392911]Phase 2128 participants (Anticipated)Interventional2011-06-30Completed
A Phase II Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 8 Weeks of Treatment in Adult Patients With Newly Diagnosed Drug-Sensitive or Multi D[NCT01498419]Phase 2207 participants (Actual)Interventional2012-03-31Completed
Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial[NCT00640887]Phase 248 participants (Anticipated)Interventional2009-02-28Completed
Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)[NCT01637558]Phase 4200 participants (Actual)Interventional2012-11-30Completed
A Phase II Randomized, Open-label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis[NCT00728507]Phase 2121 participants (Actual)Interventional2009-11-30Terminated (stopped due to Funding withdrawn)
A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis[NCT01785186]Phase 2365 participants (Actual)Interventional2013-04-30Completed
A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177]Phase 496 participants (Actual)Interventional2013-01-31Completed
TBTC Study 31 PK/PD: Population Pharmacokinetic and Pharmacodynamic Study of Efficacy and Safety of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis in the Study 31 Treatment Trial: Intensive PK Sampling[NCT02563327]Phase 360 participants (Anticipated)Interventional2016-05-30Recruiting
Phase 2 Randomized Trial of a Moxifloxacin-Containing Regimen For Treatment of Smear-Positive Pulmonary Tuberculosis in Adults With and Without HIV Infection[NCT00082173]Phase 2170 participants (Actual)Interventional2004-10-31Completed
DNA Sequencing of MDR TB in Eastern Siberia[NCT02508610]630 participants (Anticipated)Observational2013-11-30Recruiting
A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of An[NCT00130247]Phase 3394 participants (Actual)Interventional2002-04-08Completed
Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment[NCT01724723]Phase 450 participants (Anticipated)Interventional2012-12-31Not yet recruiting
International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatm[NCT00216333]Phase 41,500 participants Interventional2003-12-31Recruiting
A Phase II Dose Ranging Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of PA-824 in Adult Participants With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis[NCT00944021]Phase 269 participants (Actual)Interventional2009-08-31Completed
Early Bactericidal Activity of Standard Drugs Used to Treat Mycobacterium Avium Complex: a Pilot Study[NCT04287049]Phase 230 participants (Anticipated)Interventional2020-02-24Recruiting
A Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Alone, TMC207 Plus Pyrazinamide,TMC207 Plus PA-824,PA-824 Plus Pyrazinamide and PA-824 Plus Pyrazinamide and Moxifloxacin, in Adult Patients Wit[NCT01215851]Phase 285 participants (Actual)Interventional2010-10-31Completed
NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis[NCT02371681]Phase 2262 participants (Actual)Interventional2015-02-25Completed
A Phase 2 Randomized, Open-label Trial of Daily Rifapentine 450mg or 600mg in Place of Rifampicin 600mg for Intensive Phase Treatment of Smear-positive Pulmonary Tuberculosis[NCT00814671]Phase 2153 participants (Actual)Interventional2010-04-30Completed
Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012]Phase 3300 participants (Actual)Interventional2001-02-28Active, not recruiting
Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons[NCT00351702]Phase 3650 participants (Actual)Interventional2001-02-28Completed
URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299]Phase 4302 participants (Actual)Interventional2017-04-07Completed
TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789]555 participants (Actual)Interventional2020-11-17Active, not recruiting
The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033]Phase 3650 participants InterventionalCompleted
Efficacy of Simultaneous Versus Sequential Antiretroviral Therapy and Antituberculosis Treatment in Patients With AIDS and Active Tuberculosis. Open, Randomized and Controlled, Multisite Clinical Trial.[NCT00737724]63 participants (Actual)Interventional2008-03-31Terminated (stopped due to Other published trials showed definitive expected superiority of Group 1)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Combined Failure of Bacteriological Cure and Relapse as Defined by Culture Using Liquid Media (Mycobacteria Growth Indicator Tube-MGIT).

The secondary analysis of efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome) based on MGIT. Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)

Interventionparticipants with failure or relapse (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)65
Regimen 2 - 2MHRZ/2MHR98
Regimen 3 - 2EMRZ/2MR131

Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ).

The primary efficacy outcome was the proportion of patients who had bacteriologically or clinically defined failure or relapse within 18 months after randomization (a composite unfavorable outcome). Culture-negative status was defined as two negative-culture results at different visits without an intervening positive result. The date of culture-negative status was defined as the date of the first negative-culture result. This status continued until there were two positive cultures, without an intervening negative culture, or until there was a single positive culture that was not followed by two negative cultures. Relapse strains were those shown to be identical on 24-locus Mycobacterial interspersed repetitive units (MIRU) analysis. For the final 18 month study visit when both L-J samples were contaminated or missing, if the subject could not be brought back, liquid medium culture results were used in place of solid medium culture results. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)

Interventionparticipants with failure or relapse (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)43
Regimen 2 - 2MHRZ/2MHR78
Regimen 3 - 2EMRZ/2MR105

Number of Patients Who Are Culture Negative (Liquid MGIT Culture)

Number of patients who are TB MGIT culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks

Interventionparticipants who are culture negative (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)235
Regimen 2 - 2MHRZ/2MHR274
Regimen 3 - 2EMRZ/2MR260

Number of Patients Who Are Culture Negative (Solid LJ Culture)

Number of patients who are TB LJ culture negative at 8 weeks. (NCT00864383)
Timeframe: 8 weeks

Interventionparticipants who are culture negative (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)352
Regimen 2 - 2MHRZ/2MHR394
Regimen 3 - 2EMRZ/2MR401

Number of Patients With Grade 3 or 4 Adverse Events (Using a Modified Division of Acquired Immunodeficiency Syndrome National Institute of Allergy and Infectious Diseases [DAIDS] Scale of Adverse Event Reporting)

The number of participants includes all patients who had at least one grade 3 or 4 adverse event. (NCT00864383)
Timeframe: 18 months (within one year of completion of therapy)

Interventionparticipants with Grade 3 or 4 AEs (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)123
Regimen 2 - 2MHRZ/2MHR127
Regimen 3 - 2EMRZ/2MR111

Sensitivity Analyses Assuming All Losses to Follow-up and Non-tuberculous Deaths Have a Favourable Outcome Using Solid (L-J) Media.

"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Favorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months

Interventionparticipants with unfavorable outcome (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)87
Regimen 2 - 2MHRZ/2MHR132
Regimen 3 - 2EMRZ/2MR132

Sensitivity Analysis Assuming All Losses to Follow-up and Non-tuberculous Deaths Have an Unfavorable Outcome Using Solid (L-J) Media.

"Sensitivity Analysis of Primary Efficacy Results of All Randomized Subjects Imputing Unfavorable for Missing Outcomes. Analysis is the number of subjects with an unfavorable outcome. Favorable outcome is defined as the number of subjects with a negative TB culture status at 18 months (at or after 72 weeks), who had not already been classified as having an unfavorable outcome, and whose last positive TB culture result (isolated positive culture) was followed by at least two negative culture results." (NCT00864383)
Timeframe: 18 months

Interventionparticipants with unfavorable outcome (Number)
Regimen 1 - 2EHRZ/4HR (Control Regimen)172
Regimen 2 - 2MHRZ/2MHR219
Regimen 3 - 2EMRZ/2MR217

Time to First Culture Negative Sputum Sample (LJ Solid Media)

Culture negative for TB using LJ cultures. (NCT00864383)
Timeframe: 18 months

InterventionTime to culture negative status / weeks (Median)
Regimen 1 - 2EHRZ/4HR (Control Regimen)6.0
Regimen 2 - 2MHRZ/2MHR6.0
Regimen 3 - 2EMRZ/2MR6.0

Time to First Culture Negative Sputum Sample (MGIT Liquid Media)

(NCT00864383)
Timeframe: 18 months

InterventionTime to culture negative status / weeks (Median)
Regimen 1 - 2EHRZ/4HR (Control Regimen)11.9
Regimen 2 - 2MHRZ/2MHR8.0
Regimen 3 - 2EMRZ/2MR8.0

Comparison of the Rate of Treatment Success at 18 Months (After Treatment Initiation) Between Arms B and C

Estimation of the lower bound of a one-sided 95% confidence interval of the difference in success rates between arms B and C. If the lower bound is greater than -7%, this will be evidence that the treatment-shortening arm is not inferior to the standard duration arm. (NCT02821832)
Timeframe: 18 months

,,
InterventionParticipants (Count of Participants)
CuredConfirmed relapsesLate withdrawal, lost to follow-upProbable relapsesTreatment Failure
Arm A21751311
Arm B1211910
Arm C1179634

Percentage of Participants Who Discontinue Due to an Adverse Event in Each Experimental Arm.

(NCT01498419)
Timeframe: 8 weeks

Interventionpercentage of participants (Number)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)13
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)19
Drug Sensitive: Rifafour12
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)12

Percentage of Patients With Sputum Culture Conversion at 8 Weeks on Liquid Media

Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB. This was measured at visit 24(Day 57). (NCT01498419)
Timeframe: Day 57 after eight weeks of daily treatment

Interventionpercentage of patients (Number)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)65.7
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)71.4
Drug Sensitive: Rifafour37.8
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)50.0

Percentage of Patients With Sputum Culture Conversion at 8 Weeks on Solid Media

Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB. (Day 57) (NCT01498419)
Timeframe: Day 57 after eight weeks of daily treatment

Interventionpercentage of participants (Number)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)82.9
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)94.3
Drug Sensitive: Rifafour87.5
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)62.5

The Rate of Change in Colony Forming Units (CFUs) Using Non-linear Mixed Effects Modeling of the Serial Sputum Colony Counts (SSCC) Over 8 Weeks of Treatment.

The primary efficacy endpoint was bactericidal activity characterized by the daily rate of change in mean log10CFU counts during 8 weeks of treatment (bactericidal activity assessed by CFU on solid media for days 0-56). (NCT01498419)
Timeframe: 8 weeks

Interventionlog10CFU/ml/day (Mean)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)0.133
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)0.155
Drug Sensitive: Rifafour0.112
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)0.117

The Rate of Change in Time to Sputum Culture Positivity (TTP) Through 8 Weeks in the MGIT System in Sputum Over 8 Weeks in Participants as Derived From a Non-linear Regression Model.

Measurement of TTP in liquid culture media Mycobacteria growth indicator tube (MGIT) using standard procedures (NCT01498419)
Timeframe: 8 weeks

Interventionlog10hours/day (Mean)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)0.020
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)0.020
Drug Sensitive: Rifafour0.017
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)0.015

Time to Sputum Conversion Using Data From Weekly Cultures Through 8 Weeks on Liquid Media

liquid culture = Mycobacteria growth indicator tube (MGIT) Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB (NCT01498419)
Timeframe: 8 weeks

Interventiondays (Median)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)42.0
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)49.0
Drug Sensitive: Rifafour56.0
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)56.0

Time to Sputum Conversion Using Data From Weekly Cultures Through 8 Weeks on Solid Media

Sputum culture conversion is defined as a change from a positive growth of M. tuberculosis in a sputum sample to negative M. tuberculosis growth sputum sample in patients with pulmonary TB (NCT01498419)
Timeframe: 8 weeks

Interventiondays (Median)
Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)28.0
Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)28.0
Drug Sensitive: Rifafour35.0
Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)35.0

To Compare, by Treatment Group, the Percentage of Patients With a Negative Sputum Culture at the End of Intensive Phase Therapy.

LJ culture conversion (NCT00728507)
Timeframe: Week 8

Interventionpercentage of participants (Number)
HPZM78.3
HRZE84.3

Pharmacokinetics Including AUC, Cl, t1/2, Vd, and Protein Binding

"Pharmacokinetic parameters will be assessed for rifampicin, moxifloxacin and SQ109:~area under the plasma concentration curve from dosing to the end of the dosing interval (AUC 0-24) (in h*ng/mL)~the observed maximum concentration (Cmax( (in ng/mL)~time to reach Cmax (Tmax)(in hours)~the minimum observed plasma concentration 24 hours following the last dose (Cmin) (in hours),~clearance (Cl) (in mL/minute),~volume of distribution (Vd) (in L),~elimination half-life (T1/2,) (in hours)~free (protein-unbound) fraction (for rifampicin only) (in percent)." (NCT01785186)
Timeframe: 0 - 12 weeks

InterventionRifampicin AUC(mg*h/l) (Geometric Mean)
HRZQ17.4
Arm 1 (R35)170
HR20ZQ68.3
HR20ZM57.8
HRZE24.2

Sputum Culture Conversion (2 Negative Cultures) Using Liquid Media

From enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media. (NCT01785186)
Timeframe: 0 - 12 weeks

Interventiondays (Median)
Arm 1 (R35)48
HRZQ63
HR20ZQ66
HR20ZM55
HRZE62

Frequency of Adverse Events

All Adverse Events (AE), and AEs considered to be drug-related will coded using standard AE dictionaries. (NCT01785186)
Timeframe: 0 - 12 weeks

,,,,
Interventionparticipants (Number)
Number of Patients with at least 1 AENumber of patients with at least 1 SAE
Arm 1 (R35)534
HR20ZM494
HR20ZQ425
HRZE926
HRZQ494

Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications

Proportion of patients with Grade 3 or 4 adverse reactions attributable to study medications (NCT00082173)
Timeframe: 8 weeks

InterventionParticipants (Number)
Experimental Arm0
Control Arm0

Proportion of Patients With Sterile Sputum Cultures

Proportion of patients with sterile sputum cultures (NCT00082173)
Timeframe: 8 weeks

InterventionParticipants (Number)
Experimental Arm59
Control Arm45

Acquired Drug Resistance in Patients Who Relapsed

(NCT00130247)
Timeframe: 2 years

InterventionParticipants (Number)
4-Month Arm0
6-Month Arm0

Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-TB Treatment - Per-protocol

Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment. (NCT00130247)
Timeframe: 30 months

InterventionParticipants (Number)
4-Month Arm13
6-Month Arm3

Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat

Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment. (NCT00130247)
Timeframe: 30 months

InterventionParticipants (Number)
4-Month Arm13
6-Month Arm3

Relapses at 1 and 2 Years

(NCT00130247)
Timeframe: 1 and 2 years after successful completion of initial anti-TB treatment

,
InterventionParticipants (Number)
Relapses at 1 yearRelapses at 2 years
4-Month Arm1013
6-Month Arm33

Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Intention to Treat

A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence. (NCT00130247)
Timeframe: 2 years

,
InterventionParticipants (Number)
Treatment FailuresRelapses
4-Month Arm013
6-Month Arm03

Treatment Failures or Relapses at 2 Years After Completion of TB Treatment: Per Protocol

A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence. (NCT00130247)
Timeframe: 2 years

,
InterventionParticipants (Number)
Treatment FailuresRelapses
4-Month Arm013
6-Month Arm03

Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).

(NCT00944021)
Timeframe: 14 consecutive days of treatment

Interventionlog10CFU/ml/day (Mean)
PA-824 50 mg/qd0.063
PA-824 100mg/qd0.091
PA-824 150mg/qd0.078
PA-824 200mg/qd0.112
Rifafour e-275mg0.177

Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-2).

(NCT00944021)
Timeframe: Two consecutive days of treatment

Interventionlog10CFU/ml/day (Mean)
PA-824 50 mg/qd0.093
PA-824 100mg/qd0.111
PA-824 150mg/qd-0.009
PA-824 200mg/qd0.160
Rifafour e-275mg0.470

Early Bactericidal Activity (EBA) Measured as the Mean Rate of Reduction of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 2-14).

(NCT00944021)
Timeframe: Days 2-14 of 14 consecutive days of treatment

Interventionlog10CFU/ml/day (Mean)
PA-824 50 mg/qd0.059
PA-824 100mg/qd0.088
PA-824 150mg/qd0.096
PA-824 200mg/qd0.104
Rifafour e-275mg0.128

Pharmacokinetics- Area Under the Plasma Concentration Time Curve From Zero to Infinity (AUC 0 to Infinity) (Day 1).

(NCT00944021)
Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment

Interventionng * hour/mL (Mean)
PA-824 50 mg/qd11923.94
PA-824 100mg/qd18408.59
PA-824 150mg/qd28654.83
PA-824 200mg/qd38485.04

Pharmacokinetics- Maximum Observed Plasma Concentration (Cmax) (Day 1).

(NCT00944021)
Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment

Interventionng/mL (Mean)
PA-824 50 mg/qd465.3
PA-824 100mg/qd662.3
PA-824 150mg/qd994.7
PA-824 200mg/qd1183.0

Pharmacokinetics- Terminal Elimination Phase Half-life (t1/2) (Day 1).

(NCT00944021)
Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, and 24 hours post-dose on Day 1 of treatment

Interventionhours (Mean)
PA-824 50 mg/qd16.142
PA-824 100mg/qd18.597
PA-824 150mg/qd19.005
PA-824 200mg/qd21.092

Pharmacokinetics- Terminal Elimination Phase Half-life (t1/2) (Day 14).

(NCT00944021)
Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 24 and 30 hours post-dose on Day 14 of 14 consecutive days of treatment

Interventionhour (Mean)
PA-824 50 mg/qd18.645
PA-824 100mg/qd19.274
PA-824 150mg/qd20.207
PA-824 200mg/qd23.811

Pharmacokinetics-Maximum Observed Plasma Concentration (Cmax) (Day 14).

(NCT00944021)
Timeframe: 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12,16, 24, and 30 hours post-dose on Day 14 of 14 consecutive days of treatment

Interventionng/mL (Mean)
PA-824 50 mg/qd777.3
PA-824 100mg/qd1116.5
PA-824 150mg/qd1543.9
PA-824 200mg/qd2223.8

Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-14).

(NCT00944021)
Timeframe: Fourteen consecutive days of treatment

Interventionhours/day (Mean)
PA-824 50 mg/qd2.621
PA-824 100mg/qd4.969
PA-824 150mg/qd4.633
PA-824 200mg/qd4.640
Rifafour e-275mg13.364

Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-2).

(NCT00944021)
Timeframe: Two consecutive days of treatment

Interventionhours/day (Mean)
PA-824 50 mg/qd1.483
PA-824 100mg/qd-1.345
PA-824 150mg/qd4.867
PA-824 200mg/qd3.096
Rifafour e-275mg37.016

Rate of Change in Increased Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 2-14).

(NCT00944021)
Timeframe: Days 2-14 of 14 consecutive days of treatment

Interventionhours/day (Mean)
PA-824 50 mg/qd2.958
PA-824 100mg/qd5.744
PA-824 150mg/qd4.594
PA-824 200mg/qd5.391
Rifafour e-275mg9.422

Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).

Log10 CFU rates of change were calculated for each individual patient from the slopes β1 and β2 of the bi-linear regression fitted to the data for each individual patient (log10CFU versus Day). Mean log10 CFU changes from baseline were compared. A higher slope value indicates a greater change in log10 CFU from baseline. Note that to facilitate interpretation the sign of these slopes are reversed for logCFU. A positive slope value therefore indicates a reduction in log10 CFU from baseline. (NCT01215851)
Timeframe: 14 consecutive days of treatment

Interventionlog10CFU/ml/day (Mean)
TMC2070.061
TMC207 and Pyrazinamide0.131
PA-824 and Pyrazinamide0.154
PA-824 and Moxifloxacin and Pyrazinamide0.233
Rifafour e-275 mg0.140
TMC207 and PA-8240.114

Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-2).

Log10 CFU rates of change were calculated for each individual patient from the slopes β1 and β2 of the bi-linear regression fitted to the data for each individual patient (log10CFU versus Day). Mean log10 CFU changes from baseline were compared. A higher slope value indicates a greater change in log10 CFU from baseline. Note that to facilitate interpretation the sign of these slopes are reversed for logCFU. A positive slope value therefore indicates a reduction in log10 CFU from baseline. (NCT01215851)
Timeframe: Day 0-2

Interventionlog10CFU/ml/day (Mean)
TMC207-0.022
TMC207 and Pyrazinamide0.079
PA-824 and Pyrazinamide0.170
PA-824 and Moxifloxacin and Pyrazinamide0.315
Rifafour e-275 mg0.177
TMC207 and PA-8240.114

Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 2-14).

Log10 CFU rates of change were calculated for each individual patient from the slopes β1 and β2 of the bi-linear regression fitted to the data for each individual patient (log10CFU versus Day). Mean log10 CFU changes from baseline were compared. A higher slope value indicates a greater change in log10 CFU from baseline. Note that to facilitate interpretation the sign of these slopes are reversed for logCFU. A positive slope value therefore indicates a reduction in log10 CFU from baseline. (NCT01215851)
Timeframe: Day 2-14

Interventionlog10CFU/ml/day (Mean)
TMC2070.076
TMC207 and Pyrazinamide0.143
PA-824 and Pyrazinamide0.148
PA-824 and Moxifloxacin and Pyrazinamide0.222
Rifafour e-275 mg0.135
TMC207 and PA-8240.114

Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 7-14).

Log10 CFU rates of change were calculated for each individual patient from the slopes β1 and β2 of the bi-linear regression fitted to the data for each individual patient (log10CFU versus Day). Mean log10 CFU changes from baseline were compared. A higher slope value indicates a greater change in log10 CFU from baseline. Note that to facilitate interpretation the sign of these slopes are reversed for logCFU. A positive slope value therefore indicates a reduction in log10 CFU from baseline. (NCT01215851)
Timeframe: Day 7-14

Interventionlog10CFU/ml/day (Mean)
TMC2070.123
TMC207 and Pyrazinamide0.152
PA-824 and Pyrazinamide0.124
PA-824 and Moxifloxacin and Pyrazinamide0.175
Rifafour e-275 mg0.136
TMC207 and PA-8240.114

Rate of Change in Time to Sputum Culture Positivity (TTP)(Hours) in Liquid Culture Media (Days 0-14)

The TTP was measured in the Mycobacterial Growth Indicator Tube (MGIT) (Bactec MGIT960) automated liquid culture system from overnight sputum. TTP rates of change were calculated for each individual patient from the slopes β1 and β2 of the bi-linear regression fitted to the data for each individual patient (TTP versus Day). (NCT01215851)
Timeframe: 14 Days

Interventiontime (h) to positive per day (Mean)
TMC2075.414
TMC207 and Pyrazinamide9.970
PA-824 and Pyrazinamide8.805
PA-824 and Moxifloxacin and Pyrazinamide18.482
Rifafour e-275 mg11.841
TMC207 and PA-8245.855

Percentage of Participants With Negative Lowenstein Jensen Cultures at Week 8

(NCT00814671)
Timeframe: 8 weeks

Interventionpercentage of participants w/LJ cx con (Number)
RPT45085
RIF 60094
RPT 60096

Pharmacokinetics of Rifapentine

area under the concentration time curve (AUC[0-24]) for rifapentine administered once daily at doses of 450 mg or 600 mg in the context of multi drug intensive phase TB treatment (NCT00814671)
Timeframe: 8 weeks

Interventionug x h/ml (Median)
Rifapentine 450 mg330
Rifapentine 600 mg435

Time to Stable Culture Conversion on Liquid MGIT Media

Time (in days) to stable culture conversion on liquid MGIT media (NCT00814671)
Timeframe: 12 weeks

Interventiondays (Median)
RPT45050
RIF 60059
RPT 60057

Time to Stable Culture Conversion on Solid Medium

Time to stable culture conversion (in days) on Lowenstein Jensen solid medium (NCT00814671)
Timeframe: 12 weeks

Interventiondays (Median)
RPT45037
RIF 60043
RPT 60036

Tolerability

percentage of participants discontinuing assigned treatment (NCT00814671)
Timeframe: 10 weeks

Interventionpercentage of participants (Number)
RPT4502.0
RIF 6008.3
RPT 6002.0

Cumulative Incidence of Participants Experiencing a Grade 3/4 Hepatotoxicity

Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

Interventionpercent (Number)
INH and Vitamin B68.3

Number of Participants Who Discontinued Treatment

Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

InterventionParticipants (Count of Participants)
INH and Vitamin B632

Number of Participants With Alanine Transaminase (ALT) or Aspartate Transaminase (AST) Elevations at Study Screening

Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit

InterventionParticipants (Count of Participants)
Study Screening80

Number of Participants With Latent Tuberculosis at Study Screening.

Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit

InterventionParticipants (Count of Participants)
Study Screening308

INH Concentration in Hair: (INH Pmol + Acetyl INH Pmol) Per mg of Hair

INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation

Interventionpmol/mg (Median)
at 3 monthsat 6 months
INH and Vitamin B636.037.8

Percentage of Participants With Suboptimal INH Medication Adherence

Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)

Interventionpercentage of participants (Number)
at 3 monthsat 6 months
INH and Vitamin B631.343.9

Self-reported INH Medication Adherence: Number of Days Taking INH in the Past 30 Days

"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH

Interventiondays (Median)
at 3 monthsat 6 months
INH and Vitamin B63030

Self-reported INH Medication Adherence by the Self Rating Single Item (SRSI) Scale

The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH

InterventionParticipants (Count of Participants)
At 3 months72558043At 6 months72558043
ExcellentVery goodGoodFairPoorVery poor
INH and Vitamin B6160
INH and Vitamin B679
INH and Vitamin B638
INH and Vitamin B62
INH and Vitamin B6124
INH and Vitamin B690
INH and Vitamin B641
INH and Vitamin B64
INH and Vitamin B60
INH and Vitamin B61

Reviews

51 reviews available for pyrazinamide and Pulmonary Consumption

ArticleYear
Tuberculosis treatment in children: The changing landscape.
    Paediatric respiratory reviews, 2020, Volume: 36

    Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Humans; Is

2020
Multiple tuberculomas in an immunocompetent patient and their diagnostic challenge in a high prevalence country: Case report and literature review.
    The Indian journal of tuberculosis, 2020, Volume: 67, Issue:3

    Topics: Antitubercular Agents; Blindness; Brain; Brain Diseases; Cerebellar Ataxia; Dexamethasone; Drug Ther

2020
Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB.
    Current HIV/AIDS reports, 2020, Volume: 17, Issue:6

    Topics: Anti-HIV Agents; Antitubercular Agents; Drug Interactions; Extensively Drug-Resistant Tuberculosis;

2020
The Biology and Epidemiology of Mycobacterium africanum.
    Advances in experimental medicine and biology, 2017, Volume: 1019

    Topics: Africa, Western; Animals; Antitubercular Agents; Bacterial Typing Techniques; Genetic Variation; Gen

2017
Severe disseminated tuberculosis in HIV-negative refugees.
    The Lancet. Infectious diseases, 2019, Volume: 19, Issue:10

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Ethambutol; Fluorine Radioisotopes; HIV Infections;

2019
PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.
    Expert opinion on investigational drugs, 2013, Volume: 22, Issue:7

    Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Drug Res

2013
Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Follow-Up Studies; Humans; Meta-Analysis as Topic; Microbiological Techniques; Mycobacterium tubercu

2013
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
    Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:6

    Topics: Antitubercular Agents; Diabetes Mellitus; Drug Monitoring; Ethambutol; HIV Infections; Humans; Isoni

2014
Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.
    Expert review of anti-infective therapy, 2015, Volume: 13, Issue:5

    Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Niacinamide; Pyrazinamide; Tuberculosis,

2015
Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Fluoroquinolones; Humans

2015
Clinical research in the treatment of tuberculosis: current status and future prospects.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:12

    Topics: Antitubercular Agents; Biomedical Research; Clinical Trials as Topic; Drug Therapy, Combination; Flu

2015
Tuberculosis and silicosis: epidemiology, diagnosis and chemoprophylaxis.
    Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2008, Volume: 34, Issue:11

    Topics: Antibiotics, Antitubercular; Brazil; Humans; Isoniazid; Occupational Exposure; Pyrazinamide; Rifampi

2008
Efforts towards the development of new antitubercular agents: potential for thiolactomycin based compounds.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2008, Sep-09, Volume: 11, Issue:2

    Topics: Animals; Antitubercular Agents; Drug Design; Ethambutol; Isoniazid; Microbial Sensitivity Tests; Mol

2008
The near future: improving the activity of rifamycins and pyrazinamide.
    Tuberculosis (Edinburgh, Scotland), 2010, Volume: 90, Issue:3

    Topics: Administration, Inhalation; Antitubercular Agents; Area Under Curve; Biological Availability; Dosage

2010
Bronchiectatic air bronchograms in pulmonary tuberculosis: a case report and literature review.
    Military medicine, 2010, Volume: 175, Issue:5

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Bronchiectasis; Bronchoalveolar Lavage; Bronchos

2010
Pyrazinamide pharmacokinetics and efficacy in adults and children.
    Tuberculosis (Edinburgh, Scotland), 2012, Volume: 92, Issue:1

    Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Child; Child, Preschool; Dose-Response R

2012
Unilateral and painless development of isoniazid induced gynecomastia during re-treatment of pulmonary tuberculosis.
    The Journal of the Association of Physicians of India, 2011, Volume: 59

    Topics: Adolescent; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Gyn

2011
Molecular biology of drug resistance in Mycobacterium tuberculosis.
    Current topics in microbiology and immunology, 2013, Volume: 374

    Topics: Antitubercular Agents; Biological Transport; Biotransformation; Drug Resistance, Multiple, Bacterial

2013
Leprosy and tuberculosis co-infection: clinical and immunological report of two cases and review of the literature.
    The American journal of tropical medicine and hygiene, 2013, Volume: 88, Issue:2

    Topics: Adult; Brazil; Coinfection; Female; Humans; Immunity, Cellular; Interferon-gamma; Interleukin-12; Is

2013
Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Expert opinion on drug safety, 2004, Volume: 3, Issue:3

    Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination

2004
[The present state of short course chemotherapy including pyrazinamide in Japan].
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2004, Volume: 42, Issue:6

    Topics: Antitubercular Agents; Humans; Japan; Pyrazinamide; Tuberculosis, Pulmonary

2004
[A case of fulminant hepatic failure associated with pyrazinamide in a woman with hypoalbuminemia].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2005, Volume: 102, Issue:5

    Topics: Antitubercular Agents; Female; Humans; Hypoalbuminemia; Liver Failure; Middle Aged; Pyrazinamide; Tu

2005
Advances in the treatment of tuberculosis.
    Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5

    Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Ag

2007
New drugs in respiratory disorders: II.
    British medical journal (Clinical research ed.), 1983, Mar-19, Volume: 286, Issue:6369

    Topics: Adult; Aged; Amantadine; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Cephalosporins;

1983
Treatment of tuberculosis. The Mitchell lecture 1979.
    Journal of the Royal College of Physicians of London, 1980, Volume: 14, Issue:2

    Topics: Animals; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Thera

1980
Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance?
    The American review of respiratory disease, 1981, Volume: 123, Issue:3

    Topics: Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, Combination; Ethionamide

1981
Bacteriologic basis of short-course chemotherapy for tuberculosis.
    Clinics in chest medicine, 1980, Volume: 1, Issue:2

    Topics: Animals; Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Guinea Pigs;

1980
[Pharmacology, toxicology and clinical use of pyrazinamide (author's transl)].
    Praxis und Klinik der Pneumologie, 1981, Volume: 35, Issue:12

    Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; H

1981
Tuberculosis.
    The Medical clinics of North America, 1980, Volume: 64, Issue:3

    Topics: Alcohol Drinking; Carrier State; Chemical and Drug Induced Liver Injury; Ethambutol; Humans; Isoniaz

1980
What's new in tuberculosis?
    The American journal of medicine, 1981, Volume: 71, Issue:1

    Topics: Aged; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isonia

1981
Whither short-course chemotherapy?
    British journal of diseases of the chest, 1981, Volume: 75, Issue:4

    Topics: Animals; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Humans

1981
Outpatient management of tuberculosis.
    American family physician, 1996, Volume: 53, Issue:5

    Topics: Algorithms; Ambulatory Care; Antitubercular Agents; Drug Administration Schedule; Drug Interactions;

1996
[Pyrazinamide-containing initial intensive short course chemotherapy of pulmonary tuberculosis].
    Kekkaku : [Tuberculosis], 1997, Volume: 72, Issue:10

    Topics: Aged; Aged, 80 and over; Antitubercular Agents; Humans; Liver; Pyrazinamide; Risk Factors; Tuberculo

1997
[Antitubercular chemotherapy].
    Revue des maladies respiratoires, 1997, Volume: 14 Suppl 5

    Topics: Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Protocols; Drug

1997
[Short-course chemotherapy of tuberculosis with pyrazinamide].
    Nihon rinsho. Japanese journal of clinical medicine, 1998, Volume: 56, Issue:12

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Humans

1998
[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Kekkaku : [Tuberculosis], 2001, Volume: 76, Issue:1

    Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; E

2001
[Sharp syndrome complicating pulmonary tuberculosis: apropos of a case].
    Dakar medical, 1999, Volume: 44, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Antibodies, Antinuclear; Antitubercular Agents; Autoimmune Diseases;

1999
Advances in the treatment of tuberculosis.
    Journal of the Royal Naval Medical Service, 1976,Summer, Volume: 62, Issue:2

    Topics: Aminosalicylic Acids; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Pyrazinamide

1976
The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
    Tubercle, 1978, Volume: 59, Issue:1

    Topics: Acetylation; Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Top

1978
[Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1991, Volume: 46, Issue:8

    Topics: Biological Availability; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber

1991
The role of pyrazinamide in tuberculosis chemotherapy.
    Chest, 1988, Volume: 94, Issue:4

    Topics: Humans; Pyrazinamide; Tuberculosis, Pulmonary

1988
Antituberculosis agents.
    The Medical clinics of North America, 1988, Volume: 72, Issue:3

    Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol

1988
[Treatment of pleuropulmonary tuberculosis in 1985].
    Annales de medecine interne, 1985, Volume: 136, Issue:1

    Topics: Aminoglycosides; Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Thioa

1985
[Results of chemotherapy in tuberculosis].
    Pneumonologie. Pneumonology, 1971, Volume: 145

    Topics: Ambulatory Care; Anti-Bacterial Agents; Antitubercular Agents; Drug Synergism; Ethambutol; Ethionami

1971
General considerations in intermittent drug therapy of pulmonary tuberculosis.
    Postgraduate medical journal, 1971, Volume: 47, Issue:553

    Topics: Aminosalicylic Acids; Antitubercular Agents; Clinical Trials as Topic; Ethambutol; Ethionamide; Huma

1971
The impact of chemotherapy on the care of patients with tuberculosis.
    The American review of respiratory disease, 1974, Volume: 109, Issue:6

    Topics: Antitubercular Agents; Aspirin; Bacteriological Techniques; BCG Vaccine; Drug Therapy, Combination;

1974
Newer and second-line drugs in the treatment of drug-resistant tuberculosis in children.
    The Medical clinics of North America, 1967, Volume: 51, Issue:5

    Topics: Anti-Bacterial Agents; Antitubercular Agents; Child, Preschool; Cycloserine; Drug Resistance, Microb

1967
[Chemotherapeutic studies on advanced tuberculosis in mice].
    Bibliotheca tuberculosea, 1965, Volume: 21

    Topics: Aminosalicylic Acids; Animals; Antitubercular Agents; Drug Resistance, Microbial; Drug Synergism; Et

1965
Tuberculosis in Hong Kong ten years later.
    Tubercle, 1973, Volume: 54, Issue:3

    Topics: Aminosalicylic Acids; BCG Vaccine; Child, Preschool; China; Cycloserine; Drug Resistance, Microbial;

1973
[Results of 2 or 3 secondary drug combinations in the retreatment of chronic pulmonary tuberculosis].
    Revista clinica espanola, 1968, Apr-30, Volume: 109, Issue:2

    Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Cycloserine; Drug Synergism; Ethambutol;

1968
Chemotherapy of pulmonary tuberculosis.
    Annals of internal medicine, 1969, Volume: 70, Issue:2

    Topics: Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Hospitalization

1969

Trials

208 trials available for pyrazinamide and Pulmonary Consumption

ArticleYear
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biological

2007
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biological

2007
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biological

2007
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biological

2007
Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.
    Antimicrobial agents and chemotherapy, 2022, 02-15, Volume: 66, Issue:2

    Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Middle Aged; Mycob

2022
Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial.
    Trials, 2022, Aug-17, Volume: 23, Issue:1

    Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Multicenter Studies as Topic; P

2022
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
    American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7

    Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazin

2023
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
    American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7

    Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazin

2023
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
    American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7

    Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazin

2023
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
    American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7

    Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazin

2023
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
    The New England journal of medicine, 2023, Mar-09, Volume: 388, Issue:10

    Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Et

2023
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
    BMC pulmonary medicine, 2019, Aug-14, Volume: 19, Issue:1

    Topics: Adult; Antitubercular Agents; Ethambutol; Female; HIV Seropositivity; Humans; Incidence; Isoniazid;

2019
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
    Antimicrobial agents and chemotherapy, 2020, 03-24, Volume: 64, Issue:4

    Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Line

2020
Telacebec (Q203), a New Antituberculosis Agent.
    The New England journal of medicine, 2020, 03-26, Volume: 382, Issue:13

    Topics: Administration, Oral; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Combina

2020
Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
    Trials, 2020, May-05, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cost-Benefit Analysis; Directly Observed Therapy; El

2020
Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial.
    Pulmonary pharmacology & therapeutics, 2021, Volume: 70

    Topics: Dry Powder Inhalers; Humans; Isoniazid; Levofloxacin; Powders; Pyrazinamide; Rifampin; Tuberculosis,

2021
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:11

    Topics: Adult; Antibiotics, Antitubercular; Dose-Response Relationship, Drug; Double-Blind Method; Drug Ther

2017
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:11

    Topics: Adult; Antibiotics, Antitubercular; Dose-Response Relationship, Drug; Double-Blind Method; Drug Ther

2017
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:11

    Topics: Adult; Antibiotics, Antitubercular; Dose-Response Relationship, Drug; Double-Blind Method; Drug Ther

2017
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:11

    Topics: Adult; Antibiotics, Antitubercular; Dose-Response Relationship, Drug; Double-Blind Method; Drug Ther

2017
Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.
    International journal of immunopathology and pharmacology, 2017, Volume: 30, Issue:4

    Topics: Adult; Antitubercular Agents; Asian People; Chemical and Drug Induced Liver Injury; Drug Therapy, Co

2017
Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.
    EBioMedicine, 2017, Volume: 25

    Topics: Adult; Aged; Antitubercular Agents; Biomarkers; Drug Combinations; Ethambutol; Female; Humans; Isoni

2017
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
    The Lancet. Infectious diseases, 2019, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Substitution; Drug Therapy, Combination;

2019
Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 11-28, Volume: 67, Issue:suppl_3

    Topics: Adolescent; Adult; Antitubercular Agents; Artificial Intelligence; Dose-Response Relationship, Drug;

2018
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m
    Trials, 2019, Jan-16, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical

2019
Efficacy and safety of cholecalciferol-augmented anti-tuberculosis therapy for treatment of naïve patients with pulmonary tuberculosis: A randomized, controlled, clinical study.
    The Indian journal of tuberculosis, 2019, Volume: 66, Issue:1

    Topics: Adult; Antitubercular Agents; Cholecalciferol; Drug Therapy, Combination; Egypt; Ethambutol; Female;

2019
Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
    BMJ open, 2019, 03-01, Volume: 9, Issue:3

    Topics: Adult; Antibiotics, Antitubercular; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans

2019
Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
    BMJ open, 2019, 03-01, Volume: 9, Issue:3

    Topics: Adult; Antibiotics, Antitubercular; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans

2019
Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
    BMJ open, 2019, 03-01, Volume: 9, Issue:3

    Topics: Adult; Antibiotics, Antitubercular; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans

2019
Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
    BMJ open, 2019, 03-01, Volume: 9, Issue:3

    Topics: Adult; Antibiotics, Antitubercular; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans

2019
Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019, Volume: 25, Issue:12

    Topics: Age Factors; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug

2019
Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:9

    Topics: Adult; Antitubercular Agents; Area Under Curve; Coinfection; Drug Administration Schedule; Drug Dosa

2013
Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2013, Volume: 17, Issue:10

    Topics: Adult; Antitubercular Agents; Biomarkers; CD4 Lymphocyte Count; Coinfection; Dietary Supplements; Dr

2013
The pyrazinamide susceptibility breakpoint above which combination therapy fails.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:9

    Topics: Adolescent; Adult; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Fem

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combi

2014
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.
    Trials, 2014, Sep-09, Volume: 15

    Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Dr

2014
Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:10

    Topics: Africa; Antitubercular Agents; Asia; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol

2014
A four-month gatifloxacin-containing regimen for treating tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination

2014
A four-month gatifloxacin-containing regimen for treating tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination

2014
A four-month gatifloxacin-containing regimen for treating tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination

2014
A four-month gatifloxacin-containing regimen for treating tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Antitubercular Agents; Blood Glucose; Drug Administration Schedule; Drug Therapy, Combination

2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, C

2014
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
    American journal of respiratory and critical care medicine, 2015, May-01, Volume: 191, Issue:9

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Bacterial Load; Drug Dosage Calculations; Drug Thera

2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul
    Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979

    Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethamb

2015
Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:7

    Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; F

2015
Effects on type 2 diabetes complicated with pulmonary tuberculosis: regiment of insulin, isoniazid, rifampicin, pyrazinamide and ethambutol versus the regiment plus Qi-boosting and Yin-nourishing decoction of Traditional Chinese Medicine.
    Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2015, Volume: 35, Issue:3

    Topics: Adult; Aged; Antitubercular Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drugs, Chi

2015
Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Coinfection; Ethambutol; Femal

2016
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.
    PloS one, 2015, Volume: 10, Issue:10

    Topics: Adult; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male; Pyrazinamide; Tanzania; T

2015
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:4

    Topics: Anti-Bacterial Agents; Area Under Curve; Coinfection; Drug Dosage Calculations; Ethambutol; Female;

2016
A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, Volume: 20, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Ethambutol; Female

2016
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
    PloS one, 2016, Volume: 11, Issue:5

    Topics: Adult; Antitubercular Agents; Case-Control Studies; Drug Therapy, Combination; Female; Fluoroquinolo

2016
Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial.
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Adult; Africa; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Administration Sc

2016
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1

    Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; E

2017
[Relapse rate of pulmonary tuberculosis within two years following completion of twice weekly intermittent chemotherapy].
    Kekkaku : [Tuberculosis], 2008, Volume: 83, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Directly Observed Therapy; Drug Administratio

2008
Pyrazinamide serum levels in childhood tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2008, Volume: 12, Issue:9

    Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Humans; Infan

2008
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670

    Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedu

2009
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670

    Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedu

2009
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670

    Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedu

2009
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670

    Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedu

2009
Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2009, Volume: 13, Issue:6

    Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Female; Huma

2009
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.
    American journal of respiratory and critical care medicine, 2009, Sep-15, Volume: 180, Issue:6

    Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; F

2009
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.
    American journal of respiratory and critical care medicine, 2009, Sep-15, Volume: 180, Issue:6

    Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; F

2009
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.
    American journal of respiratory and critical care medicine, 2009, Sep-15, Volume: 180, Issue:6

    Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; F

2009
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.
    American journal of respiratory and critical care medicine, 2009, Sep-15, Volume: 180, Issue:6

    Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; F

2009
Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:10

    Topics: Acetylcysteine; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Inju

2010
Assessment of protective role of polyherbal preparation, Livina, against anti-tubercular drug induced liver dysfunction.
    Indian journal of experimental biology, 2010, Volume: 48, Issue:3

    Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Chemica

2010
Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial.
    JAMA, 2011, Apr-13, Volume: 305, Issue:14

    Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Male

2011
Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2011, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Drug Combinations; Drug

2011
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12

    Topics: Antitubercular Agents; Area Under Curve; Child, Preschool; Coinfection; Female; HIV Infections; Huma

2011
Phase II dose-ranging trial of the early bactericidal activity of PA-824.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; Humans;

2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Lancet (London, England), 2012, Sep-15, Volume: 380, Issue:9846

    Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind

2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Lancet (London, England), 2012, Sep-15, Volume: 380, Issue:9846

    Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind

2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Lancet (London, England), 2012, Sep-15, Volume: 380, Issue:9846

    Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind

2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Lancet (London, England), 2012, Sep-15, Volume: 380, Issue:9846

    Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind

2012
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Antiviral therapy, 2013, Volume: 18, Issue:1

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Deoxyc

2013
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:2

    Topics: Antimalarials; Bacterial Load; Bacteriological Techniques; Diagnostic Techniques, Respiratory System

2013
Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2002, Volume: 6, Issue:11

    Topics: Adult; Antitubercular Agents; Drug Combinations; Female; Humans; Isoniazid; Male; Mycobacterium tube

2002
Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2002, Volume: 6, Issue:12

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule;

2002
Comparative evaluation of efficacy and safety profile of three anti-tuberculous regimens in Mangalore.
    Indian journal of medical sciences, 2002, Volume: 56, Issue:7

    Topics: Adult; Antitubercular Agents; Dizziness; Drug Therapy, Combination; Ethambutol; Female; Follow-Up St

2002
The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2003, Volume: 7, Issue:6

    Topics: Adult; Aged; Antitubercular Agents; Bronchodilator Agents; Drug Interactions; Drug Therapy, Combinat

2003
Use of Rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2003, Volume: 7, Issue:4

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Antitubercular Agents; Double-Blind Method; Female; Granu

2003
[Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis].
    Problemy tuberkuleza i boleznei legkikh, 2003, Issue:11

    Topics: Adolescent; Adult; Drug Combinations; Ethambutol; Female; Humans; Isoniazid; Male; Middle Aged; Myco

2003
Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
    Tropical medicine & international health : TM & IH, 2004, Volume: 9, Issue:5

    Topics: Adult; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Fem

2004
The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2004, Volume: 8, Issue:2

    Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; HIV Infections; Humans; Isoniaz

2004
Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study.
    BMC infectious diseases, 2004, Oct-22, Volume: 4

    Topics: Adjuvants, Immunologic; Adult; Amikacin; Antitubercular Agents; Ciprofloxacin; Drug Resistance, Bact

2004
Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2004, Volume: 8, Issue:11

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Male; Microbial Sensitivi

2004
[Optimization of tuberculosis complex chemotherapy with the use of moxifloxacin].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2004, Volume: 49, Issue:6

    Topics: Adolescent; Adult; Animals; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female;

2004
Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2005, Volume: 9, Issue:3

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Child; Child, Preschool; Dose-Response Relationship,

2005
Evaluation of modified short course chemotherapy in active pulmonary tuberculosis patients with human immunodeficiency virus infection in University College Hospital, Ibadan, Nigeria--a preliminary report.
    African journal of medicine and medical sciences, 2004, Volume: 33, Issue:3

    Topics: Acne Vulgaris; Adolescent; Adult; Age Distribution; Aged; Antitubercular Agents; Drug Therapy, Combi

2004
Short-course chemotherapy for paediatric respiratory tuberculosis: 5-year report.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2005, Volume: 9, Issue:6

    Topics: Antitubercular Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combinat

2005
[Randomized control study on domestic fixed-dose combinations in the initial treatment of smears positive tuberculosis].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2004, Volume: 27, Issue:10

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Protocols; Drug Therapy, Combination; Femal

2004
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    American journal of respiratory and critical care medicine, 2006, Apr-15, Volume: 173, Issue:8

    Topics: Adult; Antitubercular Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combi

2006
Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis.
    The Indian journal of tuberculosis, 2007, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacte

2007
Nutritional status of persons with HIV infection, persons with HIV infection and tuberculosis, and HIV-negative individuals from southern India.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Mar-15, Volume: 46, Issue:6

    Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antitubercular Agents; Body Composition; Drug

2008
Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients.
    Pakistan journal of pharmaceutical sciences, 2008, Volume: 21, Issue:2

    Topics: Adolescent; Adult; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Monitoring; Drug Th

2008
Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study.
    Tubercle, 1980, Volume: 61, Issue:2

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Clinical Trials as Topic; Drug Administration Schedu

1980
Comparison of a conventional and an initial 2-month intensive drug regimen for treating pulmonary tuberculosis in Swaziland.
    Tubercle, 1984, Volume: 65, Issue:2

    Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy,

1984
Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India.
    Tubercle, 1983, Volume: 64, Issue:2

    Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistanc

1983
Controlled clinical trial of 4 short-couse regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis.
    Tubercle, 1983, Volume: 64, Issue:3

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu

1983
[Short-term chemotherapy of tuberculosis. Cooperative French trial].
    Revue francaise des maladies respiratoires, 1983, Volume: 11, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination;

1983
Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study.
    The American review of respiratory disease, 1984, Volume: 129, Issue:6

    Topics: Adolescent; Adult; Algeria; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Sch

1984
A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society.
    British journal of diseases of the chest, 1984, Volume: 78, Issue:4

    Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combina

1984
[A comparison of PZA and EB in short course chemotherapy. Report of the 22nd series of controlled trial of chemotherapy].
    Kekkaku : [Tuberculosis], 1984, Volume: 59, Issue:11

    Topics: Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Humans; Middle Aged; M

1984
Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.
    The American review of respiratory disease, 1984, Volume: 130, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Evaluation Studies as Top

1984
[Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study].
    Schweizerische medizinische Wochenschrift, 1983, Dec-24, Volume: 113, Issue:51

    Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Humans;

1983
A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association.
    The American review of respiratory disease, 1982, Volume: 126, Issue:3

    Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combina

1982
[Short-term chemotherapy of pulmonary tuberculosis. Bacteriologic results].
    Archives de l'Institut Pasteur d'Algerie. Institut Pasteur d'Algerie, 1980, Volume: 54

    Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Humans; Isoniazi

1980
[Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
    Kekkaku : [Tuberculosis], 1980, Volume: 55, Issue:1

    Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy,

1980
Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study.
    Tubercle, 1980, Volume: 61, Issue:1

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Tri

1980
Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.
    The American review of respiratory disease, 1981, Volume: 123, Issue:2

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu

1981
Pyrazinamide deamidase activity in tuberculous disease.
    The American review of respiratory disease, 1981, Volume: 124, Issue:1

    Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Evaluation; Humans; Pyrazinamide; Random Alloc

1981
A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association.
    British journal of diseases of the chest, 1981, Volume: 75, Issue:2

    Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Female; Humans;

1981
Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months.
    Tubercle, 1981, Volume: 62, Issue:2

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu

1981
BTA short-course chemotherapy studies.
    Chest, 1981, Volume: 80, Issue:6

    Topics: Clinical Trials as Topic; Ethambutol; Female; Hepatitis; Humans; Isoniazid; Liver Function Tests; Ma

1981
A study of the characteristics and course of sputum smear-negative pulmonary tuberculosis.
    Tubercle, 1981, Volume: 62, Issue:3

    Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combi

1981
Short-course chemotherapy for pulmonary tuberculosis. A 100-day interrupted regimen.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1981, Dec-19, Volume: 60, Issue:25

    Topics: Adult; Antibiotics, Antitubercular; Clinical Trials as Topic; Drug Administration Schedule; Drug Com

1981
Chemotherapy for tuberculosis today.
    The American review of respiratory disease, 1982, Volume: 125, Issue:3 Pt 2

    Topics: Antitubercular Agents; Clinical Trials as Topic; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifamp

1982
[Comparative study of the treatment of pulmonary tuberculosis with isoprodian and pyrazinamide as well as isoprodian and rifampicin].
    Wiener medizinische Wochenschrift (1946), 1982, Nov-30, Volume: 132, Issue:22

    Topics: Adult; Aged; Antitubercular Agents; Dapsone; Drug Combinations; Drug Therapy, Combination; Humans; I

1982
[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose].
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1995, Volume: 76, Issue:5

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Drug Tol

1995
Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University-Case Western University Research Collaboration.
    Lancet (London, England), 1994, Nov-12, Volume: 344, Issue:8933

    Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Drug Eruptions; Drug Hypersensitivity; Dru

1994
A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1995, Volume: 78, Issue:6

    Topics: Adolescent; Adult; Antitubercular Agents; Drug Combinations; Female; Follow-Up Studies; Humans; Ison

1995
[Analysis of course and treatment results after treatment of pulmonary tuberculosis with early introduction of interrupted observation--preliminary report].
    Pneumonologia i alergologia polska, 1995, Volume: 63, Issue:5-6

    Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, C

1995
[Contemporary methods in the diagnosis and treatment of intrathoracic tuberculosis in children].
    Problemy tuberkuleza, 1994, Issue:6

    Topics: Administration, Oral; Child; Child, Preschool; Drug Therapy, Combination; Ethambutol; Follow-Up Stud

1994
Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1995, Volume: 76, Issue:2

    Topics: Adolescent; Adult; Biological Availability; Cross-Over Studies; Dietary Carbohydrates; Dietary Fats;

1995
[Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood--a pilot project].
    Pneumologie (Stuttgart, Germany), 1994, Volume: 48, Issue:10

    Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Thera

1994
[Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
    Kekkaku : [Tuberculosis], 1994, Volume: 69, Issue:11

    Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Male; Mid

1994
A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection.
    American journal of respiratory and critical care medicine, 1994, Volume: 150, Issue:6 Pt 1

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Etha

1994
Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.
    The American review of respiratory disease, 1993, Volume: 148, Issue:6 Pt 1

    Topics: Adult; Aged; Ciprofloxacin; Drug Therapy, Combination; Ethambutol; Female; HIV Seropositivity; HIV-1

1993
[Combined chemotherapy of patients with tuberculosis - new regimens and dosage forms].
    Problemy tuberkuleza, 1993, Issue:5

    Topics: Antitubercular Agents; Dosage Forms; Drug Administration Schedule; Drug Combinations; Drug Therapy,

1993
Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1993, Volume: 74, Issue:2

    Topics: Adult; Anti-Bacterial Agents; Drug Interactions; Drug Therapy, Combination; Humans; Male; Middle Age

1993
Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 1993, Volume: 48, Issue:3

    Topics: Adult; Biological Availability; Capsules; Drug Administration Schedule; Drug Combinations; Half-Life

1993
Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa.
    AIDS (London, England), 1995, Volume: 9, Issue:10

    Topics: Adolescent; Adult; Africa, Western; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercul

1995
Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1996, Volume: 22, Issue:5

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Ciproflo

1996
Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Indian pediatrics, 1996, Volume: 33, Issue:4

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Dose-Response Relationship, Drug; Drug Th

1996
A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1996, Volume: 86, Issue:8

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Black People; Body Weight; Drug Administration Sched

1996
Low antituberculosis drug concentrations in patients with AIDS.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:9

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona

1996
Low antituberculosis drug concentrations in patients with AIDS.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:9

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona

1996
Low antituberculosis drug concentrations in patients with AIDS.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:9

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona

1996
Low antituberculosis drug concentrations in patients with AIDS.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:9

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona

1996
Low antituberculosis drug concentrations in patients with AIDS.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:9

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona

1996
Low antituberculosis drug concentrations in patients with AIDS.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:9

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona

1996
Low antituberculosis drug concentrations in patients with AIDS.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:9

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona

1996
Low antituberculosis drug concentrations in patients with AIDS.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:9

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona

1996
Low antituberculosis drug concentrations in patients with AIDS.
    The Annals of pharmacotherapy, 1996, Volume: 30, Issue:9

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona

1996
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
    The New England journal of medicine, 1997, Sep-18, Volume: 337, Issue:12

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema

1997
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
    The New England journal of medicine, 1997, Sep-18, Volume: 337, Issue:12

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema

1997
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
    The New England journal of medicine, 1997, Sep-18, Volume: 337, Issue:12

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema

1997
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
    The New England journal of medicine, 1997, Sep-18, Volume: 337, Issue:12

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema

1997
A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1997, Volume: 1, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antitubercular Agents; Child; Drug Administration Sch

1997
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
    Lancet (London, England), 1998, Mar-14, Volume: 351, Issue:9105

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; F

1998
Prospective study of corticosteroid as an adjunct in the treatment of endobronchial tuberculosis in adults.
    Respirology (Carlton, Vic.), 1997, Volume: 2, Issue:4

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Bronchoscopy; Chi-Square Distribution; Drug Therapy,

1997
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1998, Volume: 26, Issue:5

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D

1998
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1998, Volume: 26, Issue:5

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D

1998
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1998, Volume: 26, Issue:5

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D

1998
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1998, Volume: 26, Issue:5

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; D

1998
Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report.
    American journal of respiratory and critical care medicine, 1998, Volume: 157, Issue:6 Pt 1

    Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; F

1998
[Lomefloxacin in complex treatment of acute progressive form of pulmonary tuberculosis].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1998, Volume: 43, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Animals; Anti-Infective Agents; Antibiotics, Antitubercular; Antit

1998
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.
    AIDS (London, England), 1998, Dec-24, Volume: 12, Issue:18

    Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antibiotics, Antitubercular; A

1998
[Long-term efficacy of full course intermittent short-course chemotherapy on new smear positive tuberculosis patients].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 1997, Volume: 20, Issue:3

    Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Follow-Up Studies; Humans; Isoniazid;

1997
Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1999, Volume: 3, Issue:2

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Combinations; Follow-Up Studies; Humans; I

1999
[Hyperuricemia and arthralgia during pyrazinamide treatment].
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 1999, Volume: 37, Issue:2

    Topics: Antitubercular Agents; Arthralgia; Drug Administration Schedule; Humans; Pyrazinamide; Retrospective

1999
Twice weekly vs. daily chemotherapy for childhood tuberculosis.
    The Pediatric infectious disease journal, 2000, Volume: 19, Issue:5

    Topics: Antitubercular Agents; Child, Preschool; Drug Administration Schedule; Female; Humans; Infant; Isoni

2000
[Controlled clinical trial on efficacy of 5-month regimens and whole course intermittent 6-month regimens in treating bacillary pulmonary tuberculosis].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 1998, Volume: 21, Issue:7

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; H

1998
Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report.
    African journal of medicine and medical sciences, 2000, Volume: 29, Issue:1

    Topics: Adolescent; Adult; Antitubercular Agents; Developing Countries; Drug Administration Schedule; Drug T

2000
[Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 1998, Volume: 21, Issue:11

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid

1998
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
    AIDS (London, England), 2001, Nov-09, Volume: 15, Issue:16

    Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combi

2001
Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy.
    The Pediatric infectious disease journal, 2002, Volume: 21, Issue:2

    Topics: Adolescent; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool; Directly Ob

2002
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2002, Volume: 6, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Chil

2002
Side-effects of drugs used in directly observed treatment short-course in newly diagnosed pulmonary tuberculosis subjects in Nigerians: a controlled clinical study.
    The Nigerian postgraduate medical journal, 2002, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Antitubercular Agents; Clinical Protocols; Directly Observed Therapy; Drug Therap

2002
Short-course treatment in pulmonary tuberculosis.
    East African medical journal, 1975, Volume: 52, Issue:9

    Topics: Adolescent; Adult; Africa, Eastern; Antitubercular Agents; Humans; Isoniazid; Middle Aged; Pyrazinam

1975
Short-course chemotherapy in pulmonary tuberculosis.
    The Journal of antimicrobial chemotherapy, 1977, Volume: 3, Issue:4

    Topics: Clinical Trials as Topic; Developing Countries; Drug Therapy, Combination; Humans; Isoniazid; Pyrazi

1977
Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study.
    The American review of respiratory disease, 1978, Volume: 118, Issue:1

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu

1978
Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. East African and British Medical Research Councils.
    Lancet (London, England), 1978, Aug-12, Volume: 2, Issue:8085

    Topics: Adolescent; Adult; Africa, Eastern; Aged; Clinical Trials as Topic; Drug Administration Schedule; Dr

1978
Sputum-smear-negative pulmonary tuberculosis: controlled trial of 3-month and 2-month regimens of chemotherapy.
    Lancet (London, England), 1979, Jun-30, Volume: 1, Issue:8131

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Male;

1979
Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report.
    The American review of respiratory disease, 1978, Volume: 118, Issue:2

    Topics: Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Dr

1978
The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
    Tubercle, 1978, Volume: 59, Issue:1

    Topics: Acetylation; Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Clinical Trials as Top

1978
Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.
    The American review of respiratory disease, 1979, Volume: 119, Issue:4

    Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Clinical Trials as Topic; Drug Thera

1979
Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration.
    Tubercle, 1979, Volume: 60, Issue:1

    Topics: Adolescent; Adult; Aged; Allopurinol; Aspirin; Clinical Trials as Topic; Double-Blind Method; Female

1979
[Controlled trial of 6 to 8 month chemotherapeutic regimens in the treatment of pulmonary tuberculosis. A study of Hong Kong Chest Service/British Medical Research Council/].
    Bulletin of the International Union against Tuberculosis, 1978, Volume: 53, Issue:4

    Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Hong Kong; H

1978
[Short term chemotherapy of tuberculosis. Evaluation of an 18-week-long treatment including pyrazinamide (preliminary results)].
    Bulletin of the International Union against Tuberculosis, 1978, Volume: 53, Issue:4

    Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Humans; Ison

1978
A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: results up to 30 months.
    Tubercle, 1975, Volume: 56, Issue:3

    Topics: Antibody Formation; Body Weight; Clinical Trials as Topic; Cycloserine; Drug Combinations; Drug Resi

1975
Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study.
    The American review of respiratory disease, 1976, Volume: 114, Issue:3

    Topics: Adolescent; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Humans; Isoniazi

1976
Investigations of allergic status and blood counts in Chinese patients receiving daily or intermittent rifampicin in Hong Kong.
    Clinical allergy, 1975, Volume: 5, Issue:2

    Topics: ABO Blood-Group System; Blood Cell Count; China; Clinical Trials as Topic; Cycloserine; Drug Hyperse

1975
Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong.
    Tubercle, 1975, Volume: 56, Issue:2

    Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Microbial; Female;

1975
Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hon
    The American review of respiratory disease, 1991, Volume: 143, Issue:4 Pt 1

    Topics: Adolescent; Adult; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Drug

1991
Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    The American review of respiratory disease, 1991, Volume: 143, Issue:4 Pt 1

    Topics: Adolescent; Adult; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female;

1991
Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks duration in Algeria. Algerian Working Group/British Medical Research Council Cooperative Study.
    Tubercle, 1991, Volume: 72, Issue:2

    Topics: Adolescent; Adult; Aged; Algeria; Antitubercular Agents; Drug Administration Schedule; Drug Therapy,

1991
[A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment].
    Revue des maladies respiratoires, 1990, Volume: 7, Issue:3

    Topics: Drug Combinations; Drug Resistance, Microbial; Follow-Up Studies; Humans; Isoniazid; Mycobacterium t

1990
Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India.
    Tubercle, 1990, Volume: 71, Issue:4

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Micro

1990
USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.
    Annals of internal medicine, 1990, Mar-15, Volume: 112, Issue:6

    Topics: Adult; Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Data Interpretation,

1990
Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1990, Apr-21, Volume: 77, Issue:8

    Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Humans; Isoniazid; Male;

1990
[Tisamide in the complex treatment of tuberculosis].
    Problemy tuberkuleza, 1990, Issue:7

    Topics: Adult; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Rifamp

1990
A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis.
    The Pediatric infectious disease journal, 1990, Volume: 9, Issue:11

    Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Follo

1990
Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.
    The American review of respiratory disease, 1989, Volume: 140, Issue:6

    Topics: Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Isoniazid; Patie

1989
[Therapeutic trial of a combination of isoniazid, rifampicin and pyrazinamide in the first 2 months of treatment of pulmonary tuberculosis].
    Revue des maladies respiratoires, 1989, Volume: 6, Issue:1

    Topics: Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Combinations; Drug Therapy,

1989
A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.
    The American review of respiratory disease, 1989, Volume: 139, Issue:4

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu

1989
[Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Schweizerische medizinische Wochenschrift, 1989, Mar-11, Volume: 119, Issue:10

    Topics: Adult; Antitubercular Agents; Drug Combinations; Ethambutol; Female; Humans; Isoniazid; Male; Middle

1989
Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    The American review of respiratory disease, 1985, Volume: 132, Issue:2

    Topics: Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Dr

1985
Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    The American review of respiratory disease, 1988, Volume: 137, Issue:5

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combi

1988
Adrenal function in tuberculosis.
    British journal of diseases of the chest, 1986, Volume: 80, Issue:1

    Topics: Acute Disease; Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aged; Child; Child, P

1986
Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis.
    Tubercle, 1988, Volume: 69, Issue:1

    Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination;

1988
Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions.
    Tubercle, 1988, Volume: 69, Issue:4

    Topics: Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Dr

1988
Pulmonary tuberculosis treated with isoprodian and rifampicin or pyrazinamide.
    Chemotherapy, 1987, Volume: 33, Issue:3

    Topics: Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Dapsone; Drug Combinations; Drug Thera

1987
[Short-term chemotherapy of tuberculosis with 5-month regimens with and without pyrazinamide in the 2d phase (TA-82)].
    Revista medica de Chile, 1986, Volume: 114, Issue:7

    Topics: Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Dr

1986
Short-course chemotherapy of pulmonary tuberculosis in pneumoconiotic patients.
    The American review of respiratory disease, 1987, Volume: 136, Issue:4

    Topics: Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Iso

1987
[Results of a shortened (6 months) schedule of treatment of pulmonary tuberculosis using INH, RMP and PZA].
    Pneumonologia polska, 1987, Volume: 55, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Female; Humans; Isoniazid;

1987
United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide.
    Tubercle, 1987, Volume: 68, Issue:2 Suppl

    Topics: Clinical Trials as Topic; Drug Combinations; Female; Humans; Isoniazid; Male; Patient Compliance; Py

1987
Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade.
    European journal of respiratory diseases, 1986, Volume: 68, Issue:1

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu

1986
Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study.
    Tubercle, 1986, Volume: 67, Issue:1

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination;

1986
A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore.
    The American review of respiratory disease, 1986, Volume: 134, Issue:1

    Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as

1986
[Clinical trial of initial intensive short-course chemotherapy supplemented by pyrazinamide for pulmonary tuberculosis--report of the 26th A series of controlled trials of chemotherapy--Cooperative Study Unit of Chemotherapy of Tuberculosis of National Sa
    Kekkaku : [Tuberculosis], 1986, Volume: 61, Issue:7

    Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy,

1986
[Daily ultrashort chemotherapy and intermittent short-term chemotherapy with 4 drugs of communicable pulmonary tuberculosis treated for the first time. Results of a cooperative multicenter study].
    Zeitschrift fur Erkrankungen der Atmungsorgane, 1986, Volume: 167, Issue:1-2

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu

1986
Controlled clinical trial of three short-course regimens of chemotherapy for pulmonary tuberculosis in Nigeria--a preliminary report.
    Tubercle, 1986, Volume: 67, Issue:3

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Clinical Trials as Topic; Drug Administration Schedu

1986
Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania/British Medical Research Council Study.
    The American review of respiratory disease, 1985, Volume: 131, Issue:5

    Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Resistance, Microbial; Female; Humans; Isoniazid;

1985
Operational evaluation of treatment for tuberculosis. Results of 8- and 12-month regimens in Peru.
    The American review of respiratory disease, 1985, Volume: 132, Issue:4

    Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Th

1985
[Which is the best drug combination for the short-term therapy of tuberculosis? A prospective randomized study with 190 patients].
    Schweizerische medizinische Wochenschrift, 1985, Sep-28, Volume: 115, Issue:39

    Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug

1985
[Controlled study comparing 3 daily chemotherapy regimens for six months in pulmonary tuberculosis in routine practice in Algiers. Results at 30 months].
    Revue des maladies respiratoires, 1985, Volume: 2, Issue:4

    Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combinati

1985
Uric acid disposition during intermittent chemotherapy of pulmonary tuberculosis with regimens containing pyrazinamide & rifampicin.
    The Indian journal of medical research, 1985, Volume: 82

    Topics: Drug Administration Schedule; Drug Therapy, Combination; Humans; Pyrazinamide; Rifampin; Tuberculosi

1985
The combination of ethambutol, capreomycin and a third drug in chronic pulmonary tuberculosis with bacterial polyresistance.
    Antibiotica et chemotherapia. Fortschritte. Advances. Progres, 1970, Volume: 16

    Topics: Administration, Oral; Aminosalicylic Acids; Antitubercular Agents; Capreomycin; Chronic Disease; Cli

1970
General considerations in intermittent drug therapy of pulmonary tuberculosis.
    Postgraduate medical journal, 1971, Volume: 47, Issue:553

    Topics: Aminosalicylic Acids; Antitubercular Agents; Clinical Trials as Topic; Ethambutol; Ethionamide; Huma

1971
Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.
    Lancet (London, England), 1972, May-20, Volume: 1, Issue:7760

    Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Clinical Trials as Topic; Drug Combi

1972
Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report.
    Lancet (London, England), 1973, Jun-16, Volume: 1, Issue:7816

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Resistance, Microbial; Female; Humans; Isoniazi

1973
Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils.
    Lancet (London, England), 1974, Aug-03, Volume: 2, Issue:7875

    Topics: Adolescent; Adult; Africa, Eastern; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Dr

1974
Interaction aspects of antimycobacterial drugs in the chemotherapy of tuberculosis. I. Role of individual antituberculous drugs in drug regimens used in the chemotherapy of human tuberculosis.
    Chemotherapy, 1974, Volume: 20, Issue:3

    Topics: Aminosalicylic Acids; Antitubercular Agents; Clinical Trials as Topic; Cycloserine; Drug Evaluation;

1974
Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.
    Lancet (London, England), 1974, Nov-09, Volume: 2, Issue:7889

    Topics: Administration, Oral; Adolescent; Adult; Africa; Clinical Trials as Topic; Drug Combinations; Drug E

1974
[Short-term treatment of pulmonary tuberculosis].
    Bulletin of the International Union against Tuberculosis, 1974, Volume: 49, Issue:1

    Topics: Adolescent; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Evaluation S

1974
Evaluation of results of chemotherapy in tuberculosis with special consideration of ethambutol.
    Antibiotica et chemotherapia. Fortschritte. Advances. Progres, 1970, Volume: 16

    Topics: Aminosalicylic Acids; Clinical Trials as Topic; Cycloserine; Drug Combinations; Electronic Data Proc

1970
Streptomycin plus pas plus pyrazinamide in the retreatment of pulmonary tuberculosis in East Africa.
    East African medical journal, 1972, Volume: 49, Issue:1

    Topics: Aminosalicylic Acids; Clinical Trials as Topic; Drug Combinations; Humans; Pyrazinamide; Streptomyci

1972
Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials.
    The American review of respiratory disease, 1973, Volume: 107, Issue:2

    Topics: Adolescent; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Ethambutol; Evaluation Studies as

1973
Streptomycin plus PAS plus pyrazinamide in the retreatment of pulmonary tuberculosis in East Africa: second report. A co-operative study in East African and British Medical Research Councils.
    Tubercle, 1973, Volume: 54, Issue:4

    Topics: Administration, Oral; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Female; Humans; Injecti

1973
[Controlled comparison of daily and intermittent treatment regimens with rifampicin].
    Bulletin of the International Union against Tuberculosis, 1974, Volume: 49, Issue:1

    Topics: Clinical Trials as Topic; Drug Therapy, Combination; Humans; Pyrazinamide; Rifampin; Time Factors; T

1974
A Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Research Council Investigation.
    Tubercle, 1974, Volume: 55, Issue:1

    Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Cycloserine; Drug Administration Schedule; D

1974
A controlled clinical trial of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy in Hong Kong: second report:-the results at 12 months.
    Tubercle, 1974, Volume: 55, Issue:3

    Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Administration Schedule; Drug Hypersensitivity; Dr

1974
A controlled clinical trial of small daily doses of rifampicin in the prevention of adverse reactions to the drug in a once-weekly regimen of chemotherapy. A Hong Kong Tuberculosis Treatment Services-British Medical Research Council Investigation.
    Clinical allergy, 1974, Volume: 4, Issue:1

    Topics: Adult; Alanine Transaminase; Antibodies; Ethambutol; Female; Fever; Humans; Jaundice; Male; Middle A

1974
Clinical experience of intermittent treatment in the United Kingdom.
    Tubercle, 1968, Volume: 49

    Topics: Aminosalicylic Acids; Clinical Trials as Topic; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuber

1968
[Clinical studies on the ketogenic effect of certain antitubercular drugs in patients with diabetes and pulmonary tuberculosis].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1968, May-01, Volume: 21, Issue:9

    Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; E

1968
[Toxic reactions during treament with pyrazinamide in pulmonary tuberculosis].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1968, Volume: 36, Issue:4

    Topics: Adult; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Female; Humans; Male; Middl

1968
[Results of treatment with a combined 3-drug regimen of secondary drugs in chronic cavernous pulmonary tuberculosis. A study under auspices of the International Union against Tuberculosis].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1968, Volume: 36, Issue:9

    Topics: Adult; Aged; Clinical Trials as Topic; Cycloserine; Drug Resistance, Microbial; Ethionamide; Female;

1968
A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis.
    Bulletin of the International Union against Tuberculosis, 1968, Volume: 41

    Topics: Clinical Trials as Topic; Cycloserine; Ethionamide; Humans; Isoniazid; Prospective Studies; Pyrazina

1968
A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis.
    Tubercle, 1969, Volume: 50, Issue:2

    Topics: Adolescent; Adult; Aspartate Aminotransferases; Clinical Trials as Topic; Drug Resistance, Microbial

1969
Streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis--second report. A co-operative study in East African hospitals, clinics and laboratories with the collaboration of the East African and British Medical Research Councils.
    Tubercle, 1970, Volume: 51, Issue:4

    Topics: Africa, Eastern; Clinical Trials as Topic; Drug Resistance, Microbial; Follow-Up Studies; Humans; Mi

1970
Streptomycin plus PAS plus pyrazinamide in the retreatment of pulmonary tuberxulisis in East Africa.
    Tubercle, 1971, Volume: 52, Issue:3

    Topics: Adolescent; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Costs and Cost Analysis; Drug Res

1971
Controlled clinical trials with Isoxyl.
    Antibiotica et chemotherapia. Fortschritte. Advances. Progres, 1970, Volume: 16

    Topics: Clinical Trials as Topic; Cycloserine; Drug Combinations; Drug Synergism; Ethionamide; Evaluation St

1970
Madras study of supervised once-weekly chemotherapy in the treatment of pulmonary tuberculosis: laboratory aspects.
    Tubercle, 1968, Volume: 49

    Topics: Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Humans; India; Isoniazid; Myco

1968
A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis.
    Bulletin of the World Health Organization, 1970, Volume: 43, Issue:1

    Topics: Adolescent; Adult; Child; Humans; India; Isoniazid; Microbial Sensitivity Tests; Middle Aged; Pyrazi

1970
[Comparison between morphazinamide and pyrazinamide in retreatment of pulmonary tuberculosis].
    Minerva medica, 1965, Sep-05, Volume: 56, Issue:71

    Topics: Antitubercular Agents; Clinical Trials as Topic; Humans; Pyrazinamide; Pyrazines; Tuberculosis, Pulm

1965

Other Studies

798 other studies available for pyrazinamide and Pulmonary Consumption

ArticleYear
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3

    Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Drug Synergism; Female; L

2007
Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11

    Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Female; Guinea Pigs; Isoniazid; Lung; Metro

2008
Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3

    Topics: Adult; Antitubercular Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administra

2010
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5

    Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; E

2010
Early phase of effective treatment induces distinct transcriptional changes in Mycobacterium tuberculosis expelled by pulmonary tuberculosis patients.
    Scientific reports, 2021, 09-08, Volume: 11, Issue:1

    Topics: Adult; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male; Mycobacterium tuberculosi

2021
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
    MMWR. Morbidity and mortality weekly report, 2022, Feb-25, Volume: 71, Issue:8

    Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Drug Administration Schedul

2022
High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 10-29, Volume: 75, Issue:9

    Topics: Adult; Antitubercular Agents; Bacillus; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Sputu

2022
Drug concentration at the site of disease in children with pulmonary tuberculosis.
    The Journal of antimicrobial chemotherapy, 2022, 05-29, Volume: 77, Issue:6

    Topics: Adult; Antitubercular Agents; Child; Ethambutol; Humans; Infant; Isoniazid; Pyrazinamide; South Afri

2022
Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3

    Topics: Adult; Antitubercular Agents; Clofazimine; Humans; Microbial Sensitivity Tests; Mycobacterium tuberc

2023
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
    Antimicrobial agents and chemotherapy, 2022, 12-20, Volume: 66, Issue:12

    Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberc

2022
Individualising therapy for drug-sensitive tuberculosis.
    The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:10

    Topics: Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Humans; Is

2019
Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients.
    The Journal of antimicrobial chemotherapy, 2019, 12-01, Volume: 74, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Diabetes Complications; Diabetes Mellitus; Fe

2019
Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis.
    The Journal of infectious diseases, 2020, 04-07, Volume: 221, Issue:9

    Topics: Adult; Antitubercular Agents; Brazil; Ethambutol; Female; HIV Seropositivity; Humans; Isoniazid; Mal

2020
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative?
    The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12

    Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, P

2019
Detection of Mutations in Mycobacterium tuberculosis pncA Gene by Modified High-Resolution Melting Curve Analysis of PCR Products.
    Bulletin of experimental biology and medicine, 2019, Volume: 168, Issue:2

    Topics: Amidohydrolases; Antitubercular Agents; Base Sequence; Drug Resistance, Bacterial; Mycobacterium tub

2019
Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:4

    Topics: Antitubercular Agents; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Multiple,

2020
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis.
    BMC infectious diseases, 2020, Jan-29, Volume: 20, Issue:1

    Topics: Adult; Antitubercular Agents; Cycloserine; Extensively Drug-Resistant Tuberculosis; Female; Humans;

2020
Tuberculosis treatment: one-shot approach or cascade of regimens?
    The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:2

    Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, P

2020
Treatment outcome of tuberculosis treatment regimens in Kandahar, Afghanistan.
    The Indian journal of tuberculosis, 2020, Volume: 67, Issue:1

    Topics: Adolescent; Adult; Afghanistan; Antitubercular Agents; Cohort Studies; Cough; Drug Therapy, Combinat

2020
High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda.
    PloS one, 2020, Volume: 15, Issue:5

    Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sens

2020
An Unexpected Cause of Conjunctivitis in an Adolescent.
    Clinical pediatrics, 2020, Volume: 59, Issue:13

    Topics: Adolescent; Antitubercular Agents; Conjunctivitis; Diagnosis, Differential; Ethambutol; Glucocortico

2020
Irreversible neuropathy in extremely-drug resistant tuberculosis: An unfortunate clinical conundrum.
    The Indian journal of tuberculosis, 2020, Volume: 67, Issue:3

    Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Clofazimine; Cycloserine; Deprescriptions; Diaryl

2020
Gitelman-like syndrome: A rare complication of using aminoglycosides in tuberculosis - A case report.
    The Indian journal of tuberculosis, 2020, Volume: 67, Issue:3

    Topics: Alkalosis; Antitubercular Agents; Capreomycin; Clofazimine; Cycloserine; Deprescriptions; Ethionamid

2020
Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 11-02, Volume: 73, Issue:9

    Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Pharmaceutical Preparations; Prospective

2021
Effect of interval between food intake and drug administration at fasting condition on the plasma concentrations of first-line anti-tuberculosis drugs in Chinese population.
    Medicine, 2020, Oct-30, Volume: 99, Issue:44

    Topics: Administration, Oral; Adult; Antitubercular Agents; China; Drug Administration Schedule; Eating; Eth

2020
Five-year microevolution of a multidrug-resistant Mycobacterium tuberculosis strain within a patient with inadequate compliance to treatment.
    BMC infectious diseases, 2021, Apr-29, Volume: 21, Issue:1

    Topics: Adult; Antitubercular Agents; Argentina; Drug Resistance, Multiple, Bacterial; Female; Humans; Isoni

2021
Two cases of tuberculous retropharyngeal abscess in adults.
    The Journal of international medical research, 2021, Volume: 49, Issue:5

    Topics: Adult; Female; Humans; Male; Mycobacterium tuberculosis; Pyrazinamide; Retropharyngeal Abscess; Rifa

2021
Pulmonary Tuberculosis in Older Adults: Increased Mortality Related to Tuberculosis Within Two Months of Treatment Initiation.
    Drugs & aging, 2021, Volume: 38, Issue:9

    Topics: Aged; Antitubercular Agents; Humans; Pyrazinamide; Retrospective Studies; Tuberculosis; Tuberculosis

2021
A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line anti-tuberculosis regimen.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 142

    Topics: Amikacin; Animals; Antigens, Bacterial; Antitubercular Agents; BCG Vaccine; Disease Models, Animal;

2021
Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2017, Volume: 51

    Topics: Adult; Alleles; Antitubercular Agents; Asian People; Chemical and Drug Induced Liver Injury; Cytochr

2017
Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:8

    Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Synergism; Drug Therapy

2017
Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2018, Volume: 24, Issue:1

    Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te

2018
Poncet's disease in human immunodeficiency virus: a case report.
    BMC research notes, 2017, Jun-12, Volume: 10, Issue:1

    Topics: Adult; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Arthritis, Reactive; Etha

2017
Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:8

    Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; HIV Infections

2017
Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model.
    Tuberculosis (Edinburgh, Scotland), 2017, Volume: 105

    Topics: Animals; Antitubercular Agents; Bacterial Load; Colony Count, Microbial; Disease Models, Animal; DNA

2017
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:9

    Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones;

2017
Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.
    Microbiome, 2017, 07-07, Volume: 5, Issue:1

    Topics: Animals; Antitubercular Agents; Clostridiales; Drug Combinations; Dysbiosis; Gastrointestinal Microb

2017
Massive choroidal granuloma as the presenting feature of disseminated tuberculosis in immunocompetent patients.
    Clinical & experimental optometry, 2018, Volume: 101, Issue:4

    Topics: Adolescent; Adult; Antitubercular Agents; Choroid Diseases; Drug Combinations; Ethambutol; Female; G

2018
Serum levels of soluble urokinase plasminogen activator receptor (suPAR) as a marker of tuberculosis treatment efficacy.
    The Indian journal of tuberculosis, 2017, Volume: 64, Issue:3

    Topics: Adult; Aged; Antitubercular Agents; Biomarkers; Drug Monitoring; Drug Therapy, Combination; Ethambut

2017
Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:10

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Femal

2017
Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017, 08-01, Volume: 21, Issue:8

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cohort Studies; Drug Resistance, Bacterial; Female;

2017
The clinical recovery of tuberculosis patients undergoing specific treatment is associated with changes in the immune and neuroendocrine responses.
    Pathogens and disease, 2017, 09-29, Volume: 75, Issue:7

    Topics: Adult; Antitubercular Agents; C-Reactive Protein; Case-Control Studies; Dehydroepiandrosterone; Etha

2017
Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.
    BMJ open, 2017, 09-18, Volume: 7, Issue:9

    Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Biomedical Research; CD4 Lymphocyte Count; Coh

2017
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Respiratory medicine, 2017, Volume: 131

    Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort

2017
Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit.
    PloS one, 2017, Volume: 12, Issue:10

    Topics: Adult; Aged; Antitubercular Agents; Asian People; China; Clinical Audit; Ethambutol; Female; Fluoroq

2017
Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.
    PloS one, 2017, Volume: 12, Issue:10

    Topics: Adolescent; Adult; Africa South of the Sahara; Aged; Aged, 80 and over; Amidohydrolases; Antitubercu

2017
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:2

    Topics: Anti-HIV Agents; Antitubercular Agents; Child; Drug Administration Schedule; Drug Combinations; Drug

2018
Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing.
    Respiratory medicine, 2017, Volume: 133

    Topics: Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Fema

2017
A retrospective study on tuberculosis treatment outcomes at Jinka General Hospital, southern Ethiopia.
    BMC research notes, 2017, Dec-04, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; Ethiopia; Fema

2017
A Painful Red Eye.
    JAMA ophthalmology, 2018, Mar-01, Volume: 136, Issue:3

    Topics: Alcoholism; Antitubercular Agents; Conjunctival Diseases; Ethambutol; Eye Pain; Glucocorticoids; Hum

2018
Treatment outcomes and tolerability of the revised WHO anti-tuberculosis drug dosages for children.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2018, 02-01, Volume: 22, Issue:2

    Topics: Antitubercular Agents; Child, Preschool; Cohort Studies; Female; HIV Infections; Humans; Infant; Inf

2018
Antituberculosis Treatment in a Patient with Celiac Disease.
    Archivos de bronconeumologia, 2018, Volume: 54, Issue:6

    Topics: Aged; Antitubercular Agents; Celiac Disease; Diarrhea; Diet, Gluten-Free; Drug Compounding; Drug Sub

2018
[DRESS syndrome secondary to pyrazinamide: An uncommon complication of tuberculosis treatment].
    Revue des maladies respiratoires, 2018, Volume: 35, Issue:1

    Topics: Adrenal Cortex Hormones; Adult; Antitubercular Agents; Coinfection; Drug Hypersensitivity Syndrome;

2018
Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
    BMC pulmonary medicine, 2018, Feb-20, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Aftercare; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Directly O

2018
Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.
    Tuberculosis (Edinburgh, Scotland), 2018, Volume: 109

    Topics: Amidohydrolases; Antitubercular Agents; DNA Mutational Analysis; Drug Resistance, Multiple, Bacteria

2018
Development and characterization of high payload combination dry powders of anti-tubercular drugs for treating pulmonary tuberculosis.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, Jun-15, Volume: 118

    Topics: Aerosols; Antitubercular Agents; Cell Line; Cell Survival; Chemistry, Pharmaceutical; Drug Combinati

2018
[Management and treatment difficulties of multi-drug resistant pulmonary tuberculosis in a pediatric case].
    Mikrobiyoloji bulteni, 2018, Volume: 52, Issue:1

    Topics: Adult; Antitubercular Agents; Female; Humans; Infant; Isoniazid; Mycobacterium tuberculosis; Pyrazin

2018
Perianal ulcerative skin tuberculosis: A case report.
    Medicine, 2018, Volume: 97, Issue:22

    Topics: Aged; Antitubercular Agents; Ethambutol; Fissure in Ano; Humans; Isoniazid; Male; Mycobacterium tube

2018
Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:11

    Topics: Adult; Antitubercular Agents; Diabetes Mellitus; Female; Glycated Hemoglobin; Humans; Isoniazid; Mal

2018
Optic Perineuritis Due to Tuberculosis.
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2019, Volume: 39, Issue:2

    Topics: Adult; Antitubercular Agents; Bronchoscopy; Drug Therapy, Combination; Humans; Isoniazid; Magnetic R

2019
Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis.
    PloS one, 2018, Volume: 13, Issue:9

    Topics: Aerosols; Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Therapy, Comb

2018
Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment.
    mBio, 2018, 11-20, Volume: 9, Issue:6

    Topics: Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Female; Haiti; Hum

2018
Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis.
    Mucosal immunology, 2019, Volume: 12, Issue:3

    Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug-Related Side Effects and Adverse

2019
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    PLoS medicine, 2019, Volume: 16, Issue:4

    Topics: Adult; Antitubercular Agents; Decision Support Techniques; Disease Progression; Drug Administration

2019
Tuberculosis in Older Adults: Seattle and King County, Washington.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 03-03, Volume: 70, Issue:6

    Topics: Aged; Antitubercular Agents; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary; Washington

2020
Serum pyrazinamide concentrations in patients with pulmonary tuberculosis.
    Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2019, 04-18, Volume: 45, Issue:2

    Topics: Antitubercular Agents; Brazil; Dose-Response Relationship, Drug; Female; Humans; Male; Mycobacterium

2019
A Rare Case of a Tuberculosis Patient with Sarcoidosis.
    Folia medica, 2019, Jun-01, Volume: 61, Issue:2

    Topics: Adult; Antitubercular Agents; Deprescriptions; Ethambutol; Female; Glucocorticoids; Humans; Isoniazi

2019
Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10

    Topics: Antitubercular Agents; Bacterial Load; Biological Assay; Biomarkers, Pharmacological; Computer Simul

2019
Isoniazid- and streptomycin-resistant miliary tuberculosis complicated by intracranial tuberculoma in a Japanese infant.
    The Tohoku journal of experimental medicine, 2013, Volume: 229, Issue:3

    Topics: Antitubercular Agents; Drug Substitution; Drug Therapy, Combination; Ethambutol; Ethionamide; Female

2013
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.
    Emerging infectious diseases, 2013, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Therapy, Combination; Etham

2013
Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:7

    Topics: Adult; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; T

2013
[Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide].
    Kekkaku : [Tuberculosis], 2013, Volume: 88, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In

2013
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8

    Topics: Adult; Antitubercular Agents; Area Under Curve; Drug Evaluation; Drug Therapy, Combination; Female;

2013
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8

    Topics: Adult; Antitubercular Agents; Area Under Curve; Drug Evaluation; Drug Therapy, Combination; Female;

2013
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8

    Topics: Adult; Antitubercular Agents; Area Under Curve; Drug Evaluation; Drug Therapy, Combination; Female;

2013
Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8

    Topics: Adult; Antitubercular Agents; Area Under Curve; Drug Evaluation; Drug Therapy, Combination; Female;

2013
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8

    Topics: Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Drug Evaluation, Preclinic

2013
Serum drug concentrations predictive of pulmonary tuberculosis outcomes.
    The Journal of infectious diseases, 2013, Nov-01, Volume: 208, Issue:9

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Area Under Curve; Female; Humans; Isoniazid; Male; M

2013
Treating pyrazinamide mono-resistant pulmonary tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2013, Volume: 17, Issue:9

    Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Drug

2013
Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:11

    Topics: Adult; Antitubercular Agents; Biological Availability; Diabetes Mellitus, Type 2; Drug Administratio

2013
A case of skin and lung tuberculosis: diagnostic difficulties.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2013, Volume: 148, Issue:5

    Topics: Antitubercular Agents; Bronchitis; Bronchoalveolar Lavage Fluid; Bronchoscopy; CD4-CD8 Ratio; Diagno

2013
Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Animals; Antitubercular Agents; Biomarkers; Cytokines; Disease Models, Animal; Female; Gene Expressi

2013
Olfactory disturbance related to pyrazinamide.
    QJM : monthly journal of the Association of Physicians, 2014, Volume: 107, Issue:3

    Topics: Antitubercular Agents; Drug Combinations; Humans; Isoniazid; Male; Middle Aged; Olfaction Disorders;

2014
Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2013, Volume: 17, Issue:11

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antitubercular Agents; Area Under Curve; Directly Obs

2013
Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2013, Volume: 17, Issue:11

    Topics: Adult; Antitubercular Agents; Automation, Laboratory; Colony Count, Microbial; Drug Monitoring; Drug

2013
Clonal expansion of Mycobacterium tuberculosis isolates and coexisting drug resistance in patients newly diagnosed with pulmonary tuberculosis in Hanoi, Vietnam.
    BMC research notes, 2013, Nov-05, Volume: 6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clone Cells; DNA, Bacterial; Drug

2013
Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2013, Volume: 17, Issue:12

    Topics: Adult; Aged; Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Ther

2013
Rapid detection of Mycobacterium tuberculosis and pyrazinamide susceptibility related to pncA mutations in sputum specimens through an integrated gene-to-protein function approach.
    Journal of clinical microbiology, 2014, Volume: 52, Issue:1

    Topics: Adult; Amidohydrolases; Antitubercular Agents; Humans; Microbial Sensitivity Tests; Molecular Diagno

2014
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:2

    Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolon

2014
[Thrombocytopenia induced by rifampicin not previously sensitized: a case presentation].
    Revue des maladies respiratoires, 2013, Volume: 30, Issue:9

    Topics: Adult; Antibiotics, Antitubercular; Ethambutol; Female; Humans; Immunization; Isoniazid; Purpura, Th

2013
[A clinical investigation of seven patients with pulmonary tuberculosis who developed mixed liver injury during oral anti-tuberculosis treatment].
    Kekkaku : [Tuberculosis], 2013, Volume: 88, Issue:9

    Topics: Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy

2013
Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:1

    Topics: Antitubercular Agents; Female; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Tuberculosis, Pulmon

2014
Reply to "strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment response".
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:1

    Topics: Antitubercular Agents; Female; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Tuberculosis, Pulmon

2014
[Antimicrobial resistance in tuberculosis].
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2013, Volume: 26, Issue:4

    Topics: Antitubercular Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambutol;

2013
The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury;

2014
[Hypothermia due to anti-tuberculosis drugs: first case].
    Revue de pneumologie clinique, 2014, Volume: 70, Issue:5

    Topics: Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Comb

2014
Characterisation of pyrazinamide-resistant Mycobacterium tuberculosis strains isolated in Poland and Germany.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:4

    Topics: Amidohydrolases; Antitubercular Agents; Bacteriological Techniques; DNA Mutational Analysis; DNA, Ba

2014
Prevalence of extended treatment in pulmonary tuberculosis patients receiving first-line therapy and its association with recurrent tuberculosis in Beijing, China.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2014, Volume: 108, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; China; Cohort Studies; Cost of Il

2014
Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:9

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Isoniazid

2014
Association of serum levels of iron, copper, and zinc, and inflammatory markers with bacteriological sputum conversion during tuberculosis treatment.
    Biological trace element research, 2014, Volume: 160, Issue:2

    Topics: Adult; Antitubercular Agents; Biomarkers; C-Reactive Protein; Copper; Ethambutol; Hemoglobins; Host-

2014
Novel bronchoscopic balloon dilation for patients with bronchostenosis caused by bronchial tuberculosis: a case report.
    Journal of medical case reports, 2014, Jun-24, Volume: 8

    Topics: Antitubercular Agents; Bronchial Diseases; Bronchoscopy; Constriction, Pathologic; Dilatation; Etham

2014
Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets.
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Chemistry, Pharmaceutical; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Quality Control; Rifa

2014
Pulmonary tuberculoma in a patient with chronic hepatitis C: a clinical pitfall in the treatment strategy.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:15

    Topics: Antitubercular Agents; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up St

2014
False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:10

    Topics: Aged; Amikacin; Amino Acid Sequence; Antibiotics, Antitubercular; Bacterial Proteins; DNA-Directed R

2014
Investigating gender disparities in the profile and treatment outcomes of tuberculosis in Ebonyi state, Nigeria.
    Epidemiology and infection, 2015, Volume: 143, Issue:5

    Topics: Adult; Antitubercular Agents; Cohort Studies; Coinfection; Ethambutol; Female; Health Status Dispari

2015
Treatment options and outcomes of hospitalised tuberculosis patients: a nationwide study.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Preschool; Ethambut

2015
Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Journal of Korean medical science, 2015, Volume: 30, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antitubercular Agents; Aspartate A

2015
Counting pyrazinamide in regimens for multidrug-resistant tuberculosis.
    Annals of the American Thoracic Society, 2015, Volume: 12, Issue:5

    Topics: Adult; Aged; Antitubercular Agents; Female; Follow-Up Studies; Humans; Male; Mycobacterium tuberculo

2015
Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
    The Indian journal of tuberculosis, 2014, Volume: 61, Issue:4

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Arthralgia; Ataxia; Chemical and Drug Induced Liver

2014
Six- vs. eight-month anti-tuberculosis regimen for pulmonary tuberculosis under programme conditions.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:3

    Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid; Logistic Mod

2015
Effective anti-tuberculosis therapy correlates with plasma small RNA.
    The European respiratory journal, 2015, Volume: 45, Issue:6

    Topics: Adult; Antitubercular Agents; Biomarkers; Coinfection; Ethambutol; Female; Gene Expression Profiling

2015
New drug combination may shorten tuberculosis treatment, study says.
    BMJ (Clinical research ed.), 2015, Mar-18, Volume: 350

    Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Nitroimidazoles; Pyrazinamide; Tuberc

2015
New effective antituberculosis regimens.
    Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979

    Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazi

2015
Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDC + Z for tuberculosis treatment in Brazil: a cohort study.
    BMC infectious diseases, 2015, Feb-21, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Brazil; Cohort Studies; Drug Combinations; Et

2015
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.
    BMC infectious diseases, 2015, Mar-14, Volume: 15

    Topics: Adolescent; Antitubercular Agents; Area Under Curve; Child; Child, Preschool; Ethambutol; Ethnicity;

2015
Advanced stage of chronic kidney disease is risk of poor treatment outcome for smear-positive pulmonary tuberculosis.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2015, Volume: 21, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cardiovascular Diseases; Child; D

2015
Pyridoxine induced rosacea-like dermatitis.
    Acta clinica Croatica, 2015, Volume: 54, Issue:1

    Topics: Antitubercular Agents; Drug Combinations; Drug Eruptions; Female; Humans; Isoniazid; Middle Aged; Py

2015
IL-37 Expression is Upregulated in Patients with Tuberculosis and Induces Macrophages Towards an M2-like Phenotype.
    Scandinavian journal of immunology, 2015, Volume: 82, Issue:4

    Topics: Antitubercular Agents; Arginase; B7-2 Antigen; Cell Differentiation; Cells, Cultured; Ethambutol; Fe

2015
Drug-induced myopathy in a patient with pulmonary tuberculosis.
    BMJ case reports, 2015, Jul-15, Volume: 2015

    Topics: Adult; Antitubercular Agents; Arthralgia; Creatine Kinase; Humans; Male; Muscle Weakness; Muscular D

2015
The relationship between chitotriosidase activity and tuberculosis.
    Epidemiology and infection, 2015, Volume: 143, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Biomarkers; Case-Control Studies; China; Etha

2015
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni

2016
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni

2016
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni

2016
Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni

2016
[The effect of renal replacement therapy on the plasma concentration of antituberculosis drugs].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2015, Volume: 38, Issue:5

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Kidney Diseases; Male; Mi

2015
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Admin

2016
Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:2

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Genome, Bacteria

2016
Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:2

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Co

2016
Repeat exposure to active tuberculosis and risk of re-infection.
    The Medical journal of Australia, 2016, Feb-01, Volume: 204, Issue:2

    Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Emergency Service, Hospital; E

2016
Global Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of Ethambutol.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Antitubercular Agents; Biotransformation; Case-Contr

2016
Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
    BMC pulmonary medicine, 2016, Feb-04, Volume: 16

    Topics: Adolescent; Adult; Antitubercular Agents; China; Cohort Studies; Drug Resistance, Bacterial; Drug Th

2016
Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.
    Tuberculosis (Edinburgh, Scotland), 2016, Volume: 98

    Topics: Adult; Amidohydrolases; Antitubercular Agents; China; DNA Mutational Analysis; Drug Resistance, Mult

2016
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:8

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Combinations; Female; Isoniazid; Mice;

2016
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:8

    Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; China; Drug Therapy, Combination; Female;

2016
Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:9

    Topics: Adult; Age Factors; Aged; Amidohydrolases; Antitubercular Agents; China; Codon; Cross-Sectional Stud

2016
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.
    The Lancet. Infectious diseases, 2016, Volume: 16, Issue:10

    Topics: Anti-Infective Agents; Antitubercular Agents; Asia; Fluoroquinolones; Humans; Microbial Sensitivity

2016
A quantitative adaptation of the Wayne test for pyrazinamide resistance.
    Tuberculosis (Edinburgh, Scotland), 2016, Volume: 99

    Topics: Adult; Antitubercular Agents; Area Under Curve; Calibration; Drug Resistance, Bacterial; Female; Hum

2016
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:10

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Area Under Cur

2016
Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.
    PloS one, 2016, Volume: 11, Issue:8

    Topics: Antitubercular Agents; Area Under Curve; Bacterial Load; Bacteriological Techniques; Biomarkers; Eth

2016
[EVALUATION OF THE EFFICIENCY OF TREATMENT AND THE CHOICE OF CONTROL COMPUTED TOMOGRAPHY TIME IN CHILDREN WITH MINOR FORMS OF INTRATHORACIC TUBERCULOSIS].
    Tuberkulez i bolezni legkikh, 2010, Issue:1

    Topics: Antitubercular Agents; Child; Child, Preschool; Comparative Effectiveness Research; Drug Monitoring;

2010
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
    The European respiratory journal, 2016, Volume: 48, Issue:4

    Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Cl

2016
The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.
    JCI insight, 2016, 09-08, Volume: 1, Issue:14

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; Drug Resistance, Bacterial;

2016
Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study.
    Genetics and molecular research : GMR, 2016, Sep-02, Volume: 15, Issue:3

    Topics: Adult; Age Factors; Alleles; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ethambut

2016
Gitelman-like Syndrome with Kanamycin Toxicity.
    The Journal of the Association of Physicians of India, 2016, Volume: 64, Issue:5

    Topics: Adult; Alkalosis; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fl

2016
Role of Risorine in the Treatment of Drug - Susceptible Pulmonary Tuberculosis: A Pilot Study.
    The Journal of the Association of Physicians of India, 2016, Volume: 64, Issue:11

    Topics: Adult; Alkaloids; Antitubercular Agents; Benzodioxoles; Cytochrome P-450 Enzyme Inhibitors; Drug Com

2016
A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:3

    Topics: Antitubercular Agents; Bayes Theorem; Biological Availability; Computer Simulation; Drug Administrat

2017
The biodistribution of 5-[18F]fluoropyrazinamide in Mycobacterium tuberculosis-infected mice determined by positron emission tomography.
    PloS one, 2017, Volume: 12, Issue:2

    Topics: Amidohydrolases; Animals; Antitubercular Agents; Female; Fluorine Radioisotopes; Mice; Mice, Inbred

2017
Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.
    BMC infectious diseases, 2017, 02-02, Volume: 17, Issue:1

    Topics: Adult; Antitubercular Agents; Diabetes Complications; Dose-Response Relationship, Drug; Drug Therapy

2017
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, May-15, Volume: 64, Issue:10

    Topics: Adult; Antitubercular Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; HIV

2017
Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:5

    Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Drug Dosage Calculations; Drug Therapy,

2017
Primary drug resistance against Mycobacterium tuberculosis in Karachi.
    JPMA. The Journal of the Pakistan Medical Association, 2008, Volume: 58, Issue:3

    Topics: Adolescent; Adult; Antitubercular Agents; Bronchoscopy; Drug Resistance, Multiple, Bacterial; Ethamb

2008
Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolin

2008
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models

2008
Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide.
    Kekkaku : [Tuberculosis], 2008, Volume: 83, Issue:7

    Topics: Antitubercular Agents; Data Collection; Female; Humans; Hyperuricemia; Male; Middle Aged; Pyrazinami

2008
Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.
    Journal of clinical microbiology, 2008, Volume: 46, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amidohydrolases; Amino Acid Substitution; Antitubercular

2008
An unusual case of a pleural effusion with an abdominal mass.
    The Indian journal of tuberculosis, 2008, Volume: 55, Issue:3

    Topics: Adult; Antitubercular Agents; Drainage; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Ma

2008
Tuberculosis in a patient on temozolomide: a case report.
    Journal of neuro-oncology, 2009, Volume: 92, Issue:1

    Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Ant

2009
Gynecomastia: a rare adverse effect of isoniazid.
    Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2008, Volume: 34, Issue:11

    Topics: Adolescent; Antitubercular Agents; Diagnosis, Differential; Gynecomastia; Humans; Isoniazid; Male; P

2008
Tuberculosis incidence among contacts of active pulmonary tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2009, Volume: 13, Issue:2

    Topics: Adolescent; Adult; Antitubercular Agents; Brazil; Carrier State; Cohort Studies; Disease Transmissio

2009
Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs.
    The Indian journal of medical research, 2008, Volume: 128, Issue:5

    Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Male; Microbial Sensitiv

2008
[A role of the HLA-DRB1* genotype in the complex therapy of pulmonary tuberculosis].
    Problemy tuberkuleza i boleznei legkikh, 2008, Issue:12

    Topics: Alleles; Antibiotics, Antitubercular; Antitubercular Agents; Disease Progression; Drug Resistance, B

2008
[Acute respiratory distress syndrome: a manifestation of immune reconstitution in an HIV-negative patient with tuberculosis].
    Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:2

    Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Seronegativity; Humans; Isoniaz

2009
[Optimization of chemotherapy regimens in children with primary pulmonary tuberculosis].
    Problemy tuberkuleza i boleznei legkikh, 2009, Issue:1

    Topics: Adolescent; Age Factors; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool

2009
Coccidioides immitis and Mycobacterium tuberculosis diagnosed by endoscopic ultrasound.
    Journal of the South Carolina Medical Association (1975), 2009, Volume: 105, Issue:1

    Topics: Adult; Antibiotics, Antitubercular; Antifungal Agents; Antitubercular Agents; Coccidioides; Coccidio

2009
Isoniazid induced gynaecomastia: a case report.
    The Indian journal of tuberculosis, 2009, Volume: 56, Issue:1

    Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Gynecomastia; Humans; Isoniazid; Male;

2009
[Fever and thin-walled cavitary lung lesions].
    Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:6

    Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Fever; Humans; Isoniazid; Male;

2009
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E

2009
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E

2009
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E

2009
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E

2009
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E

2009
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E

2009
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E

2009
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E

2009
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E

2009
Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey.
    The new microbiologica, 2009, Volume: 32, Issue:2

    Topics: Amidohydrolases; Amino Acid Substitution; Antitubercular Agents; DNA, Bacterial; Drug Resistance, Ba

2009
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
    American journal of respiratory and critical care medicine, 2009, Sep-15, Volume: 180, Issue:6

    Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination;

2009
Pulmonary tuberculosis presenting as fever without source in a pediatric patient with acute lymphoblastic leukemia.
    Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Azithromycin; Child, Preschoo

2009
Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:10

    Topics: Animals; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Isoni

2009
Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.
    Respirology (Carlton, Vic.), 2009, Volume: 14, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Drug Therapy, Combination;

2009
Experimental ocular tuberculosis in guinea pigs.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2009, Volume: 127, Issue:9

    Topics: Aerosols; Animals; Antitubercular Agents; Disease Models, Animal; DNA, Bacterial; Guinea Pigs; Isoni

2009
[Relapse rate of tuberculosis treated with standard regimen of chemotherapy].
    Kekkaku : [Tuberculosis], 2009, Volume: 84, Issue:9

    Topics: Adolescent; Aged; Aged, 80 and over; Child; Diabetes Complications; Drug Administration Schedule; Fe

2009
Non conversion of sputum smears in new smear positive pulmonary tuberculosis patients in Yaoundé, Cameroon.
    East African medical journal, 2009, Volume: 86, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Came

2009
Evaluation of standard chemotherapy in the guinea pig model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5

    Topics: Animals; Animals, Outbred Strains; Antitubercular Agents; Biomarkers; CD8-Positive T-Lymphocytes; Di

2010
Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2009, Volume: 13, Issue:3

    Topics: Adult; Antitubercular Agents; Case-Control Studies; Female; Humans; Intestinal Absorption; Isoniazid

2009
Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2010, Volume: 20, Issue:4

    Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female;

2010
Role of 2-month sputum smears in predicting culture conversion in pulmonary tuberculosis.
    The European respiratory journal, 2011, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male;

2011
[A 95 year old woman with bilateral nodular pulmonary pattern].
    Medicina clinica, 2012, Feb-04, Volume: 138, Issue:2

    Topics: Aged, 80 and over; Antitubercular Agents; Drug Therapy, Combination; Dyspnea; Emergencies; Fatal Out

2012
Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis.
    The European respiratory journal, 2010, Volume: 36, Issue:1

    Topics: Antitubercular Agents; British Columbia; Ethambutol; Female; Humans; Isoniazid; Longitudinal Studies

2010
Posttreatment reactivation of tuberculosis in mice caused by Mycobacterium tuberculosis disrupted in mce1R.
    The Journal of infectious diseases, 2010, Sep-01, Volume: 202, Issue:5

    Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Female; Humans; Isoniazi

2010
[Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
    Pneumonologia i alergologia polska, 2010, Volume: 78, Issue:4

    Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Ison

2010
Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of mycobacterium tuberculosis from South India.
    International journal of molecular sciences, 2010, Jul-07, Volume: 11, Issue:7

    Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; India; Microbial Sensiti

2010
A nodulo-ulcerative lesion on the nose.
    Dermatology online journal, 2010, Aug-15, Volume: 16, Issue:8

    Topics: Aged, 80 and over; Antitubercular Agents; Chronic Disease; Ethambutol; Female; Humans; Isoniazid; Lu

2010
Activity of pyrazinamide in the guinea pig model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:12

    Topics: Animals; Antitubercular Agents; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Therapy, Co

2010
[Sputum smear conversion during intensive TB treatment phase according to HIV status, in hospitalised patients in Togo].
    Medecine et maladies infectieuses, 2011, Volume: 41, Issue:3

    Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Ethambutol; Female; F

2011
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
    American journal of respiratory and critical care medicine, 2011, May-01, Volume: 183, Issue:9

    Topics: Animals; Anti-Inflammatory Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cortisone; Di

2011
Harnessing the full sterilising activity of rifamycins.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2011, Volume: 15, Issue:4

    Topics: Animals; Antitubercular Agents; Drug Design; Humans; Pyrazinamide; Rifampin; Rifamycins; Time Factor

2011
An apparently healthy young man with a peculiar-looking chest radiograph.
    Canadian family physician Medecin de famille canadien, 2011, Volume: 57, Issue:3

    Topics: Adult; Antibiotics, Antitubercular; Drug Therapy, Combination; Ethambutol; Fever; HIV Seropositivity

2011
[Pulmonary paragonimiasis].
    Archivos de bronconeumologia, 2011, Volume: 47, Issue:12

    Topics: Adult; Animals; Anthelmintics; Antitubercular Agents; Caulobacteraceae; Delayed Diagnosis; Ecuador;

2011
[Cutaneous reaction after pyrazinamide initiation].
    Medecine et maladies infectieuses, 2011, Volume: 41, Issue:9

    Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Eruptions; Drug Therapy, Combination; Dysgeusi

2011
Pulmonary tuberculosis in infants less than one year old: implications for early diagnosis.
    Tuberkuloz ve toraks, 2011, Volume: 59, Issue:1

    Topics: Antitubercular Agents; Early Diagnosis; Family; Female; Hospitals, Pediatric; Hospitals, Teaching; H

2011
Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India.
    The Indian journal of medical research, 2011, Volume: 133

    Topics: Adult; Antitubercular Agents; Communicable Disease Control; Directly Observed Therapy; Enzyme-Linked

2011
Metabolic regulation of mycobacterial growth and antibiotic sensitivity.
    PLoS biology, 2011, Volume: 9, Issue:5

    Topics: Acetyl Coenzyme A; Anaerobiosis; Animals; Antitubercular Agents; Bacterial Load; Bacterial Proteins;

2011
Multifocal tuberculosis revealed by multiple cutaneous gummas in the immunocompetent.
    Dermatology online journal, 2011, May-15, Volume: 17, Issue:5

    Topics: Antitubercular Agents; Clavicle; Drug Therapy, Combination; Ethambutol; Humans; Immunocompetence; Is

2011
Tuberculous damaged lung in a child.
    Pediatric pulmonology, 2011, Volume: 46, Issue:12

    Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Ethambutol; Female; Granuloma; Humans; Ison

2011
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1

    Topics: Animals; Antitubercular Agents; Aza Compounds; Biological Availability; Disease Models, Animal; Drug

2012
When tuberculosis comes back: who develops recurrent tuberculosis in california?
    PloS one, 2011, Volume: 6, Issue:11

    Topics: Adult; Antitubercular Agents; California; Drug Therapy, Combination; Female; HIV; HIV Infections; Hu

2011
[Sudden decrease in visual acuity and pulmonary infiltrates].
    Enfermedades infecciosas y microbiologia clinica, 2012, Volume: 30, Issue:3

    Topics: Adrenal Cortex Hormones; Antitubercular Agents; Ethambutol; Humans; Isoniazid; Laser Coagulation; Ma

2012
Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2

    Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; I

2012
A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
    Microbial drug resistance (Larchmont, N.Y.), 2012, Volume: 18, Issue:4

    Topics: Antitubercular Agents; Biological Transport; Biotransformation; Drug Resistance, Bacterial; Humans;

2012
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple

2012
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple

2012
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple

2012
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple

2012
[Paradoxical radiologic progression despite appropriate anti-tuberculous therapy].
    Mikrobiyoloji bulteni, 2012, Volume: 46, Issue:2

    Topics: Aged; Antitubercular Agents; Bronchoalveolar Lavage Fluid; Bronchoscopy; Ethambutol; Humans; Isoniaz

2012
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Administra

2012
Pyrazinamide-induced sideroblastic anaemia.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2012, Volume: 16, Issue:8

    Topics: Adult; Anemia, Sideroblastic; Antitubercular Agents; Humans; Male; Pyrazinamide; Tuberculosis, Pulmo

2012
Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11

    Topics: Antitubercular Agents; Area Under Curve; Body Weight; Drug Dosage Calculations; Ethnicity; Female; H

2012
Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
    Tuberkuloz ve toraks, 2012, Volume: 60, Issue:2

    Topics: Adult; Age Factors; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Drug

2012
Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11

    Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination;

2012
Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis.
    Artificial cells, nanomedicine, and biotechnology, 2013, Volume: 41, Issue:1

    Topics: Animals; Antitubercular Agents; Drug Delivery Systems; Drug Therapy, Combination; Humans; Isoniazid;

2013
[Directly observed treatment for tuberculosis in a Buenos Aires City hospital].
    Medicina, 2012, Volume: 72, Issue:5

    Topics: Adult; Antitubercular Agents; Argentina; Directly Observed Therapy; Drug Therapy, Combination; Etham

2012
Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study.
    BMC research notes, 2012, Dec-12, Volume: 5

    Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Drug Administration Schedule; Fem

2012
Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2002, Volume: 6, Issue:8

    Topics: Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Bilirubin; Chemical and Dr

2002
[The study on the duration of treatment in the standard short course chemotherapy containing pyrazinamide].
    Kekkaku : [Tuberculosis], 2002, Volume: 77, Issue:7

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Pyrazinamide

2002
Pulmonary alveolar proteinosis and tuberculosis in a diabetic patient: a rare or a seldom diagnosed association?
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2002, Volume: 6, Issue:4

    Topics: Adult; Diabetes Complications; Female; Humans; Isoniazid; Mycobacterium tuberculosis; Pulmonary Alve

2002
[Chemotherapy with isoniazid and rifampicin for pulmonary tuberculosis].
    Kekkaku : [Tuberculosis], 2002, Volume: 77, Issue:8

    Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Japan; Pyrazinamide; Reference

2002
An ex vivo culture model for screening drug activity against in vivo phenotypes of Mycobacterium tuberculosis.
    Microbiology (Reading, England), 2002, Volume: 148, Issue:Pt 10

    Topics: Animals; Antitubercular Agents; BCG Vaccine; Cells, Cultured; Culture Media; Female; Humans; Lucifer

2002
Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida.
    Chest, 2002, Volume: 122, Issue:4

    Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Case-Control Studies; Coh

2002
Tuberculosis re-treatment outcomes within the public service in Nairobi, Kenya.
    East African medical journal, 2002, Volume: 79, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag

2002
[Pulmonary tuberculosis presenting as tubercular lupus].
    Revue des maladies respiratoires, 2002, Volume: 19, Issue:4

    Topics: Adolescent; Antitubercular Agents; Biopsy; Drug Combinations; Female; Humans; Isoniazid; Lupus Vulga

2002
[Myrin P in the combined treatment of tuberculosis].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2002, Volume: 47, Issue:6

    Topics: Adolescent; Adult; Antitubercular Agents; Drug Combinations; Drug Resistance, Multiple, Bacterial; E

2002
Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2002, Volume: 6, Issue:11

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antitubercular; Child; Drug Therapy, Co

2002
Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2002, Volume: 6, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Anti-Bacterial Agents; Antib

2002
[The evolution of threshold values of air conduction in the extended high frequency range (9-18 kHz) in patients suffering from the pulmonary tuberculosis treated with combination of SM, INH, RFM, and PZA].
    Pneumonologia i alergologia polska, 2002, Volume: 70, Issue:5-6

    Topics: Adult; Antitubercular Agents; Audiometry, Pure-Tone; Auditory Threshold; Case-Control Studies; Deafn

2002
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
    American journal of respiratory and critical care medicine, 2003, May-15, Volume: 167, Issue:10

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D

2003
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
    American journal of respiratory and critical care medicine, 2003, May-15, Volume: 167, Issue:10

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D

2003
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
    American journal of respiratory and critical care medicine, 2003, May-15, Volume: 167, Issue:10

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D

2003
Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
    American journal of respiratory and critical care medicine, 2003, May-15, Volume: 167, Issue:10

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Confidence Intervals; D

2003
Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
    Chest, 2003, Volume: 123, Issue:1

    Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induc

2003
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    American journal of respiratory and critical care medicine, 2003, Jun-01, Volume: 167, Issue:11

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug In

2003
Perianal tuberculosis: a rare case of skin ulceration?
    Acta dermato-venereologica, 2002, Volume: 82, Issue:6

    Topics: Adult; Antitubercular Agents; Anus Diseases; Ethambutol; Humans; Male; Pyrazinamide; Skin Ulcer; Tre

2002
Drug-resistant Mycobacterium tuberculosis among new tuberculosis patients, Yangon, Myanmar.
    Emerging infectious diseases, 2003, Volume: 9, Issue:2

    Topics: AIDS-Related Opportunistic Infections; Drug Resistance, Bacterial; Ethambutol; Humans; Isoniazid; My

2003
The decline of high drug resistance rate of pulmonary Mycobacterium tuberculosis isolates from a southern Taiwan medical centre, 1996-2000.
    International journal of antimicrobial agents, 2003, Volume: 21, Issue:3

    Topics: Antitubercular Agents; Cycloserine; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial

2003
Low level of compliance with tuberculosis treatment in children: monitoring by urine tests.
    Annals of tropical paediatrics, 2003, Volume: 23, Issue:1

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Therapy, Combination; Humans; Isonia

2003
[Clinical evaluation on the duration of hospitalization for patients with pulmonary tuberculosis].
    Kekkaku : [Tuberculosis], 2003, Volume: 78, Issue:2

    Topics: Antitubercular Agents; Humans; Length of Stay; Pyrazinamide; Retrospective Studies; Tuberculosis, Pu

2003
Treatment outcome of tuberculosis among Saudi nationals: role of drug resistance and compliance.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2003, Volume: 9, Issue:4

    Topics: Antibiotics, Antitubercular; Female; Humans; Isoniazid; Male; Mycobacterium tuberculosis; Prevalence

2003
[Tuberculous peripheral multifocal choroiditis].
    Archivos de la Sociedad Espanola de Oftalmologia, 2003, Volume: 78, Issue:3

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antitubercular Agents; Choroiditis; Drug Therapy, Co

2003
Follow-up of compliance with tuberculosis treatment in children: monitoring by urine tests.
    Pediatric pulmonology, 2003, Volume: 36, Issue:1

    Topics: Antitubercular Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administratio

2003
[The short-term and long-term treatment outcomes in patients with pulmonary tuberculosis positive for drug-resistant and sensitive strains].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2003, Volume: 26, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Drug Therapy, Combination;

2003
[Follow-up observation on relapse of smear negative pulmonary tuberculosis after short-course chemotherapy].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2003, Volume: 26, Issue:2

    Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male

2003
Widespread pyrazinamide-resistant Mycobacterium tuberculosis family in a low-incidence setting.
    Journal of clinical microbiology, 2003, Volume: 41, Issue:7

    Topics: Amidohydrolases; Antitubercular Agents; Case-Control Studies; DNA Transposable Elements; Drug Resist

2003
Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:9

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Biocompatible Materia

2003
[Determination of Mycobacterium tuberculosis' sensitivity to pyrazinamide on a BACTEC-960 bacteriological analyzer].
    Problemy tuberkuleza i boleznei legkikh, 2003, Issue:7

    Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide

2003
Pyrazinamide (aldinamide*) in the treatment of pulmonary tuberculosis.
    Transactions of the annual meeting. National Tuberculosis Association, 1952, Volume: 48

    Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1952
Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study.
    American review of tuberculosis, 1954, Volume: 69, Issue:3

    Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1954
Observations on pyrazinamide (Aldinamide) in pulmonary tuberculosis.
    American review of tuberculosis, 1954, Volume: 69, Issue:3

    Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1954
The chemotherapy of pulmonary tuberculosis with pyrazinamide used alone and in combination with streptomycin, para-aminosalicylic acid, or isoniazid.
    American review of tuberculosis, 1954, Volume: 70, Issue:3

    Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Streptomycin; Tube

1954
Pyrazinamide-isoniazid in tuberculosis. I. Results in 58 patients with pulmonary lesions one year after the start of therapy.
    American review of tuberculosis, 1954, Volume: 70, Issue:4

    Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1954
Experience with pyrazinamide.
    Diseases of the chest, 1955, Volume: 27, Issue:1

    Topics: Aminosalicylic Acid; Niacin; Nicotinic Acids; Pyrazinamide; Streptomycin; Tuberculosis; Tuberculosis

1955
Pyrazinamide-isoniazid in tuberculosis. III. Observations with reduced dosage of pyrazinamide.
    American review of tuberculosis, 1955, Volume: 72, Issue:6

    Topics: Clinical Protocols; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pu

1955
Pyrazinamide-isoniazid: comparison with isoniazid-para-aminosalicylic acid in active pulmonary tuberculosis with the choice of regimens determined by chance.
    American review of tuberculosis, 1956, Volume: 73, Issue:5

    Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Pyrimidines; Tuberculosis; Tu

1956
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
    Minerva medica, 1956, Oct-06, Volume: 47, Issue:80

    Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub

1956
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
    Minerva medica, 1956, Oct-06, Volume: 47, Issue:80

    Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub

1956
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
    Minerva medica, 1956, Oct-06, Volume: 47, Issue:80

    Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub

1956
[Possible therapeutic use of new preparations with antituberculous action (pyrazinamide and cycloserine); preliminary note].
    Minerva medica, 1956, Oct-06, Volume: 47, Issue:80

    Topics: Anti-Bacterial Agents; Cycloserine; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tub

1956
[Clinical experiences with pyrazinamide].
    Schweizerische Zeitschrift fur Tuberkulose und Pneumonologie. Revue suisse de la tuberculose et de pneumonologie. Rivista svizzera della tubercolosi e della pneumonologia, 1956, Volume: 13, Issue:6

    Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Streptomycin; Tuberculosis; T

1956
[Further observations on pyrazinamide].
    Schweizerische Zeitschrift fur Tuberkulose und Pneumonologie. Revue suisse de la tuberculose et de pneumonologie. Rivista svizzera della tubercolosi e della pneumonologia, 1956, Volume: 13, Issue:6

    Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Dermatologic Agents; Isoniazid; Pyrazinamide; Tu

1956
Pyrazinamide together with oxytetracycline in patients with tubercle bacilli resistant to streptomycin, PAS and isoniazid.
    The British journal of tuberculosis and diseases of the chest, 1957, Volume: 51, Issue:2

    Topics: Aminosalicylic Acid; Bacillus; Isoniazid; Lacticaseibacillus casei; Niacin; Nicotinic Acids; Oxytetr

1957
[Treatment of chronic pulmonary tuberculosis with pyrazinamide].
    Gazzetta medica italiana, 1956, Volume: 115, Issue:12

    Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1956
[Behavior of the Middlebrook-Dubos reaction and of phagocytosis in pulmonary tuberculosis treated with pyrazinamide].
    Minerva medica, 1957, Feb-07, Volume: 48, Issue:11

    Topics: Humans; Niacin; Nicotinic Acids; Phagocytosis; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
[Elimination of urinary 17-ketosteroids in pulmonary tuberculosis treated with pyrazinamide].
    Minerva medica, 1957, Feb-07, Volume: 48, Issue:11

    Topics: 17-Ketosteroids; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Steroids; Tuberculosis; Tuberculosis

1957
[Determination of prothrombin time (Quick test) and plasma fibrinogen in pulmonary tuberculosis treated with pyrazinamide].
    Minerva medica, 1957, Feb-07, Volume: 48, Issue:11

    Topics: Fibrinogen; Humans; Niacin; Nicotinic Acids; Prothrombin Time; Pyrazinamide; Tuberculosis; Tuberculo

1957
[Blood iodine precipitation and cholesteremia in pulmonary tuberculosis treated with pyrazinamide].
    Minerva medica, 1957, Feb-07, Volume: 48, Issue:11

    Topics: Cholesterol; Humans; Iodine; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulm

1957
[Peripheral blood picture in pulmonary tuberculosis treated with pyrazinamide].
    Minerva medica, 1957, Feb-07, Volume: 48, Issue:11

    Topics: Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
[Blood proteins in pulmonary tuberculosis treated with pyrazinamide; electrophoresis and serodiagnosis].
    Minerva medica, 1957, Feb-07, Volume: 48, Issue:11

    Topics: Blood Proteins; Electrophoresis; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberc

1957
[Pyrazinamide in the treatment of pulmonary tuberculosis].
    Minerva medica, 1957, Feb-14, Volume: 48, Issue:13

    Topics: Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
[Liver function and pyrazinamide therapy of pulmonary tuberculosis].
    Gazzetta medica italiana, 1957, Volume: 116, Issue:1

    Topics: Liver; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
Pyrazinamide-isoniazid in patients with previous isoniazid therapy.
    American review of tuberculosis, 1957, Volume: 75, Issue:5

    Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
[Treatment of pulmonary tuberculosis with high alternating dosage of pyrazinamide and isoniazid].
    Gazzetta medica italiana, 1957, Volume: 116, Issue:6

    Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
[Pyrazinamide in pulmonary tuberculosis; behavior of blood proteins].
    Il Policlinico. Sezione pratica, 1957, May-27, Volume: 64, Issue:21

    Topics: Blood Proteins; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
[Pyrazinamide-isoniazid mixture in the treatment of chronic pulmonary tuberculosis].
    Minerva medica, 1957, Jun-06, Volume: 48, Issue:45

    Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
Comparative efficacy of the concurrent use of pyrazinamide and isoniazid with that of other forms of therapy in the treatment of pulmonary tuberculosis.
    Diseases of the chest, 1957, Volume: 32, Issue:4

    Topics: Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
[Pyrazinamide & pyrazinamide with isoniazid in pulmonary tuberculosis; comparison with other chemotherapeuticantibiotic combinations].
    Minerva medica, 1957, Sep-01, Volume: 48, Issue:70

    Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
Pyrazinamide and cycloserine in the treatment of pulmonary tuberculosis.
    American review of tuberculosis, 1957, Volume: 76, Issue:6

    Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Niacin; Nicotinic Acids; Pyrazinami

1957
[Pyrazinamide and gastric functional response in pulmonary tuberculosis].
    Minerva medica, 1957, Oct-27, Volume: 48, Issue:86

    Topics: Humans; Niacin; Nicotinic Acids; Pyrazinamide; Stomach; Tuberculosis; Tuberculosis, Pulmonary

1957
[Pyrazinamide in therapy of cavitary tuberculosis resistant to usual therapy].
    Acta tuberculosea Belgica, 1957, Volume: 48, Issue:5

    Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
Pyrazinamide and viomycin in the surgical treatment of pulmonary tuberculosis.
    American review of tuberculosis, 1958, Volume: 77, Issue:1

    Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary; Viomycin

1958
[Combined pyrazinamide and isoniazid in therapy of pulmonary tuberculosis].
    Gazzetta medica italiana, 1957, Volume: 116, Issue:10

    Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
[Liver function tests of pulmonary tuberculosis patients treated with pyrazinamide].
    Lotta contro la tubercolosi, 1957, Volume: 27, Issue:11

    Topics: Liver; Liver Function Tests; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulm

1957
[Experience on the use of pyrazinamide in the treatment of pulmonary tuberculosis. I. Clinical results].
    Gazzetta medica italiana, 1957, Volume: 116, Issue:12

    Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1957
[Experience on the use of pyrazinamide in the treatment of pulmonary tuberculosis. II. Hepatic function & blood proteins in the scope of clinical changes].
    Gazzetta medica italiana, 1957, Volume: 116, Issue:12

    Topics: Blood Proteins; Liver; Pyrazinamide; Tuberculosis; Tuberculosis, Hepatic; Tuberculosis, Pulmonary

1957
[Pyrazinamide and gastric functional response in pulmonary tuberculosis].
    Lotta contro la tubercolosi, 1957, Volume: 27, Issue:12

    Topics: Niacin; Nicotinic Acids; Pyrazinamide; Stomach; Tuberculosis; Tuberculosis, Pulmonary

1957
[Radiological records of the results of combined pyrazinamide-streptomycin-isoniazid therapy].
    Gazzetta medica italiana, 1958, Volume: 117, Issue:4

    Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Radiology; Streptomycin; Tuberculosis; Tuberculosi

1958
Clinical and biological investigations on the new antituberculosis drugs (pyrazinamide and cycloserine).
    Diseases of the chest, 1958, Volume: 34, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cycloserine; Niacin; Nico

1958
[Studies on the changes of the daily amount of tubercle bacilli present in sputum and its resistance against drugs, when patients have been treated with anti-tuberculous agents. I. Combined therapy with pyrazinamide and isonicotinic acid hydrazide].
    Kekkaku : [Tuberculosis], 1958, Volume: 33, Issue:6

    Topics: Bacillus; Humans; Isoniazid; Lung; Pyrazinamide; Sputum; Tuberculosis; Tuberculosis, Pulmonary

1958
Pulmonary resection for tuberculosis under protection of viomycin, promizole and pyrazinamide.
    Diseases of the chest, 1958, Volume: 34, Issue:5

    Topics: Niacin; Nicotinic Acids; Pneumonectomy; Pyrazinamide; Sulfathiazole; Sulfathiazoles; Thiazoles; Tube

1958
Treatment of drug-resistant cases of pulmonary tuberculosis with cycloserine and pyrazinamide.
    Tubercle, 1958, Volume: 39, Issue:5

    Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Niacin; Nicotinic Acids; Pyrazinami

1958
Cycloserine combined with pyrazinamide in the treatment of pulmonary tuberculosis.
    American review of tuberculosis, 1958, Volume: 78, Issue:6

    Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Niacin; Nicotinic Acids; Pyrazinami

1958
[Pyrazinamide in solution, for topical use, in the treatment of tuberculous empyema].
    Minerva medica, 1958, Aug-29, Volume: 49, Issue:69

    Topics: Empyema, Tuberculous; Humans; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pul

1958
Pyrazinamide in low dosage in combination with isoniazid or paraaminosalicylic acid in the treatment of pulmonary tuberculosis.
    American review of tuberculosis, 1959, Volume: 79, Issue:1

    Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, P

1959
The use of pyrazinamide plus isoniazid in the treatment of pulmonary tuberculosis.
    Tubercle, 1959, Volume: 40, Issue:1

    Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1959
[Tests of liver function during pyrazinamide therapy].
    Minerva pediatrica, 1959, Mar-31, Volume: 11, Issue:13

    Topics: Child; Humans; Infant; Isoniazid; Liver; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberc

1959
[Observations on therapy of pulmonary tuberculosis with viomycin pyrazinamide & cycloserine].
    Giornale di clinica medica, 1959, Volume: 40, Issue:5

    Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Humans; Niacin; Nicotinic Acids; Py

1959
[A clinical experience report on combined therapy of pulmonary tuberculosis with cycloserine-pyrazinamide].
    Wiener medizinische Wochenschrift (1946), 1961, Jan-21, Volume: 111

    Topics: Cycloserine; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1961
Retreatment of pulmonary tuberculosis. Experiences with various combinations of pyrazinamide, cycloserine, and kanamycin in patients excreting tubercle bacilli resistant to both streptomycin and isoniazid.
    The American review of respiratory disease, 1960, Volume: 82

    Topics: Anti-Bacterial Agents; Bacillus; Cycloserine; Humans; Isoniazid; Kanamycin; Pyrazinamide; Retreatmen

1960
[Pyrazinamide in the treatment of pulmonary tuberculosis].
    Gruzlica (Warsaw, Poland : 1926), 1960, Volume: 28

    Topics: Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1960
[Cycloserine associated with other chemio-antibiotics in the treatment of pulmonary tuberculosis. Clinical contribution on pyrazinamidecycloserine association].
    Minerva medica, 1961, Jan-17, Volume: 52

    Topics: Anti-Bacterial Agents; Cycloserine; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1961
Retreatment of tuberculous patients: an experience with the combined use of high doses of isoniazid, pyrazinamide and cycloserine.
    Southern medical journal, 1961, Volume: 54

    Topics: Cycloserine; Isoniazid; Pyrazinamide; Retreatment; Tuberculosis; Tuberculosis, Pulmonary

1961
[Experiences with a pyrazinamide-INH combination in the treatment of pulmonary tuberculosis].
    Die Medizinische Welt, 1960, Oct-15, Volume: 42

    Topics: Antitubercular Agents; Humans; Pyrazinamide; Tuberculosis, Pulmonary

1960
Resectional therapy for pulmonary tuberculosis at Summount, 1950-1957; 807 cases. V. Resectional therapy for pulmonary tuberculosis under viomycin and pyrazinamide coverage.
    Diseases of the chest, 1961, Volume: 39

    Topics: Pyrazinamide; Tuberculosis, Pulmonary; Viomycin

1961
Pyrazinamide-isoniazid treated tuberculous patients: a five year follow-up.
    The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 1959, Volume: 111

    Topics: Follow-Up Studies; Humans; Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1959
[Therapy of pulmonary tuberculosis with pyrazinamide].
    Beitrage zur Klinik der Tuberkulose und spezifischen Tuberkulose-Forschung, 1960, Volume: 122

    Topics: Antitubercular Agents; Humans; Pyrazinamide; Tuberculosis, Pulmonary

1960
Treatment of pulmonary tuberculosis with isoniazid and pyrazinamide: experience in 114 cases.
    Diseases of the chest, 1959, Volume: 36

    Topics: Humans; Isoniazid; Pyrazinamide; Tuberculosis, Pulmonary

1959
[The use of Piazofoline in the pre- and post-operative treatment of pulmonary tuberculosis].
    Minerva medica, 1962, Jun-02, Volume: 53

    Topics: Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1962
[Piazofoline in the therapy of pulmonary tuberculosis].
    Minerva medica, 1962, Jun-02, Volume: 53

    Topics: Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1962
[Results in the treatment of chronic pulmonary tuberculosis in adults with pyrazinamide in association with PAS].
    Gruzlica (Warsaw, Poland : 1926), 1962, Volume: 30

    Topics: Aminosalicylic Acid; Pyrazinamide; Tuberculosis, Pulmonary

1962
[The treatment of pulmonary tuberculosis with the drugs of the 2d series (Aetina, d-cycloserine and pyrazinamide) with special reference to experiences with Aetina].
    Zeitschrift fur arztliche Fortbildung, 1962, May-15, Volume: 56

    Topics: Cycloserine; Pyrazinamide; Tuberculosis, Pulmonary

1962
Successful treatment of advanced isonizid- and streptomycin-resistant pulmonary tuberculosis with ethionamide, pyrazinamide, and isoniazid.
    The American review of respiratory disease, 1962, Volume: 86

    Topics: Drug Resistance; Drug Resistance, Microbial; Ethionamide; Humans; Isoniazid; Pyrazinamide; Streptomy

1962
The tate of patients with drug-resistant tubercle bacilli and pulmonary tuberculosis.
    British journal of diseases of the chest, 1962, Volume: 56

    Topics: Anti-Bacterial Agents; Bacillus; Cycloserine; Drug Resistance; Drug Resistance, Microbial; Ethionami

1962
[On the treatment of adult-type pulmonary tuberculosis during puberty with isoniazid plus pyrazinamide].
    Der Tuberkulosearzt, 1962, Volume: 16

    Topics: Adult; Humans; Isoniazid; Puberty; Pyrazinamide; Sexual Maturation; Tuberculosis, Pulmonary

1962
[The importance of medical treatment of pulmonary tuberculosis from a new viewpoint].
    Der Internist, 1962, Volume: 3

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Dihydrostreptomycin Sulfate; Ethionamide; Ip

1962
Re-treatment therapy with cycloserine-pyrazinamide. Response in cavity closure and disappearance of tubercle bacilli from sputum.
    The American review of respiratory disease, 1962, Volume: 86

    Topics: Bacillus; Cycloserine; Humans; Lacticaseibacillus casei; Pyrazinamide; Sputum; Tuberculosis; Tubercu

1962
Ethionamide, pyrazinamide and cycloserine used successfully in the treatment of chronic pulmonary tuberculosis.
    Tubercle, 1962, Volume: 43

    Topics: Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1962
[Pyrazinamide in association with streptomycin, PAS and isoniazid in the therapy of pulmonary tuberculosis].
    Minerva medica, 1962, Sep-12, Volume: 53

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuberculos

1962
Bacteriological aspects of the use of ethionamide, pyrazinamide and cycloserine in the treatment of chronic pulmonary tuberculosis.
    Tubercle, 1962, Volume: 43

    Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Ethionamide; Humans; Pyrazinamide; Tubercu

1962
Pyrazinamide and ethionamide in the treatment of pulmonary tuberculosis in Hong Kong.
    Tubercle, 1963, Volume: 44

    Topics: Ethionamide; Hong Kong; Humans; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1963
[Various biological tests on several groups of subjects with tuberculosis subjected respectively to monotherapy with isoniazid, viomycin, pyrazinamide, cycloserine, ethioniamide and kanamycin].
    Annali dell'Istituto "Carlo Forlanini", 1962, Volume: 22

    Topics: Cycloserine; Ethionamide; Isoniazid; Kanamycin; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary;

1962
PYRAZINAMIDE COVERAGE AT THE TIME OF PULMONARY RESECTION FOR TUBERCULOSIS.
    Annals of surgery, 1963, Volume: 158

    Topics: Humans; Pneumonectomy; Postoperative Complications; Preoperative Care; Pyrazinamide; Tuberculosis; T

1963
[SYMPOSIUM: COUNTER-MEASURES IN INTRACTABLE PULMONARY TUBERCULOSIS].
    Kekkaku : [Tuberculosis], 1963, Volume: 38

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethionamide; Isoniazi

1963
[THE THERAPY OF PULMONARY TUBERCULOSIS WITH MORPHAZINAMIDE. CLINICAL CONTRIBUTION].
    La Clinica terapeutica, 1963, Aug-31, Volume: 26

    Topics: Antitubercular Agents; Humans; Pyrazinamide; Pyrazines; Tuberculosis; Tuberculosis, Pulmonary

1963
MODERN DRUG TREATMENT OF MYCOBACTERIAL DISEASES.
    The Medical clinics of North America, 1963, Volume: 47

    Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloseri

1963
SIDE EFFECTS OF AN ANTITUBERCULOUS FIVE-DRUG REGIMEN: ETHIONAMIDE, CYCLOSERINE, PYRAZINAMIDE, VIOMYCIN AND ISONIAZID.
    Acta tuberculosea et pneumologica Scandinavica, 1963, Volume: 43

    Topics: Amyloidosis; Antitubercular Agents; Cycloserine; Deafness; Drug Hypersensitivity; Duodenal Ulcer; Et

1963
[PYRAZINAMIDE IN THE TREATMENT OF PULMONARY TUBERCULOSIS IN THE PRESENCE OF VARIOUS DEGRESS OF SENSITIVITY TO BASIC DRUGS].
    Gruzlica (Warsaw, Poland : 1926), 1963, Volume: 31

    Topics: Anti-Infective Agents, Local; Antitubercular Agents; Drug Resistance; Drug Resistance, Microbial; Hu

1963
[PRELIMINARY FUNCTIONAL AND MORPHOLOGICAL HEPATIC FINDINGS IN PATIENTS TREATED WITH MORPHAZINAMIDE].
    Rivista di anatomia patologica e di oncologia, 1963, Volume: 23

    Topics: Antitubercular Agents; Fatty Liver; Humans; Liver Function Tests; Pyrazinamide; Pyrazines; Silicotub

1963
[EXPERIENCE WITH A NONSPECIFIC ANTIINFLAMMATORY AGENT IN PULMONARY TUBERCULOSIS].
    La Semana medica, 1963, Jul-08, Volume: 123

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Inflammatory Agents; Cycloserine; Drug Resistance; D

1963
DRUG RESISTANT MYCOBACTERIAL INFECTION AND ITS RESPONSE TO TREATMENT.
    The Journal of the Kentucky Medical Association, 1963, Volume: 61

    Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium; Mycobact

1963
[CHEMO-ANTIBIOTIC THERAPY IN PULMONARY TUBERCULOSIS].
    Rassegna internazionale di clinica e terapia, 1963, Sep-30, Volume: 43

    Topics: Antitubercular Agents; Cycloserine; Ethionamide; Kanamycin; Pyrazinamide; Tuberculosis; Tuberculosis

1963
RECENT ADVANCES IN TREATMENT OF ORGAN TUBERCULOSIS.
    JAMA, 1964, Mar-14, Volume: 187

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Child; Cycloserine; Ethionamide; I

1964
CHEMOTHERAPY FOR PATIENTS WITH CULTURES RESISTANT TO STREPTOMYCIN, ISONIAZID AND PAS.
    Tubercle, 1963, Volume: 44

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Czechoslovakia; Drug Resistance; Drug Resist

1963
[ETHIONAMIDE IN ASSOCIATION WITH PYRAZINAMIDE OR CYCLOSERINE IN THE TREATMENT OF CHRONIC PULMONARY TUBERCULOSIS].
    Gruzlica (Warsaw, Poland : 1926), 1963, Volume: 31

    Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Ethionamide; Pyrazinamide; Toxicology; Tub

1963
[SOME CLINICAL ASPECTS OF DRUG RESISTANCE OF TUBERCLE BACILLI ISOLATED FROM PATIENTS WITH FIBRO-CAVERNOUS TUBERCULOSIS].
    Nauchni trudove na Visshiia meditsinski institut, Sofiia, 1963, Volume: 42

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Culture Media; Drug Resistance; Drug Resistance

1963
SOME PROBLEMS IN THE MANAGEMENT OF TUBERCULOSIS.
    The British journal of clinical practice, 1964, Volume: 18

    Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents;

1964
D-CYCLOSERINE IN THE TREATMENT OF PULMONARY TUBERCULOSIS RESISTANT TO THE STANDARD DRUGS: A STUDY OF 116 CASES.
    Diseases of the chest, 1964, Volume: 45

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial;

1964
[EFFECT OF PYRAZINAMIDE ON HEMOSTATIC FACTORS OF THE ORGANISM. (PRELIMINARY COMMUNICATION)].
    Gruzlica (Warsaw, Poland : 1926), 1963, Volume: 31

    Topics: Blood Coagulation; Blood Coagulation Tests; Blood Proteins; Hemostatics; Humans; Prothrombin Time; P

1963
[ANTIMICROBIAL SCREEN IN PHTHISIOLOGICAL SURGERY].
    Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti, 1963, Volume: 42

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Antitubercular Agents; Collapse Th

1963
[ANTIBACTERIAL TREATMENT IN PATIENTS AFFLICTED WITH PULMONARY TUBERCULOSIS CAUSED BY MYCOBACTERIA RESISTANT TO THE MAJOR CHEMO-ANTIBIOTICS].
    Annali dell'Istituto "Carlo Forlanini", 1963, Volume: 23

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Colla

1963
[THE RESULTS OBTAINED WITH THE COMBINATION OF PYRAZINAMIDE AND ISONIAZID IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
    Tip Fakultesi mecmuasi, 1963, Volume: 26

    Topics: Humans; Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1963
[TREATMENT OF TUBERCULOSIS AND DIABETES BECOMING SIMILAR].
    Nederlands tijdschrift voor geneeskunde, 1964, Feb-29, Volume: 108

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Diabetes Mellitus; Ethionamide; Isoniazid; P

1964
CLINICAL ASPECTS, MEDICAL AND SURGICAL, IN THE MANAGEMENT OF BATTEY-TYPE PULMONARY DISEASE.
    Diseases of the chest, 1964, Volume: 45

    Topics: Bronchiectasis; Calcification, Physiologic; Drug Resistance; Drug Resistance, Microbial; Epidemiolog

1964
ANTIMICROBIAL THERAPY OF PULMONARY TUBERCULOSIS.
    The Journal of the Egyptian Medical Association, 1963, Volume: 46

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Cycloserine; Dihydrostreptomycin S

1963
[THE USE OF ANTIBACILLARY DRUGS].
    Les Cahiers du College de medecine des hopitaux de Paris, 1964, Volume: 5

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial;

1964
A SPUTUM SURVEY OF CASES OF PULMONARY TUBERCULOSIS TWO TO THREE YEARS AFTER STARTING TREATMENT IN A RURAL AREA IN KENYA.
    East African medical journal, 1964, Volume: 41

    Topics: Child; Drug Resistance; Drug Resistance, Microbial; Health Surveys; Humans; Infant; Isoniazid; Kenya

1964
[THE TREATMENT OF TUBERCULOSIS WITH 2ND LINE DRUGS].
    La Semana medica, 1964, Mar-16, Volume: 124

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Cyclo

1964
[ANTIMICROBIAL TREATMENT OF TUBERCULOSIS WITH SUBSIDIARY DRUGS. 2ND LINE DRUGS].
    La Semana medica, 1964, Mar-16, Volume: 124

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Antitubercular Agents; Bacteriolog

1964
INHIBITION OF PYRAZINAMIDE HYPERURICEMIA BY SMALL DOSES OF ACETYLSALICYLIC ACID.
    Annals of internal medicine, 1964, Volume: 60

    Topics: Aspirin; Blood Chemical Analysis; Drug Therapy; Humans; Hyperuricemia; Pyrazinamide; Toxicology; Tub

1964
[ASSOCIATION OF 4,4'-DIISOAMYLOXYTHIOCARBANILIDE AND PYRAZINAMIDE, AND 4,4'-DIISOAMYLOXYTHIOCARBANILIDE AND KANAMYCIN IN THE TREATMENT OF PULMONARY TUBERCULOSIS CAUSED BY BACTERIA RESISTANT TO THE 1ST LINE DRUGS].
    La Semana medica, 1964, Mar-16, Volume: 124

    Topics: Antitubercular Agents; Bacteria; Bacteriology; Drug Resistance; Drug Resistance, Microbial; Kanamyci

1964
PULMONARY TUBERCULOSIS.
    Modern treatment, 1964, Volume: 1

    Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Child; Cycloserine; Drug Resista

1964
A CONTROLLED COMPARISON OF STREPTOMYCIN PLUS PYRAZINAMIDE AND STREPTOMYCIN PLUS PAS IN THE RETREATMENT OF PATIENTS EXCRETING ISONIAZID-RESISTANT ORGANISMS.
    Tubercle, 1964, Volume: 45

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriology; Biomedical Research; Drug Resistance; Drug

1964
A SIMPLE TABLET TEST FOR THE DETECTION OF PYRAZINAMIDE IN THE URINE.
    Tubercle, 1964, Volume: 45

    Topics: Behavior; Biomedical Research; Chemical Phenomena; Chemistry; Drug Resistance; Drug Resistance, Micr

1964
TREATMENT OF PATIENTS WITH CULTURES RESISTANT TO THE PRIMARY ANTI-TUBERCULOSIS DRUGS.
    Tubercle, 1964, Volume: 45

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Bacteriological Techniques; Biomed

1964
[LUNG TUBERCULOMAS].
    Gazzetta internazionale di medicina e chirurgia, 1963, Dec-15, Volume: 67

    Topics: Adolescent; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Bronchoscopy;

1963
[APROPOS OF ETHIONAMIDE JAUNDICE].
    Le Poumon et le coeur, 1964, Volume: 20

    Topics: Alanine Transaminase; Alcoholism; Aminosalicylic Acid; Aminosalicylic Acids; Aspartate Aminotransfer

1964
RELAPSE IN TREATED CASES OF PULMONARY TUBERCULOSIS. I. THREE-YEAR FOLLOW-UP OF 312 PATIENTS DISCHARGED FROM THE HOSPITAL WITH MEDICAL APPROVAL, 1947-1954.
    The American review of respiratory disease, 1964, Volume: 90

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Communicable Disease Control; Foll

1964
[NEW DRUGS IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
    La Semana medica, 1964, Apr-13, Volume: 124

    Topics: Cycloserine; Ethionamide; Kanamycin; Pyrazinamide; Toxicology; Tuberculosis; Tuberculosis, Pulmonary

1964
[COMPLICATIONS IN THE TREATMENT OF PULMONARY TUBERCULOSIS WITH PYRAZINAMIDE].
    Srpski arhiv za celokupno lekarstvo, 1963, Volume: 91

    Topics: Pyrazinamide; Toxicology; Tuberculosis; Tuberculosis, Pulmonary

1963
[EFFECT OF PYRAZINAMIDE ON INACTIVE DUODENAL ULCER].
    Tuberkulozis es tudobetegsegek, 1964, Volume: 17

    Topics: Chemical and Drug Induced Liver Injury; Drug Therapy; Duodenal Ulcer; Hepatitis; Liver Function Test

1964
[CHEMO-ANTIBIOTIC THERAPY OF TUBERCULOSIS IN DIABETICS AND ITS REPERCUSSIONS ON GLUCIDE METABOLISM].
    Minerva medica, 1964, Aug-18, Volume: 55

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Blood Glucose; Carbohydrate Metabo

1964
ALTERNATING REGIMENS OF STREPTOMYCIN-PYAZINAMIDE, ISONIAZID-PARA-AMINOSALICYLIC ACID AT BATTEY STATE HOSPITAL.
    The American review of respiratory disease, 1964, Volume: 90

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Drug Therapy

1964
[CLINICAL EXPERIENCE WITH THE COMBINED APPEARANCE OF TUBERCULOSIS AND VIRUS HEPATITIS].
    Acta tuberculosea et pneumologica Scandinavica, 1964, Volume: 45

    Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Aminosalicylic Acids; Collapse Therapy; Drug Thera

1964
INFECTION OF MICE WITH MYCOBACTERIUM TUBERCULOSIS, STRAIN H37RA.
    The American review of respiratory disease, 1964, Volume: 90

    Topics: Animals; Isoniazid; Lung; Mice; Mycobacterium bovis; Mycobacterium tuberculosis; Pharmacology; Pyraz

1964
[ENZYMATIC STUDY OF THE LIVER IN PULMONARY TUBERCULOSIS. RESEARCH ON A POSSIBLE HEPATOTOXIC EFFECT OF ANTIBACTERIAL MEDICATIONS].
    Medicina thoracalis, 1964, Volume: 21

    Topics: Alanine Transaminase; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Aspartate Am

1964
CHEMOTHERAPY OF PREVIOUSLY TREATED PATIENTS WITH PULMONARY TUBERCULOSIS.
    Tubercle, 1964, Volume: 45

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Hypersensitivity; Drug Resistance; Drug

1964
RE-TREATMENT OF DRUG-RESISTANT PULMONARY TUBERCULOSIS AT BATTEY STATE HOSPITAL.
    The American review of respiratory disease, 1964, Volume: 90

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial;

1964
A PRELIMINARY REPORT ON A NEW ANTITUBERCULOUS DRUG 4-AMINO-2-HYDROXY-PHENYL-1, 3, 4,-OXADIAZOL-2-OL WS 127.
    Acta tuberculosea et pneumologica Scandinavica, 1964, Volume: 45

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Biomedical Research; Blood; Cyclos

1964
ANTITUBERCULOUS DRUGS AND SIDEROBLASTIC ANAEMIA.
    British journal of haematology, 1965, Volume: 11

    Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anemia; Anemia, Hypochromic; Anemia, Siderobl

1965
[AMBULATORY AND HOSPITAL THERAPY OF TUBERCULOSIS].
    Schweizerische medizinische Wochenschrift, 1964, Jun-20, Volume: 94

    Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antit

1964
DRUG RESISTANCE IN PULMONARY TUBERCULOSIS; TREATMENT WITH ETHIONAMIDE IN VARIOUS DRUG COMBINATIONS.
    Diseases of the chest, 1965, Volume: 47

    Topics: Cycloserine; Drug Combinations; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Drug Tole

1965
PYRAZINAMIDE AND ETHIONAMIDE IN RESISTANT PULMONARY TUBERCULOSIS IN AFRICANS. AN 18-MONTH FOLLOW-UP OF 32 PATIENTS.
    The Central African journal of medicine, 1965, Volume: 11

    Topics: Drug Therapy; Ethionamide; Follow-Up Studies; Pyrazinamide; Toxicology; Tuberculosis; Tuberculosis,

1965
THE USE OF ETHIONAMIDE IN COMBINED DRUG REGIMENS IN THE RE-TREATMENT OF ISONIAZID-RESISTANT PULMONARY TUBERCULOSIS.
    The American review of respiratory disease, 1965, Volume: 91

    Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resi

1965
[STUDY ON LIVER TOLERANCE TO N-(4-MORPHOLINOMETHYL-PYRAZINAMIDE) IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
    Therapeutische Umschau. Revue therapeutique, 1964, Volume: 21

    Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Tolerance; Hepatitis; Humans; Py

1964
[EXPERIENCES AND RESULT WITH SECONDARY DRUGS (ETHIONAMIDE, D-CYCLOSERINE, PYRAZINAMIDE AND VIOCIN) IN SURGICAL TREATMENT OF PULMONARY TUBERCULOSIS].
    Zeitschrift fur Tuberkulose und Erkrankungen der Thoraxorgane, 1964, Volume: 122

    Topics: Antitubercular Agents; Cycloserine; Ethionamide; Humans; Pneumonectomy; Pyrazinamide; Tuberculosis;

1964
A CONTROLLED CLINICAL TRIAL OF ETHIONAMIDE, CYCLOSERINE AND PYRAZINAMIDE IN PREVIOUSLY TREATED PATIENTS WITH PULMONARY TUBERCULOSIS.
    Tubercle, 1965, Volume: 46

    Topics: Cycloserine; Drug Therapy; Ethionamide; Isoniazid; Pyrazinamide; Radiography, Thoracic; Streptomycin

1965
CHEMOTHERAPY REGIMENS USED IN RETREATMENT OF PULMONARY TUBERCULOSIS. I. OBSERVATIONS ON THE EFFICACY OF COMBINATIONS OF KANAMYCIN, ETHIONAMIDE AND EITHER CYCLOSERINE OR PYRAZINAMIDE.
    Tubercle, 1965, Volume: 46

    Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Ethionamide; Kanamycin; Pyra

1965
CHEMOTHERAPY REGIMENS USED IN RETREATMENT OF PULMONARY TUBERCULOSIS. II. OBSERVATIONS ON THE EFFICACY OF COMBINATIONS OF ETHAMBUTOL, CAPREOMYCIN AND COMPANION DRUGS, INCLUDING 4-4 DIISOAMYLOXYTHIOSEMICARBANILIDE.
    Tubercle, 1965, Volume: 46

    Topics: Antitubercular Agents; Capreomycin; Cycloserine; Drug Resistance; Drug Resistance, Microbial; Drug T

1965
[Application of pyrazinamide in our thoracic surgery].
    Tuberkulozis, 1959, Volume: 12

    Topics: Pulmonary Surgical Procedures; Pyrazinamide; Thoracic Surgery; Thoracic Surgical Procedures; Tubercu

1959
[Early therapeutic effects of pyrazinamide treatment of pulmonary tuberculosis].
    Tuberkulozis, 1960, Volume: 13

    Topics: Pyrazinamide; Tuberculosis, Pulmonary

1960
[Primary pulmonary tuberculosis treated with pyrazinamide. Immediate clinical and radiological results and results after prolonged treatment with streptomycin and isoniazid].
    Lotta contro la tubercolosi, 1959, Volume: 29

    Topics: Humans; Isoniazid; Pyrazinamide; Radiology; Streptomycin; Tuberculosis, Pulmonary

1959
[Endocavitary aspiration with the aid of local introduction of prednisolone derivatives and chemoantibiotics].
    La Riforma medica, 1959, Aug-08, Volume: 73

    Topics: Cycloserine; Prednisolone; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1959
An investigation of the value of ethionamide with pyrazinamide or cycloserine in the treatment of chronic pulmonary tuberculosis. A report from the Research Committee of the British Tuberculosis Association.
    Tubercle, 1961, Volume: 42

    Topics: Antitubercular Agents; Cyclopropanes; Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis;

1961
[Clinical results of the use of pyrazinamide in aerosols in pulmonary tuberculosis].
    Therapeutische Umschau. Revue therapeutique, 1961, Volume: 18

    Topics: Aerosols; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1961
[Pyrazinamide in the treatment of pulmonary tuberculosis].
    Revista de la Asociacion Medica Argentina, 1962, Volume: 76

    Topics: Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1962
[Combined therapy of massive doses of isoniazid, pyrazinamide, and sulfisoxazole for patients with pulmonary tuberculosis resistant to streptomycin, paraaminosalicylic acid, and isoniazid].
    Kiyo. [Reports]. Kyoto Daigaku. Kekkaku Kenkyujo, 1961, Volume: 9

    Topics: Aminosalicylic Acid; Humans; Isoniazid; Psychotherapy, Multiple; Pyrazinamide; Streptomycin; Sulfani

1961
[Role of pyrazinamide in the treatment of pulmonary tuberculosis].
    Gruzlica (Warsaw, Poland : 1926), 1961, Volume: 29

    Topics: Pyrazinamide; Tuberculosis, Pulmonary

1961
[A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2003, Volume: 26, Issue:8

    Topics: Adolescent; Adult; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Female; Humans; Le

2003
[A clinical study on tuberculosis among young adults in Japan: analysis on patients admitted to national hospitals in Kanto- and Kinki-areas in the year 2000].
    Kekkaku : [Tuberculosis], 2003, Volume: 78, Issue:8

    Topics: Adult; Age Factors; Antitubercular Agents; Drug Resistance, Bacterial; Female; Hospitals, Public; Hu

2003
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Kekkaku : [Tuberculosis], 2003, Volume: 78, Issue:10

    Topics: Adult; Aged; Antitubercular Agents; Cohort Studies; Drug Therapy, Combination; Female; Humans; Isoni

2003
Relative versus absolute noncontagiousness of respiratory tuberculosis on treatment.
    Infection control and hospital epidemiology, 2003, Volume: 24, Issue:11

    Topics: Academic Medical Centers; Adult; Alberta; Antibiotics, Antitubercular; Antitubercular Agents; Colony

2003
Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis.
    American review of tuberculosis, 1952, Volume: 65, Issue:5

    Topics: Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary

1952
Cavitatory pulmonary tuberculosis in a 52-day-old infant.
    Journal of the Royal Society of Medicine, 2004, Volume: 97, Issue:3

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Asia; Drug Therapy, Combination; Female; Humans;

2004
Side effects of antituberculosis therapy.
    American journal of respiratory and critical care medicine, 2004, May-15, Volume: 169, Issue:10

    Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Maximum Tolerated Dose; Proportiona

2004
Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2004, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antitubercular Agents; Cohort Studi

2004
Characteristics and outcome of tuberculosis patients whose sputum smears are positive at or after 5 months of treatment.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2004, Volume: 8, Issue:3

    Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Health Surveys; Humans; Isoniaz

2004
Prescriptions and dosages of anti-tuberculosis drugs in the National Tuberculosis Control Programme of Malawi.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2004, Volume: 8, Issue:6

    Topics: Administration, Oral; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Body Weight; Commun

2004
A 32-year-old man with tuberculosis, fever, and rash.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2004, Volume: 92, Issue:5

    Topics: Adult; Antitubercular Agents; Diagnosis, Differential; Drug Hypersensitivity; Ethambutol; Exanthema;

2004
Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2004, Volume: 8, Issue:7

    Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ciprofl

2004
[Efficiency of an intensive stage of chemotherapy for tuberculosis in elderly and senile patients].
    Problemy tuberkuleza i boleznei legkikh, 2004, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Diabetes C

2004
[Bactericidal therapy in patients with tuberculosis].
    Problemy tuberkuleza i boleznei legkikh, 2004, Issue:3

    Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Chlortetracycline; Drug R

2004
Tuberculosis: medical management update.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2004, Volume: 98, Issue:3

    Topics: Adult; Antitubercular Agents; Child; Dental Staff; Ethambutol; Humans; Infectious Disease Transmissi

2004
Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2004, Volume: 8, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active;

2004
The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Nov-01, Volume: 39, Issue:9

    Topics: Antitubercular Agents; Directly Observed Therapy; Drug Resistance, Bacterial; Drug Resistance, Multi

2004
Tuberculosis control and the private health sector in Bolivia: a survey of pharmacies.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2004, Volume: 8, Issue:11

    Topics: Antitubercular Agents; Bolivia; Communicable Disease Control; Community Pharmacy Services; Cooperati

2004
[Case of pulmonary tuberculosis in late stage of pregnancy].
    Kekkaku : [Tuberculosis], 2004, Volume: 79, Issue:10

    Topics: Adult; Antitubercular Agents; Cesarean Section; Cross Infection; Drug Therapy, Combination; Ethambut

2004
Treatment outcome of new culture positive pulmonary tuberculosis in Norway.
    BMC public health, 2005, Feb-07, Volume: 5

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Drug Resist

2005
[Effectiveness of an intensive chemotherapy stage in new cases of pulmonary tuberculosis and diabetes mellitus].
    Problemy tuberkuleza i boleznei legkikh, 2004, Issue:12

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Data Interpretation, Statistical; Diabetes Melli

2004
Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons.
    Chest, 2005, Volume: 127, Issue:4

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cohort Studi

2005
Protective effect of a 50% hydroalcoholic fruit extract of Emblica officinalis against anti-tuberculosis drugs induced liver toxicity.
    Phytotherapy research : PTR, 2005, Volume: 19, Issue:3

    Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Fruit; Hepatocytes; Humans;

2005
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Aug-15, Volume: 41, Issue:4

    Topics: Adult; Antitubercular Agents; Botswana; Comorbidity; Ethambutol; Female; HIV Infections; Humans; Iso

2005
Population pharmacokinetics of pyrazinamide in elephants.
    Journal of veterinary pharmacology and therapeutics, 2005, Volume: 28, Issue:5

    Topics: Administration, Oral; Administration, Rectal; Animals; Antitubercular Agents; Area Under Curve; Elep

2005
[Improvement on chest X-ray findings after two months of antituberculous treatment].
    Kekkaku : [Tuberculosis], 2005, Volume: 80, Issue:9

    Topics: Aged; Antitubercular Agents; Female; Humans; Male; Middle Aged; Pyrazinamide; Radiography, Thoracic;

2005
Reactivation of tuberculosis after apparently adequate chemoprophylaxis.
    The Journal of infection, 2005, Volume: 51, Issue:5

    Topics: Adolescent; Antitubercular Agents; Chemoprevention; Contact Tracing; Disease Transmission, Infectiou

2005
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1

    Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati

2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1

    Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati

2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1

    Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati

2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1

    Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati

2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1

    Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati

2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1

    Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati

2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1

    Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati

2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1

    Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati

2006
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1

    Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combinati

2006
Multidrug-resistant tuberculosis in military recruits.
    Emerging infectious diseases, 2006, Volume: 12, Issue:5

    Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Female; Humans; Isoniazid; Milit

2006
[Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy].
    Kekkaku : [Tuberculosis], 2006, Volume: 81, Issue:6

    Topics: Adult; Aminosalicylic Acid; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Cy

2006
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:8

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, C

2006
Impact of country of origin on drug-resistant tuberculosis among foreign-born persons in British Columbia.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2006, Volume: 10, Issue:8

    Topics: Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Anti-Bacterial Agents; Antibiotics, Anti

2006
Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti.
    BMC public health, 2006, Aug-15, Volume: 6

    Topics: Antitubercular Agents; Cost of Illness; Directly Observed Therapy; Drug Therapy, Combination; Ethamb

2006
Ocular tuberculosis in acquired immunodeficiency syndrome.
    American journal of ophthalmology, 2006, Volume: 142, Issue:3

    Topics: Abscess; Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lympho

2006
Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:9

    Topics: Antitubercular Agents; Humans; Isoniazid; Models, Biological; Nonlinear Dynamics; Pyrazinamide; Rifa

2006
Moxifloxacin-induced arthropathy.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2007, Volume: 11, Issue:1

    Topics: Aged, 80 and over; Antitubercular Agents; Arthritis; Aza Compounds; Drug Therapy, Combination; Fluor

2007
[A case of tuberculosis showing immune reconstitution syndrome after the initiation of antiretroviral therapy for HIV infection].
    Kekkaku : [Tuberculosis], 2007, Volume: 82, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Com

2007
[Aseptic cerebral venous thrombosis and multiple cerebral tuberculomas associated with pulmonary miliary tuberculosis].
    Revue neurologique, 2007, Volume: 163, Issue:2

    Topics: Acenocoumarol; Aged; Anticoagulants; Antitubercular Agents; Confusion; Drug Therapy, Combination; Fe

2007
Trend of anti-tuberculosis drug resistance in Korea, 1994-2004.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2007, Volume: 11, Issue:5

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Ethambutol; Humans; Isoniazid; Korea; Middle

2007
Tuberculous sacro-ileitis: two cases and radiological findings.
    Le infezioni in medicina, 2007, Volume: 15, Issue:2

    Topics: Abscess; Adult; Antitubercular Agents; Arthritis, Infectious; Brucellosis; Diagnosis, Differential;

2007
Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
    Journal of medical microbiology, 2007, Volume: 56, Issue:Pt 8

    Topics: Administration, Oral; Animals; Antibiotics, Antitubercular; Antitubercular Agents; Drug Evaluation,

2007
[Principles in the performance of chemotherapy in dispensary group VI children and adolescents].
    Problemy tuberkuleza i boleznei legkikh, 2007, Issue:8

    Topics: Adolescent; Antitubercular Agents; Child; Dose-Response Relationship, Drug; Drug Administration Sche

2007
[Case of fatal liver failure due to anti-tuberculous therapy].
    Kekkaku : [Tuberculosis], 2007, Volume: 82, Issue:9

    Topics: Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Fatal Outcome; Female; Humans; I

2007
Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.
    Pakistan journal of pharmaceutical sciences, 2008, Volume: 21, Issue:1

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antitubercular Agents; Aspa

2008
[A surgically treated case of ileus caused by small intestinal tuberculosis during treatment for pulmonary tuberculosis].
    Kekkaku : [Tuberculosis], 2007, Volume: 82, Issue:12

    Topics: Adult; Antitubercular Agents; Ethambutol; Humans; Ileal Diseases; Ileus; Isoniazid; Male; Pyrazinami

2007
Treatment of isoniazid-resistant pulmonary tuberculosis.
    BMC infectious diseases, 2008, Jan-23, Volume: 8

    Topics: Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug T

2008
Peak plasma rifampicin level in tuberculosis patients with slow culture conversion.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2008, Volume: 27, Issue:6

    Topics: Adult; Antitubercular Agents; Case-Control Studies; Female; Humans; Male; Mycobacterium; Mycobacteri

2008
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4

    Topics: Animals; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug

2008
An unusual case of chylothorax complicating childhood tuberculosis.
    Pediatric pulmonology, 2008, Volume: 43, Issue:6

    Topics: Antitubercular Agents; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Bronchoscopy; Chest Tub

2008
[Morphazinamide--clinical tolerance and side effects].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1967, Volume: 35, Issue:5

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Ethionamide; Female; Gastrointestinal Diseases; Huma

1967
Pulmonary alveolar proteinosis. Treatment in a case complicated by tuberculosis.
    The American review of respiratory disease, 1967, Volume: 95, Issue:3

    Topics: Acetylcysteine; Aminosalicylic Acids; Cycloserine; Ethionamide; Heparin; Humans; Isoniazid; L-Lactat

1967
Pyrazinamide-isoniazid: its apparent influence on the reactivation rate in pulmonary tuberculosis.
    The American review of respiratory disease, 1967, Volume: 95, Issue:3

    Topics: Adult; Aminosalicylic Acids; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Middle Aged;

1967
Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again.
    Lancet (London, England), 1981, Nov-07, Volume: 2, Issue:8254

    Topics: Adult; Chemical and Drug Induced Liver Injury; Humans; Male; Pyrazinamide; Tuberculosis, Pulmonary

1981
Drug-resistant Mycobacterium tuberculosis in Korean isolates.
    The American review of respiratory disease, 1982, Volume: 126, Issue:6

    Topics: Adult; Capreomycin; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Korea; Mycobacterium

1982
[Value of pyrazinamide in the short-term treatment of tuberculosis].
    Presse medicale (Paris, France : 1983), 1983, Mar-26, Volume: 12, Issue:14

    Topics: Humans; Pyrazinamide; Time Factors; Tuberculosis, Pulmonary

1983
[Current treatment of pulmonary tuberculosis].
    Presse medicale (Paris, France : 1983), 1984, Jun-02, Volume: 13, Issue:23

    Topics: Adult; Aged; Antitubercular Agents; Child; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Tu

1984
Compliance of patients and physicians: experience and lessons from tuberculosis-II.
    British medical journal (Clinical research ed.), 1983, Jul-09, Volume: 287, Issue:6385

    Topics: Attitude of Health Personnel; Drug Administration Schedule; Drug Information Services; Drug Therapy,

1983
[In vitro studies on the inhibitory effects of rifampicin, pyrazinamide and their combination on mycobacteria with photometric measurement of turbidity].
    Praxis und Klinik der Pneumologie, 1983, Volume: 37, Issue:11

    Topics: Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Photomet

1983
[Pharmacokinetics of antitubercular agents in man].
    Minerva medica, 1984, Mar-17, Volume: 75, Issue:11

    Topics: Absorption; Antitubercular Agents; Half-Life; Humans; Isoniazid; Kinetics; Mycobacterium tuberculosi

1984
The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis.
    Tubercle, 1984, Volume: 65, Issue:1

    Topics: Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Mycobac

1984
[Short-course chemotherapy for tuberculosis in Chile. Operational considerations].
    Revista medica de Chile, 1984, Volume: 112, Issue:3

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; P

1984
[Short-course treatment of tuberculosis on a 7-month schedule with an initial intensive phase of 1 month (TA-81)].
    Revista medica de Chile, 1984, Volume: 112, Issue:3

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; H

1984
[Effectiveness of pyrazinamide combined with rifampicin and ethambutol in animal experiments].
    Problemy tuberkuleza, 1984, Issue:7

    Topics: Animals; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Ethambutol; Mi

1984
[The hepatotoxicity of pyrazinamide].
    Revista espanola de las enfermedades del aparato digestivo, 1984, Volume: 66, Issue:2

    Topics: Chemical and Drug Induced Liver Injury; Humans; Kinetics; Male; Pyrazinamide; Tuberculosis, Pulmonar

1984
A successful supervised outpatient short-course tuberculosis treatment program in an open refugee camp on the Thai-Cambodian border.
    The American review of respiratory disease, 1984, Volume: 130, Issue:5

    Topics: Adolescent; Adult; Ambulatory Care Facilities; Antitubercular Agents; Cambodia; Child; Drug Therapy,

1984
[Effect of pyrazinamide on the liver of tuberculosis patients. Electron microscopic study].
    Bulletin of the International Union against Tuberculosis, 1984, Volume: 59, Issue:3

    Topics: Adolescent; Adult; Aged; Alcoholism; Antitubercular Agents; Drug Therapy, Combination; Humans; Liver

1984
[Tuberculosis treatment today].
    Lakartidningen, 1984, Dec-05, Volume: 81, Issue:49

    Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tubercul

1984
[Studies on short-course chemotherapy of tuberculosis. II. Liver function during 6-month chemotherapy of tuberculosis with hydrazide, rifampicin and pyrazinamide].
    Pneumonologia polska, 1984, Volume: 52, Issue:10

    Topics: Humans; Isoniazid; Liver; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary

1984
Role of rifampicin in arthralgia induced by pyrazinamide.
    Tubercle, 1983, Volume: 64, Issue:2

    Topics: Drug Therapy, Combination; Humans; Joint Diseases; Pain; Pyrazinamide; Rifampin; Tuberculosis, Pulmo

1983
The tolerability and efficacy of a 6-month antituberculosis regimen containing rifampicin, isoniazid and pyrazinamide.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1983, Oct-22, Volume: 64, Issue:18

    Topics: Adolescent; Adult; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Isoniazid; Male; Middl

1983
[Comparison of 3 6-month chemotherapy regimes in pulmonary tuberculosis in routine practice in Algiers. 18th-month results].
    Revue francaise des maladies respiratoires, 1983, Volume: 11, Issue:5

    Topics: Adolescent; Adult; Antitubercular Agents; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy,

1983
[Short course chemotherapy for pulmonary tuberculosis. 3. Initial intensive regimens including pyrazinamide].
    Kekkaku : [Tuberculosis], 1983, Volume: 58, Issue:9

    Topics: Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female;

1983
[Short-term treatment of tuberculosis with and without pyrazinamide in the second phase (TA-80)].
    Revista medica de Chile, 1983, Volume: 111, Issue:7

    Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifampin; Strepto

1983
Shortest possible acceptable effective chemotherapy in ambulatory patients with pulmonary tuberculosis. Part II. Results during the 24 months after the end of chemotherapy.
    The American review of respiratory disease, 1984, Volume: 129, Issue:6

    Topics: Ambulatory Care; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Eth

1984
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
    The American review of respiratory disease, 1980, Volume: 121, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb

1980
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
    The American review of respiratory disease, 1980, Volume: 121, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb

1980
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
    The American review of respiratory disease, 1980, Volume: 121, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb

1980
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
    The American review of respiratory disease, 1980, Volume: 121, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb

1980
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
    The American review of respiratory disease, 1980, Volume: 121, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb

1980
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
    The American review of respiratory disease, 1980, Volume: 121, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb

1980
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
    The American review of respiratory disease, 1980, Volume: 121, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb

1980
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
    The American review of respiratory disease, 1980, Volume: 121, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb

1980
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
    The American review of respiratory disease, 1980, Volume: 121, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Comb

1980
[Sensitivity of M. tuberculosis to pyrazinamide (author's transl)].
    Revista medica de Chile, 1981, Volume: 109, Issue:3

    Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; In Vitro Techniques; Mycobacterium tubercu

1981
Studies in short-course chemotherapy for tuberculosis. Basis for short-course chemotherapy.
    Chest, 1981, Volume: 80, Issue:6

    Topics: Animals; Drug Therapy, Combination; Humans; Isoniazid; Mice; Mice, Inbred Strains; Mycobacterium tub

1981
Tuberculosis therapy.
    American family physician, 1983, Volume: 27, Issue:3

    Topics: Chemical and Drug Induced Liver Injury; Drug Resistance, Microbial; Drug Therapy, Combination; Human

1983
A comparative evaluation of drug combinations used in the treatment of pulmonary tuberculosis.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1983, May-14, Volume: 63, Issue:20

    Topics: Antitubercular Agents; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Pyrazinamid

1983
Hepatic complications of antituberculosis therapy revisited.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1983, Jun-18, Volume: 63, Issue:25

    Topics: Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Drug Thera

1983
Adverse effects of antituberculosis drugs causing changes in treatment.
    Tubercle, 1982, Volume: 63, Issue:4

    Topics: Antitubercular Agents; Humans; Isoniazid; Kanamycin; Pyrazinamide; Rifampin; Streptomycin; Tuberculo

1982
Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland.
    The American review of respiratory disease, 1982, Volume: 125, Issue:2

    Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Follow-Up Studies; Humans; Isoniazid; Middle Age

1982
Short-course chemotherapy for pulmonary tuberculosis. Points of interest.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1982, Jun-05, Volume: 61, Issue:23

    Topics: Adult; Ambulatory Care; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; F

1982
Modern treatment of tuberculosis.
    Comprehensive therapy, 1982, Volume: 8, Issue:9

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combi

1982
[Mycobacterium malmoense in the Federal Republic of Germany].
    Zentralblatt fur Bakteriologie, Mikrobiologie und Hygiene. 1. Abt. Originale A, Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie = International journal of microbiology and hygiene. A, Medical microbiology, infectious..., 1982, Volume: 253, Issue:2

    Topics: Aged; Agglutination Tests; Amides; Germany, West; Humans; Hydrolases; Isoniazid; Lipids; Male; Middl

1982
[Arthralgia and uricemia produced by pyrazinamide].
    Kekkaku : [Tuberculosis], 1982, Volume: 57, Issue:9

    Topics: Adolescent; Adult; Aged; Female; Humans; Joint Diseases; Male; Middle Aged; Pyrazinamide; Tuberculos

1982
Shortest possible acceptable, effective ambulatory chemotherapy in pulmonary tuberculosis: preliminary report I.
    The American review of respiratory disease, 1981, Volume: 124, Issue:3

    Topics: Ambulatory Care; Antitubercular Agents; Drug Administration Schedule; Ethionamide; Female; Humans; I

1981
Liver alterations in antituberculosis regimens containing pyrazinamide.
    Chest, 1981, Volume: 80, Issue:6

    Topics: Adolescent; Adult; Aged; Alcoholism; Antitubercular Agents; Cholestasis; Diabetes Complications; Dia

1981
Serum uric acid concentrations and arthralgia among patients treated with pyrazinamide-containing regimens in Hong Kong and Singapore.
    Tubercle, 1981, Volume: 62, Issue:3

    Topics: Humans; Joint Diseases; Pyrazinamide; Tuberculosis, Pulmonary; Uric Acid

1981
Monitoring regularity of drug intake in tuberculous patients by means of simple urine tests.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1980, Jun-14, Volume: 57, Issue:24

    Topics: Color; Drug Administration Schedule; Humans; Isoniazid; Patient Compliance; Pyrazinamide; Rifampin;

1980
A service program of antituberculosis chemotherapy with five drugs for four months in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong. Hong Kong Chest Service/British Medical Research Council.
    The American review of respiratory disease, 1980, Volume: 122, Issue:3

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Ethambutol; Heroin

1980
Controlled double-blind study of the effect of rifampin on humoral and cellular immune responses in patients with pulmonary tuberculosis and in tuberculosis contacts.
    The American review of respiratory disease, 1980, Volume: 122, Issue:3

    Topics: Adolescent; Adult; Antibody Formation; Double-Blind Method; Female; Humans; Immunity, Cellular; Ison

1980
[Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
    Pneumonologia polska, 1980, Volume: 48, Issue:7

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Hypersensitivity;

1980
Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis.
    Chest, 1994, Volume: 105, Issue:2

    Topics: Acetaminophen; Adult; Capreomycin; Ciprofloxacin; Drug Combinations; Drug Overdose; Ethambutol; Fema

1994
Oxidative stress during antituberculous therapy in young and elderly patients.
    Biomedical and environmental sciences : BES, 1995, Volume: 8, Issue:2

    Topics: Adult; Age Factors; Aged; Allantoin; Antitubercular Agents; Drug Therapy, Combination; Female; Human

1995
Relapse rates in tuberculosis patients.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1995, Volume: 85, Issue:2

    Topics: Antitubercular Agents; Drug Combinations; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid;

1995
Drugs for tuberculosis.
    The Medical letter on drugs and therapeutics, 1995, Aug-04, Volume: 37, Issue:954

    Topics: Adult; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; Hum

1995
[Allopurinol hypersensitivity. A possible cause of hepatitis and mucocutaneous eruptions in a patient undergoing antitubercular treatment].
    Revue des maladies respiratoires, 1995, Volume: 12, Issue:3

    Topics: Adult; Allopurinol; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Hypersensitivity; D

1995
Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV-uninfected individuals using ciprofloxacin and pyrazinamide. A decision analysis.
    Chest, 1995, Volume: 108, Issue:3

    Topics: Adult; Ciprofloxacin; Decision Support Techniques; Decision Trees; Health Personnel; HIV Seronegativ

1995
Short-course chemotherapy for tuberculous pleural effusion and culture-negative pulmonary tuberculosis.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1995, Volume: 76, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Fe

1995
Silicotuberculosis: long-term outcome after short-course chemotherapy.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1995, Volume: 76, Issue:1

    Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Isoniazid; Male;

1995
Antituberculous therapy and acute liver function.
    Lancet (London, England), 1995, May-06, Volume: 345, Issue:8958

    Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hong Kong; Humans; Isoni

1995
[Therapy of tuberculosis in the adult].
    Medizinische Klinik (Munich, Germany : 1983), 1995, Apr-15, Volume: 90, Issue:4

    Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Dose-Response Relationship, Dru

1995
Replacement of one lung by a large bulla in active tuberculosis.
    Thorax, 1995, Volume: 50, Issue:4

    Topics: Aged; Drug Therapy, Combination; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Tuberculosis, Pulm

1995
Antituberculous therapy and acute liver function.
    Lancet (London, England), 1995, May-06, Volume: 345, Issue:8958

    Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Isoniazid; L

1995
[Pulmonary tuberculosis in infants. Apropos of 6 cases].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1994, Volume: 1, Issue:9

    Topics: BCG Vaccine; Drug Therapy, Combination; Ethambutol; Female; Humans; Infant; Isoniazid; Male; Pyrazin

1994
Cytogenetic study of tuberculosis patients before and after tuberculostatic drug treatment.
    Mutation research, 1995, Volume: 334, Issue:2

    Topics: Adult; Antitubercular Agents; Cell Division; Chromosome Aberrations; Drug Combinations; Female; Huma

1995
Isoniazid is not always the cause of hepatitis during treatment of tuberculosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1994, Volume: 19, Issue:5

    Topics: Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Tubercul

1994
4-, 5- and 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under program conditions in Hong Kong.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1994, Volume: 75, Issue:4

    Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; F

1994
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 1994, Volume: 49, Issue:4

    Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Pro

1994
[Two pulmonary tuberculosis cases with HIV infection].
    Kekkaku : [Tuberculosis], 1994, Volume: 69, Issue:5

    Topics: Adult; Female; HIV Infections; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Streptomycin; Tuberc

1994
Clinical features, diagnosis, and treatment of tuberculosis in infants.
    Pediatrics, 1994, Volume: 94, Issue:1

    Topics: Drug Therapy, Combination; Female; Humans; Infant; Isoniazid; Male; Mycobacterium tuberculosis; Pyra

1994
Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thioacetazone-free regimen.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1994, Volume: 75, Issue:2

    Topics: Adolescent; Child; Child, Preschool; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV I

1994
Follow-up of tuberculosis patients undergoing standard anti-tuberculosis chemotherapy by using a polymerase chain reaction.
    Research in microbiology, 1994, Volume: 145, Issue:1

    Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Follow-Up Studies; Humans; Isoniazid; Mycobacteriu

1994
Serum concentrations of rifampicin and isoniazid in tuberculosis.
    Indian pediatrics, 1993, Volume: 30, Issue:9

    Topics: Adolescent; Child; Child, Preschool; Drug Therapy, Combination; Female; Half-Life; Humans; Infant; I

1993
Treatment of tuberculosis in patients with pre-existing liver disease or following hepatotoxic drug reactions.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1993, Volume: 83, Issue:6

    Topics: Chemical and Drug Induced Liver Injury; Clinical Protocols; Contraindications; Humans; Isoniazid; Li

1993
[Clinical aspects and outcome of recurrent pulmonary tuberculosis].
    Problemy tuberkuleza, 1993, Issue:5

    Topics: Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazinamide; Recurrence; R

1993
Chemotherapy of tuberculosis for patients with renal impairment.
    Nephron, 1993, Volume: 64, Issue:2

    Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Kidney Failure, Chronic; Pyrazinamide; Rifampi

1993
Cost-effectiveness analysis of three short-course anti-tuberculosis programmes compared with a standard regimen in Thailand.
    Journal of clinical epidemiology, 1993, Volume: 46, Issue:7

    Topics: Adolescent; Adult; Antitubercular Agents; Cost-Benefit Analysis; Drug Administration Schedule; Femal

1993
Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1993, Volume: 74, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Administration Schedule; Dru

1993
CDC recommends four-drug treatment of tuberculosis in multidrug-resistant era.
    American family physician, 1993, Sep-15, Volume: 48, Issue:4

    Topics: Adult; Centers for Disease Control and Prevention, U.S.; Child; Drug Therapy; Drug Therapy, Combinat

1993
Bacteriological investigations for short-course chemotherapy under the tuberculosis programme in two districts of India.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1993, Volume: 74, Issue:1

    Topics: Adolescent; Adult; Aged; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Isoniazid; M

1993
Increased insulin requirement in a patient with type 1 diabetes on rifampicin.
    Diabetic medicine : a journal of the British Diabetic Association, 1993, Volume: 10, Issue:4

    Topics: Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Humans; Insulin; Isonia

1993
Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1996, Volume: 86, Issue:2

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Colony Count, Microbial; Dose-Response Relationship,

1996
Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome.
    The Pediatric infectious disease journal, 1996, Volume: 15, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; AIDS-Related Opportunistic Infections; Antibiotics,

1996
Short-course therapy of pulmonary tuberculosis: doctor's compliance.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1996, Volume: 77, Issue:1

    Topics: Adult; Alcoholism; Ambulatory Care; Antitubercular Agents; Clinical Competence; Drug Combinations; F

1996
Growth inhibition of Mycobacterium tuberculosis by polyoxyethylene stearate present in the BACTEC pyrazinamide susceptibility test.
    Journal of clinical microbiology, 1996, Volume: 34, Issue:1

    Topics: Antitubercular Agents; Cell Division; Drug Resistance, Microbial; Humans; In Vitro Techniques; Indic

1996
The duration of excretion of viable bacilli in elderly patients on treatment for cavitating pulmonary tuberculosis.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1996, Volume: 86, Issue:8

    Topics: Aged; Antitubercular Agents; Black People; Ethambutol; Female; Humans; Isoniazid; Male; Mycobacteriu

1996
Human immunodeficiency virus infection in children with tuberculosis in Santo Domingo, Dominican Republic: prevalence, clinical findings, and response to antituberculosis treatment.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1996, Oct-01, Volume: 13, Issue:2

    Topics: AIDS Serodiagnosis; Antibiotics, Antitubercular; Antitubercular Agents; Child, Preschool; Dominican

1996
The management of mycobacterial infections in HIV seropositive individuals. Jefferiss Wing Therapeutics and Protocols Group.
    International journal of STD & AIDS, 1996, Volume: 7, Issue:4

    Topics: Adrenal Cortex Hormones; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitu

1996
Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
    The European respiratory journal, 1996, Volume: 9, Issue:10

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Arthralgia; Child; C

1996
Multiple small bowel perforations in a patient on treatment of tuberculosis.
    Journal of the Royal College of Surgeons of Edinburgh, 1996, Volume: 41, Issue:5

    Topics: Adult; Antitubercular Agents; Drug Combinations; Female; Humans; Intestinal Perforation; Isoniazid;

1996
Concurrent mucosal leishmaniasis and pulmonary tuberculosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1996, Volume: 23, Issue:4

    Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Contraindications; Drug Therapy, Combin

1996
Grand rounds--Hammersmith Hospital. Persistent fever in pulmonary tuberculosis.
    BMJ (Clinical research ed.), 1996, Dec-14, Volume: 313, Issue:7071

    Topics: Antitubercular Agents; Chronic Disease; Drug Resistance; Fever; Humans; Intestinal Absorption; Isoni

1996
Changes in the size of adrenal glands in acute pulmonary tuberculosis with therapy.
    Endocrine journal, 1996, Volume: 43, Issue:5

    Topics: Adolescent; Adrenal Glands; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Female; Human

1996
[Tuberculosis of the middle ear: a rare extrapulmonary manifestation].
    Deutsche medizinische Wochenschrift (1946), 1996, Dec-06, Volume: 121, Issue:49

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Diagnosis, Differential; Ear Diseases; Ear, Midd

1996
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.
    Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:3

    Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Microbial; Genes, Bacterial; Humans; Mutati

1997
Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms.
    Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:3

    Topics: Amidohydrolases; Antitubercular Agents; Chromosomes, Bacterial; DNA, Bacterial; Drug Resistance, Mic

1997
[Hematologic abnormalities in pulmonary tuberculosiss].
    Orvosi hetilap, 1997, Apr-27, Volume: 138, Issue:17

    Topics: Anemia; Antitubercular Agents; Ethambutol; Hematologic Diseases; Humans; Leukopenia; Pancytopenia; P

1997
Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1997, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Chemical and Drug Induced Liver Inju

1997
[Liver injury under tuberculostatic treatment].
    Praxis, 1997, Apr-09, Volume: 86, Issue:15

    Topics: Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Combinations; Female; Huma

1997
Pyrazinamide-induced granulomatous hepatitis.
    Journal of clinical gastroenterology, 1997, Volume: 24, Issue:4

    Topics: Antitubercular Agents; Biopsy; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Gr

1997
Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children.
    The Pediatric infectious disease journal, 1997, Volume: 16, Issue:8

    Topics: Adolescent; Antitubercular Agents; Blood Sedimentation; Child; Child, Preschool; Drug Tolerance; Fem

1997
[The results of retreatment of pulmonary tuberculosis using a short 6-month protocol 1985-1991 in the pneumo-phthisiology department of the Point G hospital in Bamako].
    Bulletin de la Societe de pathologie exotique (1990), 1997, Volume: 90, Issue:2

    Topics: Adolescent; Adult; Age Factors; Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Comb

1997
Problems of diagnosis and treatment of tuberculosis following renal transplantation.
    Transplantation proceedings, 1997, Volume: 29, Issue:7

    Topics: Adolescent; Adult; Antitubercular Agents; Bronchoalveolar Lavage Fluid; Drug Therapy, Combination; E

1997
[Pulmonary tuberculosis caused by Mycobacterium bovis with primary resistance to Isoniazide and pyrazinamide].
    Anales de medicina interna (Madrid, Spain : 1984), 1997, Volume: 14, Issue:8

    Topics: Adult; Antitubercular Agents; Humans; Isoniazid; Male; Mycobacterium bovis; Pyrazinamide; Tuberculos

1997
[Isolation obligation and therapy in tuberculosis].
    Deutsche medizinische Wochenschrift (1946), 1997, Oct-10, Volume: 122, Issue:41

    Topics: Antitubercular Agents; Bronchoalveolar Lavage Fluid; Female; Humans; Isoniazid; Mycobacterium tuberc

1997
[Effects of intermittent short-course chemotherapy under full-course supervision on the treatment of smear positive pulmonary tuberculosis].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 1996, Volume: 19, Issue:2

    Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Follow-Up Studies; Humans; Isoniazid;

1996
[A severe form of urinary tuberculosis in children].
    Annales d'urologie, 1997, Volume: 31, Issue:4

    Topics: Adolescent; Antitubercular Agents; Atrophy; Bacteriuria; BCG Vaccine; Child; Cystitis; Hematuria; Hu

1997
[First-time standard setting for therapy of pulmonary tuberculosis after revision of the Medical Treatment Standard--special reference to results of questionnaire survey on reality of early stage short-term PZA therapy and occurrence of the adverse effect
    Kekkaku : [Tuberculosis], 1997, Volume: 72, Issue:11

    Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy; Gout; Humans; Japan; Li

1997
[Surgical treatment of patients with multi-resistant pulmonary tuberculosis--case reports].
    Pneumonologia i alergologia polska, 1997, Volume: 65, Issue:3-4

    Topics: Adult; Antitubercular Agents; Bronchial Fistula; Drug Therapy, Combination; Ethambutol; Fatal Outcom

1997
[Reasons for chronic expectoration--case reports].
    Pneumonologia i alergologia polska, 1997, Volume: 65, Issue:3-4

    Topics: Adult; Aged; Antitubercular Agents; Capreomycin; Cycloserine; Drug Resistance, Microbial; Drug Thera

1997
[Thrombocytopenia following a re-introduction of rifampicin in a daily treatment. Apropos of a case].
    La Tunisie medicale, 1995, Volume: 73, Issue:5

    Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; D

1995
Two excellent management tools for national tuberculosis programmes: history of prior treatment and sputum status at two months.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1998, Volume: 2, Issue:3

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans;

1998
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1998, Volume: 2, Issue:1

    Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Drug Admi

1998
Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis?
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1998, Volume: 2, Issue:1

    Topics: Adult; Ambulatory Care; Antibiotics, Antitubercular; Antitubercular Agents; Cohort Studies; Confiden

1998
Short-course chemotherapy for isoniazid-resistant pulmonary tuberculosis.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 1998, Volume: 97, Issue:4

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combi

1998
Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.
    Chest, 1998, Volume: 113, Issue:5

    Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Drug Monitoring; Drug Therapy, Comb

1998
[Analysis of short-term effects of short-course intermittent chemotherapies of the World Bank Loaned Project].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 1996, Volume: 19, Issue:6

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; My

1996
Drug-resistant tuberculosis of the brain in a two-year-old child.
    Tennessee medicine : journal of the Tennessee Medical Association, 1998, Volume: 91, Issue:7

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Brain Diseases; Child, Preschool; Drug Therapy,

1998
[Recurrent tuberculosis in a psychiatric hospital, recurrent outbreaks during 1987-1996].
    Harefuah, 1998, Feb-01, Volume: 134, Issue:3

    Topics: Antitubercular Agents; Disease Outbreaks; Drug Therapy, Combination; Follow-Up Studies; Hospitals, P

1998
Current HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone-free antituberculosis treatment in Yaounde, Cameroon.
    The Central African journal of medicine, 1998, Volume: 44, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag

1998
[Eruption after the 1st dose of standard antitubercular chemotherapy. Thoughts on pyrazinamide].
    Revue des maladies respiratoires, 1998, Volume: 15, Issue:3

    Topics: Aged; Antitubercular Agents; Child; Drug Combinations; Drug Eruptions; Ethambutol; Exanthema; Female

1998
[Resistance and multiresistance to antitubercular drugs in Argentina and in other Latin American countries].
    Medicina, 1998, Volume: 58, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Antitubercular Agents; Argentina; Drug Resistance, Microbial; Dr

1998
Sequential evaluation of serum adenosine deaminase in patients treated for tuberculosis.
    Chest, 1998, Volume: 114, Issue:2

    Topics: Adenosine Deaminase; Adolescent; Adult; Antitubercular Agents; Biomarkers; Drug Therapy, Combination

1998
Phenomenon of rifampicin-induced discolouration of body fluids.
    Respiratory medicine, 1993, Volume: 87, Issue:4

    Topics: Aged; Antibiotics, Antitubercular; Antitubercular Agents; Chromogenic Compounds; Drug Interactions;

1993
Primary tuberculous tracheitis.
    The Journal of laryngology and otology, 1998, Volume: 112, Issue:6

    Topics: Antitubercular Agents; Cough; Ethambutol; Female; Humans; Isoniazid; Middle Aged; Pyrazinamide; Resp

1998
Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society.
    Thorax, 1998, Volume: 53, Issue:7

    Topics: Adult; Antitubercular Agents; Child; Child, Preschool; Disease Notification; Drug Administration Sch

1998
Longitudinal trends in serum levels of mycobacterial secretory (30 kD) and cytoplasmic (65 kD) antigens during chemotherapy of pulmonary tuberculosis patients.
    Scandinavian journal of infectious diseases, 1998, Volume: 30, Issue:4

    Topics: Antibodies, Bacterial; Antigens, Bacterial; Antitubercular Agents; Drug Therapy, Combination; Enzyme

1998
[Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Dakar medical, 1995, Volume: 40, Issue:2

    Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Th

1995
Shock and cerebral infarct after rifampin re-exposure in a patient infected with human immunodeficiency virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1998, Volume: 27, Issue:5

    Topics: Adult; Anaphylaxis; Antibiotics, Antitubercular; Antitubercular Agents; Cerebral Infarction; Drug Hy

1998
Tuberculosis of the pyriform fossa--a rare entity.
    The Journal of laryngology and otology, 1998, Volume: 112, Issue:8

    Topics: Adult; Antitubercular Agents; Diagnosis, Differential; Drug Therapy, Combination; Ethambutol; Humans

1998
The management of pulmonary tuberculosis in adults notified in Scotland in 1993.
    Respiratory medicine, 1998, Volume: 92, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Protocols; Disease Notif

1998
Therapeutic dilemma: crescentic mesangiocapillary glomerulonephritis type 1 in a patient on antituberculous therapy with rifampicin.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1999, Volume: 14, Issue:1

    Topics: Aged; Antitubercular Agents; Clarithromycin; Female; Glomerulonephritis, Membranoproliferative; Huma

1999
Good news and not such good news.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1999, Volume: 3, Issue:2

    Topics: Antitubercular Agents; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis, P

1999
Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1999, Volume: 3, Issue:2

    Topics: Antitubercular Agents; Child; Female; Humans; Male; Pyrazinamide; Tuberculosis, Pulmonary

1999
-Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-.
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1998, Volume: 5, Issue:3

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Drug Combinations; Drug Eruptions; Ethamb

1998
[Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability].
    Kekkaku : [Tuberculosis], 1999, Volume: 74, Issue:4

    Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Diabetes Complications; Drug T

1999
[Efficacy of unfixed continuation phase short-course chemotherapy].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 1997, Volume: 20, Issue:6

    Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follo

1997
[pncA gene mutations in clinical isolates of tubercle bacillus by polymerase chain reaction-direct sequencing method: in relationship to pyrazinamide resistance].
    Kekkaku : [Tuberculosis], 1999, Volume: 74, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Amidohydrolases; Drug Resistance, Microbial; Female; Genes, Bacteria

1999
The spectrum of mycobacterial disease in a Dublin teaching hospital.
    Irish medical journal, 1999, Volume: 92, Issue:3

    Topics: Adult; Antitubercular Agents; Female; Hospitals, Teaching; Humans; Isoniazid; Lung Neoplasms; Male;

1999
Four-month, four-drug preventive therapy for inactive pulmonary tuberculosis.
    American journal of respiratory and critical care medicine, 1999, Volume: 160, Issue:2

    Topics: Adult; Aged; Antitubercular Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Ad

1999
Chronic ulceration of the tongue and laryngitis: first clinical sign of asymptomatic pulmonary tuberculosis.
    The Journal of infection, 1999, Volume: 39, Issue:2

    Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Laryngitis; Male; Pyrazi

1999
[Breast abscess and pregnancy toxemia revealing multidrug resistant tuberculosis].
    Revue des maladies respiratoires, 1999, Volume: 16, Issue:5

    Topics: Abscess; Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Breas

1999
Reply to Davis and colleagues: Twice weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.
    AIDS (London, England), 1999, Dec-24, Volume: 13, Issue:18

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Resistance, Mu

1999
Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    East African medical journal, 1999, Volume: 76, Issue:6

    Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance; Dr

1999
Spinal intramedullary tuberculous lesion: medical management. Report of four cases.
    Journal of neurosurgery, 2000, Volume: 93, Issue:1 Suppl

    Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Clinical Protocols; Female; F

2000
Kinetics of circulating antibodies, immune complex and specific antibody-secreting cells in tuberculosis patients during 6 months of antimicrobial therapy.
    Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2000, Volume: 80, Issue:1

    Topics: Adult; Aged; Anti-Bacterial Agents; Antibodies, Bacterial; Antibody-Producing Cells; Antigen-Antibod

2000
[Efficiency of shorter chemotherapy courses for intrathoracic tuberculosis in children].
    Problemy tuberkuleza, 2000, Issue:3

    Topics: Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combinati

2000
[Intracranial tuberculomas developing during treatment of pulmonary tuberculosis: case report].
    Arquivos de neuro-psiquiatria, 2000, Volume: 58, Issue:2B

    Topics: Adult; Antitubercular Agents; Humans; Isoniazid; Magnetic Resonance Imaging; Male; Pyrazinamide; Rif

2000
Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis.
    Hormone research, 1999, Volume: 52, Issue:6

    Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Body Mass Index; Body Weight; Drug Therap

1999
Lipid biochemistry takes a stand against tuberculosis.
    Nature medicine, 2000, Volume: 6, Issue:9

    Topics: Acetyltransferases; Antitubercular Agents; Bacterial Proteins; Drug Therapy, Combination; Fatty Acid

2000
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
    Nature medicine, 2000, Volume: 6, Issue:9

    Topics: Animals; Antitubercular Agents; Bacterial Proteins; Enzyme Inhibitors; Fatty Acid Synthases; Humans;

2000
The comparison of tuberculosis treatments: a short course therapy and the directly observed short course treatment (DOTS), East Java Province, Indonesia.
    The Southeast Asian journal of tropical medicine and public health, 2000, Volume: 31, Issue:1

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans;

2000
Hypercalcemia in renal transplant patients with tuberculosis.
    Transplantation proceedings, 2000, Volume: 32, Issue:7

    Topics: Adult; Antitubercular Agents; Blood Urea Nitrogen; Calcitriol; Calcium; Ethambutol; Humans; Hypercal

2000
Tuberculosis after renal transplantation.
    Transplantation proceedings, 2000, Volume: 32, Issue:7

    Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Follow-Up Studies; Huma

2000
Paradoxical worsening of tuberculosis after anti-TB therapy in a kidney transplant recipient.
    Transplantation proceedings, 2000, Volume: 32, Issue:7

    Topics: Adult; Antitubercular Agents; Disease Progression; Drug Therapy, Combination; Ethambutol; Female; Hu

2000
Normouricemia in the syndrome of inappropriate antidiuretic hormone secretion.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 37, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Ethambutol; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lu

2001
[The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
    Kekkaku : [Tuberculosis], 2000, Volume: 75, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Diabe

2000
Tuberculosis treatment: dangerous regimens?
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2001, Volume: 5, Issue:1

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans;

2001
Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
    International journal of antimicrobial agents, 2001, Volume: 17, Issue:5

    Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Female; Humans; Isoniazid; Male; Micr

2001
New TB drug approved.
    AIDS patient care, 1995, Volume: 9, Issue:1

    Topics: Antitubercular Agents; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis, P

1995
[Effectiveness of chemotherapy of intrathoracic tuberculosis in children: late follow-up data].
    Problemy tuberkuleza, 2001, Issue:5

    Topics: Adolescent; Age Factors; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool

2001
Pyrazinamide induced photoallergy.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2001, Volume: 5, Issue:11

    Topics: Adult; Antitubercular Agents; Dermatitis, Photoallergic; Drug Hypersensitivity; Female; Humans; Pyra

2001
Side effects of antituberculosis treatment.
    Thorax, 2001, Volume: 56, Issue:12

    Topics: Anti-Bacterial Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy,

2001
Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-based in vitro system.
    Journal of clinical microbiology, 2002, Volume: 40, Issue:2

    Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Te

2002
Can serial qualitative polymerase chain reaction monitoring predict outcome of pulmonary tuberculosis treatment?
    Respirology (Carlton, Vic.), 2001, Volume: 6, Issue:4

    Topics: Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Humans; Isoniazid; Male; Pyrazinamide;

2001
Tuberculous pericarditis in an infant evolving during triple chemotherapy.
    European journal of pediatrics, 2002, Volume: 161, Issue:3

    Topics: Antitubercular Agents; Child, Preschool; Drug Therapy, Combination; Echocardiography; Female; Humans

2002
Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis.
    Chest, 2002, Volume: 121, Issue:5

    Topics: Aged; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Humans; Liver F

2002
[Medication-induced hepatic lesions in patients with pulmonary tuberculosis].
    Voenno-meditsinskii zhurnal, 2002, Volume: 323, Issue:5

    Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ethionamide; Humans; Pyrazinamide; Ri

2002
Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Jul-15, Volume: 35, Issue:2

    Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Bacterial Typing Techniques; DNA Fi

2002
[Role of pyrazinamide in the treatment of pulmonary tuberculosis in the light of comparison of the data of the International Antituberculosis Union in Istanbul in 1977 and the materials of the conference in Białystok].
    Pneumonologia polska, 1979, Volume: 47, Issue:10

    Topics: Congresses as Topic; Humans; International Cooperation; Poland; Pyrazinamide; Tuberculosis, Pulmonar

1979
Short-course chemotherapy for pulmonary tuberculosis.
    The American review of respiratory disease, 1975, Volume: 111, Issue:3

    Topics: Africa, Eastern; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Drug Thera

1975
Short-course chemotherapy for pulmonary tuberculosis.
    The American review of respiratory disease, 1975, Volume: 111, Issue:6

    Topics: Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Isoniazid; Pyr

1975
Hepatic complications of antituberculous therapy.
    The Quarterly journal of medicine, 1975, Volume: 44, Issue:173

    Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Hypersensi

1975
Short-course treatment in pulmonary tuberculosis.
    East African medical journal, 1977, Volume: 54, Issue:2

    Topics: Adolescent; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Thioacetazone; Time Factors; Tu

1977
Short-course (6-month) treatment of pulmonary tuberculosis (Second East African/British Medical Research Council Study).
    Bulletin of the International Union against Tuberculosis, 1976, Volume: 51, Issue:1

    Topics: Africa, Eastern; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin;

1976
Short-term chemotherapy of pulmonary tuberculosis. A controlled trial. The Research Committee of the Tuberculosis Association of India.
    Bulletin of the International Union against Tuberculosis, 1976, Volume: 51, Issue:1

    Topics: Drug Therapy, Combination; Ethambutol; Humans; India; Isoniazid; Pyrazinamide; Streptomycin; Thioace

1976
Short-course chemotherapy for tuberculosis.
    Lancet (London, England), 1979, Aug-25, Volume: 2, Issue:8139

    Topics: Adult; Ambulatory Care; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Humans;

1979
Basic mechanisms of chemotherapy.
    Chest, 1979, Volume: 76, Issue:6 Suppl

    Topics: Aminosalicylic Acid; Animals; Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combi

1979
Adverse reactions to short-course regimens containing streptomycin, isoniazid, pyrazinamide and rifampicin in Hong Kong.
    Tubercle, 1976, Volume: 57, Issue:2

    Topics: Aminosalicylic Acids; Arthritis; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Therap

1976
[Determination of the sensitivity of mycobacteria to pyrazinamide and nicotinamide (author's transl)].
    Zeitschrift fur Erkrankungen der Atmungsorgane, 1978, Volume: 151, Issue:2

    Topics: Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Mycobacterium; Niacinamide; Pyrazin

1978
[Current questions in the treatment of patients with chronic destructive pulmonary tuberculosis].
    Klinicheskaia meditsina, 1976, Volume: 54, Issue:12

    Topics: Antitubercular Agents; Cycloserine; Ethionamide; Humans; Kanamycin; Prothionamide; Pyrazinamide; Tub

1976
Recent advances in antituberculosis chemotherapy.
    Xianggang hu li za zhi. The Hong Kong nursing journal, 1979, Issue:27

    Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tubercul

1979
[Therapy of tuberculosis].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1979, Mar-01, Volume: 34, Issue:5

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Drug Resistance, Microbial; Ethambutol; Humans; I

1979
Modern management of tuberculosis.
    Comprehensive therapy, 1979, Volume: 5, Issue:10

    Topics: Adolescent; Adult; Aminosalicylic Acid; Child; Cycloserine; Drug Administration Schedule; Drug Thera

1979
[Effect and toxicity on the combined use of pyrazinamide, ethionamide and kanamycin in the retreatment of pulmonary tuberculosis (author's transl)].
    Zhonghua jie he he hu xi xi ji bing za zhi = Chinese journal of tuberculosis and respiratory diseases, 1979, Volume: 2, Issue:4

    Topics: Adolescent; Adult; Antitubercular Agents; Drug Therapy, Combination; Ethionamide; Female; Humans; Ka

1979
[Interactions of reserve antitubercular agents in combined administration].
    Problemy tuberkuleza, 1978, Issue:9

    Topics: Amides; Drug Therapy, Combination; Ethambutol; Humans; Pyrazinamide; Rifampin; Thioamides; Tuberculo

1978
[Intermittent chemotherapy of pulmonary tuberculosis (review of the literature)].
    Problemy tuberkuleza, 1978, Issue:10

    Topics: Aminosalicylic Acid; Antitubercular Agents; Drug Administration Schedule; Drug Evaluation; Drug Ther

1978
[Short term chemotherapy of tuberculosis. Current status of short term chemotherapy].
    Bulletin of the International Union against Tuberculosis, 1978, Volume: 53, Issue:4

    Topics: Antitubercular Agents; Drug Resistance, Microbial; Humans; Prognosis; Pyrazinamide; Tuberculosis; Tu

1978
Reappraisal of the activity of morphazinamide against M. tuberculosis.
    Tubercle, 1975, Volume: 56, Issue:3

    Topics: Animals; Female; Formaldehyde; Humans; Hydrolysis; Mice; Mycobacterium tuberculosis; Pyrazinamide; P

1975
Cycloserine plus ethionamide plus pyrazinamide in the treatment of patients excreting isoniazid-resistant tubercle bacilli following previous chemotherapy.
    The Indian journal of medical research, 1976, Volume: 64, Issue:1

    Topics: Adult; Cycloserine; Drug Resistance, Microbial; Drug Therapy, Combination; Ethionamide; Female; Huma

1976
Management of tuberculosis: altered role of the primary care physician.
    Postgraduate medicine, 1977, Volume: 61, Issue:4

    Topics: Adolescent; Adult; Aminosalicylic Acid; Antitubercular Agents; Child; Cycloserine; Ethambutol; Ethio

1977
Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months.
    The American review of respiratory disease, 1977, Volume: 115, Issue:5

    Topics: Adolescent; Adult; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Microbial; Hong K

1977
[Chemotherapy of lung tuberculosis].
    Vrachebnoe delo, 1977, Issue:4

    Topics: Cyclacillin; Ethambutol; Ethionamide; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuberculosis, P

1977
[Pyrazinamide treatment of patients with tuberculosis associated with gastroduodenal ulcer].
    Problemy tuberkuleza, 1977, Issue:6

    Topics: Adult; Aged; Duodenal Ulcer; Female; Humans; Male; Middle Aged; Peptic Ulcer; Pyrazinamide; Stomach

1977
Letter: Tuberculosis care in general hospitals: Arizona's experience.
    The American review of respiratory disease, 1976, Volume: 114, Issue:1

    Topics: Economics, Medical; Hospitalization; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tuberc

1976
[Treatment of tuberculosis. A care program carried out by a working group in the Swedish Pulmonary Medical Society].
    Lakartidningen, 1976, Sep-29, Volume: 73, Issue:40

    Topics: Ambulatory Care; Antitubercular Agents; Drug Interactions; Ethambutol; Eye Diseases; Female; Follow-

1976
Hong Kong tuberculosis treatment services/British Medical Research Council Study of 6- and 9-month regimens of daily and intermittent streptomycin, isoniazid and pyrazinamide for pulmonary tuberculosis.
    Bulletin of the International Union against Tuberculosis, 1976, Volume: 51, Issue:1

    Topics: Adult; Hong Kong; Humans; Isoniazid; Pyrazinamide; Streptomycin; Time Factors; Tuberculosis, Pulmona

1976
Hong Kong Tuberculosis Treatment Services/British Medical Research Council study of short-course regimens of streptomycin, isoniazid and pyrazinamide: latest results.
    Tubercle, 1975, Volume: 56, Issue:2

    Topics: Adult; Drug Evaluation; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuberculosis, Pulmonary

1975
Exacerbation of porphyria during treatment of pulmonary tuberculosis.
    The American review of respiratory disease, 1976, Volume: 113, Issue:2

    Topics: 5-Aminolevulinate Synthetase; Adult; Animals; Diet; Enzyme Induction; Humans; Liver; Male; Porphyria

1976
[Concentration of ethambutol and pyrazinamide in the blood and the resected lungs of patients with tuberculosis].
    Problemy tuberkuleza, 1976, Issue:21

    Topics: Ethambutol; Humans; Lung; Lymph Nodes; Pyrazinamide; Tuberculoma; Tuberculosis, Pulmonary

1976
Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction.
    International journal of clinical pharmacology research, 1992, Volume: 12, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Drug Monitoring; Drug Therap

1992
Fixed dose combination short course chemotherapy in the treatment of pulmonary tuberculosis.
    Ethiopian medical journal, 1992, Volume: 30, Issue:2

    Topics: Adolescent; Adult; Aged; Drug Combinations; Drug Therapy, Combination; Humans; Isoniazid; Middle Age

1992
Case holding in patients with tuberculosis in Botswana.
    BMJ (Clinical research ed.), 1992, Aug-08, Volume: 305, Issue:6849

    Topics: Botswana; Drug Therapy, Combination; Humans; Isoniazid; National Health Programs; Patient Compliance

1992
[Therapy of pulmonary tuberculosis].
    Deutsche medizinische Wochenschrift (1946), 1992, Dec-04, Volume: 117, Issue:49

    Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Humans; Inpatients; Isoniazid;

1992
[2 complications of primary pulmonary tuberculosis in children].
    Nederlands tijdschrift voor geneeskunde, 1992, May-23, Volume: 136, Issue:21

    Topics: Child; Drug Administration Schedule; Humans; Medication Errors; Pyrazinamide; Pyrilamine; Tuberculos

1992
[2 complications of primary pulmonary tuberculosis in children].
    Nederlands tijdschrift voor geneeskunde, 1992, May-23, Volume: 136, Issue:21

    Topics: Child; Humans; Medication Errors; Pyrazinamide; Pyrilamine; Tuberculosis, Pulmonary

1992
Effect of simultaneous isoniazid administration on pharmacokinetic parameters of pyrazinamide.
    Journal of the Indian Medical Association, 1991, Volume: 89, Issue:8

    Topics: Adult; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Metabolic Clearance Rate; Middle

1991
AIDS and tuberculosis in Spain. A report of 140 cases.
    The Journal of infection, 1991, Volume: 23, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Ethambutol; Female; Humans; Incidence

1991
[Standardized controlled antitubercular therapy and results in 755 patients].
    Zeitschrift fur Erkrankungen der Atmungsorgane, 1991, Volume: 177, Issue:1-2

    Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid

1991
Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
    The New England journal of medicine, 1991, Jan-31, Volume: 324, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adult; Drug Administration Schedule; Drug Therapy, Combination;

1991
Short course chemotherapy for pulmonary tuberculosis.
    Respiratory medicine, 1991, Volume: 85, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Drug Therapy, Combination;

1991
The management of pulmonary tuberculosis in adults notified in England and Wales in 1988. The British Thoracic Society Research Committee and the Medical Research Council Cardiothoracic Epidemiology Group.
    Respiratory medicine, 1991, Volume: 85, Issue:4

    Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; England; Humans; Iso

1991
Efficacy of intermittent pyrazinamide in experimental murine tuberculosis.
    Tubercle, 1991, Volume: 72, Issue:2

    Topics: Animals; Colony Count, Microbial; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid

1991
[Persistent fever syndrome in a case of childhood tuberculosis].
    Anales espanoles de pediatria, 1991, Volume: 35, Issue:2

    Topics: Child, Preschool; Fever; Fever of Unknown Origin; Humans; Hydrazines; Male; Pyrazinamide; Rifampin;

1991
The disposition of antituberculous drugs in plasma of elderly patients. I. Isoniazid and hydrazine metabolite.
    Methods and findings in experimental and clinical pharmacology, 1991, Volume: 13, Issue:8

    Topics: Acetylation; Adult; Aged; Aged, 80 and over; Aging; Female; Humans; Isoniazid; Male; Middle Aged; Py

1991
The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide.
    Methods and findings in experimental and clinical pharmacology, 1991, Volume: 13, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aging; Female; Humans; Isoniazid; Male; Metabolic Clearance Rate; Mi

1991
Effect of vitamin D on efficacy of pyrazinamide in pulmonary tuberculosis.
    The Journal of the Association of Physicians of India, 1991, Volume: 39, Issue:5

    Topics: Adolescent; Adult; Drug Synergism; Drug Therapy, Combination; Humans; Middle Aged; Pyrazinamide; Tub

1991
Chromosomal aberrations in tuberculosis patients before and after treatment with short-term chemotherapy.
    Mutation research, 1991, Volume: 259, Issue:1

    Topics: Chromosome Aberrations; Drug Therapy, Combination; Humans; Isoniazid; Mutagens; Pyrazinamide; Rifamp

1991
A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.
    Annals of internal medicine, 1990, Mar-15, Volume: 112, Issue:6

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Aspartate Aminotransferases; Cost-Benefit Analysis;

1990
[In 76% of patients with active tuberculosis treated with triple therapy (isoniazid-rifampicin-pyrazinamide) cultural conversion precedes microscopic conversion].
    Pneumologie (Stuttgart, Germany), 1990, Volume: 44 Suppl 1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Humans; Isoniazid; Ma

1990
Any questions? How should a patient be managed who is being treated for sputum positive pulmonary tuberculosis and becomes jaundiced in the third week of chemotherapy?
    Tubercle, 1990, Volume: 71, Issue:2

    Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Jaundice; Pyrazinamide; Rifampi

1990
Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
    The Central African journal of medicine, 1990, Volume: 36, Issue:4

    Topics: Alanine Transaminase; Alkaline Phosphatase; Chemical and Drug Induced Liver Injury; Drug Therapy, Co

1990
Pyrazinamide in the chemoprophylaxis of tuberculosis.
    The American review of respiratory disease, 1990, Volume: 142, Issue:6 Pt 1

    Topics: Animals; Drug Therapy, Combination; Humans; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary

1990
[Treatment of tuberculosis. Drug combinations, therapeutic problems and results in a 10-year case load].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1990, Nov-20, Volume: 110, Issue:28

    Topics: Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male

1990
[Clinical and laboratory studies in patients with pulmonary tuberculosis treated with pyrazinamide].
    Problemy tuberkuleza, 1990, Issue:11

    Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Py

1990
[Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide].
    Pneumologie (Stuttgart, Germany), 1990, Volume: 44 Suppl 1

    Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Infusions, Intravenous; I

1990
[Fulminant hepatitis induced by pyrazinamide].
    Revue de pneumologie clinique, 1990, Volume: 46, Issue:1

    Topics: Aged; Chemical and Drug Induced Liver Injury; Humans; Male; Pyrazinamide; Tuberculosis, Pulmonary

1990
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
    The American review of respiratory disease, 1986, Volume: 133, Issue:3

    Topics: Antitubercular Agents; Drug Evaluation; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; M

1986
180 doses in 26 weeks vs 56 doses in 24 weeks of chemotherapy in pulmonary tuberculosis: a preliminary report.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1988, Volume: 71, Issue:5

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; Hu

1988
[Tuberculous ulcer of the tongue: clinical case].
    Odontologia chilena, 1989, Volume: 37, Issue:2

    Topics: Adult; Female; Humans; Isoniazid; Pyrazinamide; Rifampin; Tongue Diseases; Tuberculosis; Tuberculosi

1989
[Experience with intensive short-term chemotherapy of patients with recently diagnosed destructive pulmonary tuberculosis].
    Problemy tuberkuleza, 1989, Issue:3

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazi

1989
Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1989, Jun-03, Volume: 75, Issue:11

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dapsone; Drug Combinations; Drug Evaluation; Drug Th

1989
The tuberculosis situation in east European countries.
    Bulletin of the International Union against Tuberculosis and Lung Disease, 1989, Volume: 64, Issue:1

    Topics: Adult; BCG Vaccine; Europe, Eastern; Humans; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary

1989
Tubulointerstitial nephritis associated with pyrazinamide.
    The Netherlands journal of medicine, 1989, Volume: 34, Issue:1-2

    Topics: Acute Kidney Injury; Adult; Humans; Male; Nephritis, Interstitial; Pyrazinamide; Tuberculosis, Pulmo

1989
Good tolerance of pyrazinamide in children with pulmonary tuberculosis.
    Archives of disease in childhood, 1989, Volume: 64, Issue:1

    Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Drug Therapy, Combination; Humans; Infan

1989
Effect of pyrazinamide on serum and urinary uric acid levels.
    JPMA. The Journal of the Pakistan Medical Association, 1987, Volume: 37, Issue:3

    Topics: Adolescent; Adult; Child; Female; Humans; Male; Middle Aged; Pyrazinamide; Time Factors; Tuberculosi

1987
[Fully supervised ambulatory short-course chemotherapy with an intermittent regimen for newly diagnosed smear-positive pulmonary tuberculosis].
    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 1987, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combinat

1987
[Long-term results of short-course chemotherapy in pulmonary tuberculosis (final report). The third study: comparative study of two regimens, 6RHZ and -6RHS (treatment was continued for 6 months after negative conversion of sputum by culture)].
    Kekkaku : [Tuberculosis], 1988, Volume: 63, Issue:4

    Topics: Adult; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Male; Middle A

1988
Primary antituberculosis drug resistance and acquired rifampicin resistance in Gujarat, India.
    Tubercle, 1988, Volume: 69, Issue:1

    Topics: Antitubercular Agents; Drug Resistance, Microbial; Humans; India; Isoniazid; Microbial Sensitivity T

1988
Airway obstruction secondary to tuberculosis lymph node erosion into the trachea: drainage via bronchoscopy.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1988, Volume: 99, Issue:6

    Topics: Airway Obstruction; Bronchoscopy; Drainage; Female; Humans; Infant; Isoniazid; Pyrazinamide; Radiogr

1988
[New and future drugs in pulmonary tuberculosis].
    Praxis und Klinik der Pneumologie, 1988, Volume: 42 Suppl 1

    Topics: Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Humans; Is

1988
Management and outcome of pulmonary tuberculosis in adults notified in England and Wales in 1983. Medical Research Council Tuberculosis and Chest Diseases Unit.
    Thorax, 1988, Volume: 43, Issue:8

    Topics: Adolescent; Adult; Antitubercular Agents; Bangladesh; Drug Administration Schedule; England; Ethambu

1988
Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure.
    Clinical nephrology, 1988, Volume: 30, Issue:4

    Topics: Adult; Humans; Kidney Failure, Chronic; Male; Middle Aged; Pyrazinamide; Renal Dialysis; Tuberculosi

1988
[Antituberculous chemotherapy: a constraining adverse effect of pyrazinamide].
    Revue de pneumologie clinique, 1988, Volume: 44, Issue:4

    Topics: Adult; Drug Therapy, Combination; Headache; Humans; Joint Diseases; Male; Paresthesia; Pyrazinamide;

1988
Interaction between allopurinol and pyrazinamide.
    The European respiratory journal, 1988, Volume: 1, Issue:9

    Topics: Adult; Allopurinol; Drug Interactions; Drug Therapy, Combination; Humans; Joint Diseases; Male; Pain

1988
Pyrazinamide induced thrombocytopenia.
    Tubercle, 1988, Volume: 69, Issue:3

    Topics: Adult; Humans; Male; Pyrazinamide; Thrombocytopenia; Tuberculosis, Pulmonary

1988
Pyrazinamide and rifampicin regimens for patients on maintenance dialysis.
    The International journal of artificial organs, 1988, Volume: 11, Issue:3

    Topics: Adolescent; Chromatography, High Pressure Liquid; Female; Humans; Kidney Failure, Chronic; Male; Mid

1988
[Kidney function in patients with pulmonary tuberculosis during treatment with antitubercular agents, with special reference to pyrazinamide].
    Pneumonologia polska, 1987, Volume: 55, Issue:10

    Topics: Adult; Aged; Antitubercular Agents; Glomerular Filtration Rate; Humans; Kidney; Middle Aged; Pyrazin

1987
Convulsions after treatment with pyrazinamide.
    Tubercle, 1987, Volume: 68, Issue:2

    Topics: Humans; Infant; Male; Pyrazinamide; Seizures; Tuberculosis, Pulmonary

1987
[Observations on the effect of PZA, EB and RFP on uric acid metabolism].
    Zhonghua jie he he hu xi xi ji bing za zhi = Chinese journal of tuberculosis and respiratory diseases, 1986, Volume: 9, Issue:4

    Topics: Adolescent; Adult; Arthritis; Drug Therapy, Combination; Ethambutol; Female; Gout; Humans; Male; Mid

1986
New approach to treatment of pulmonary and extrapulmonary tuberculosis. Possible ramifications of cutaneous mycobacterial infections.
    International journal of dermatology, 1987, Volume: 26, Issue:3

    Topics: Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tuberculosis, Cutaneous; Tuberc

1987
From the Centers for Disease Control. Conference on new approaches for tuberculosis preventive therapy.
    The Journal of infectious diseases, 1987, Volume: 156, Issue:3

    Topics: Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary

1987
[Chemotherapy of pulmonary tuberculosis. Sputum culture conversion in 8 weeks in 84% of patients].
    Deutsche medizinische Wochenschrift (1946), 1987, Sep-04, Volume: 112, Issue:36

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Evaluation; Drug Therapy, Co

1987
[Long-term results of short-course chemotherapy of pulmonary tuberculosis (second study--A). Results up to 6 years after the end of treatment with 4-6 month chemotherapy of pulmonary tuberculosis].
    Kekkaku : [Tuberculosis], 1987, Volume: 62, Issue:6

    Topics: Adult; Aged; Antitubercular Agents; Follow-Up Studies; Humans; Male; Pyrazinamide; Recurrence; Time

1987
Dosage schedules for tuberculosis patients.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1987, Sep-19, Volume: 72, Issue:6

    Topics: Drug Administration Schedule; Humans; Pyrazinamide; Tuberculosis, Pulmonary

1987
Short-course antituberculous chemotherapy for pulmonary and pleural disease: 5 years' experience in clinical practice.
    British journal of diseases of the chest, 1987, Volume: 81, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Administration Schedule; Eth

1987
[Studies of short-term chemotherapy of tuberculosis. III. Early and late results of 6 months' treatment of tuberculosis. Analysis of failures and recurrences during 1-5 years' observation].
    Pneumonologia polska, 1986, Volume: 54, Issue:1

    Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Isoniazid; Ma

1986
[Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
    Revue des maladies respiratoires, 1986, Volume: 3, Issue:2

    Topics: Adult; Algeria; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Eth

1986
Short-course tuberculosis therapy--a new combination product.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1986, Jul-19, Volume: 70, Issue:2

    Topics: Drug Combinations; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary

1986
[Tuberculostatics-induced systemic lupus erythematosus].
    Deutsche medizinische Wochenschrift (1946), 1986, Oct-17, Volume: 111, Issue:42

    Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Lupus Eryth

1986
Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
    Tubercle, 1986, Volume: 67, Issue:2

    Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Pres

1986
Short-course chemotherapy of pulmonary tuberculosis: a new approach to drug dosage in the initial intensive phase.
    The American review of respiratory disease, 1986, Volume: 134, Issue:6

    Topics: Antitubercular Agents; Body Weight; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifa

1986
Safety of thrice-weekly rifampicin for tuberculosis in South-East Asian refugees.
    Australian and New Zealand journal of medicine, 1985, Volume: 15, Issue:2

    Topics: Adolescent; Adult; Aged; Asia, Southeastern; Australia; Chemical and Drug Induced Liver Injury; Chil

1985
[Effects of pyrazinamide on the liver in patients with tuberculosis. An ultrastructural study].
    Medicina, 1985, Volume: 45, Issue:1

    Topics: Adolescent; Adult; Aged; Alcoholism; Antitubercular Agents; Endoplasmic Reticulum; Humans; Liver; Ma

1985
The action of antituberculosis drugs in short-course chemotherapy.
    Tubercle, 1985, Volume: 66, Issue:3

    Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Models, Biological

1985
[Chemotherapeutic treatment of pulmonary tuberculosis].
    Anales espanoles de pediatria, 1985, Volume: 22, Issue:8

    Topics: Antitubercular Agents; Ethambutol; Humans; Hydrazines; Pyrazinamide; Rifampin; Streptomycin; Tubercu

1985
Tuberculosis in an Indochinese refugee camp: epidemiology, management and therapeutic results.
    Tubercle, 1985, Volume: 66, Issue:3

    Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female

1985
Field trial of short course chemotherapy for pulmonary tuberculosis: results at 30 months.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1985, Volume: 68, Issue:6

    Topics: Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Pyrazinamide; Rifampi

1985
Ultrashort-course chemotherapy for culture-negative pulmonary tuberculosis--a qualified success.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1985, Dec-07, Volume: 68, Issue:12

    Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Follow-Up Studies; Humans; Isoniazid;

1985
Failure of a prothionamide-containing oral antituberculosis regimen.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1985, Dec-07, Volume: 68, Issue:12

    Topics: Administration, Oral; Antitubercular Agents; Dapsone; Drug Combinations; Drug Therapy, Combination;

1985
Results after retreatment of advanced pulmonary tuberculosis with rifampin and other drugs.
    The American review of respiratory disease, 1971, Volume: 104, Issue:1

    Topics: Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial;

1971
The first clinical experiences with ethambutol in chronic pulmonary tuberculosis and basilar meningitis.
    Antibiotica et chemotherapia. Fortschritte. Advances. Progres, 1970, Volume: 16

    Topics: Adult; Aminosalicylic Acids; Capreomycin; Chronic Disease; Cycloserine; Drug Combinations; Drug Resi

1970
Clinical experience with ethambutol.
    Antibiotica et chemotherapia. Fortschritte. Advances. Progres, 1970, Volume: 16

    Topics: Aminosalicylic Acids; Blood Chemical Analysis; Capreomycin; Drug Combinations; Drug Hypersensitivity

1970
Clinical results of rifampicin treatment.
    Antibiotica et chemotherapia. Fortschritte. Advances. Progres, 1970, Volume: 16

    Topics: Administration, Oral; Adult; Aged; Capreomycin; Chronic Disease; Drug Combinations; Ethambutol; Fema

1970
Shorter chemotherapy in tuberculosis.
    Lancet (London, England), 1972, May-20, Volume: 1, Issue:7760

    Topics: Developing Countries; Drug Combinations; Economics; Humans; Isoniazid; Pyrazinamide; Rifampin; Strep

1972
Technical and bacteriological aspects of a continuous survey of drug resistance in tuberculosis in South Africa.
    Tubercle, 1972, Volume: 53, Issue:1

    Topics: Aminosalicylic Acids; Computers; Cycloserine; Diffusion; Drug Resistance, Microbial; Ethionamide; Hu

1972
Treatment of resistant pulmonary tuberculosis in Hong Kong with regimens of second-line drugs.
    Tubercle, 1972, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Chemical and Drug Induced Liver Injury; Cycloserine;

1972
[Proceedings: Ambulatory chemotherapy of tuberculosis in Finland (organization)].
    Zeitschrift fur Erkrankungen der Atmungsorgane mit Folia bronchologica, 1973, Volume: 138, Issue:1

    Topics: Ambulatory Care; Aminosalicylic Acids; Antitubercular Agents; Capreomycin; Ethambutol; Ethionamide;

1973
Short-course treatment in pulmonary tuberculosis.
    East African medical journal, 1973, Volume: 50, Issue:12

    Topics: Adolescent; Adult; Africa, Eastern; Antitubercular Agents; Humans; Isoniazid; Mycobacterium tubercul

1973
Management of drug failure cases.
    Bulletin of the International Union against Tuberculosis, 1972, Volume: 47 Suppl 2

    Topics: Adult; Aged; Aminosalicylic Acids; Antitubercular Agents; Collapse Therapy; Congresses as Topic; Cyc

1972
Tuberculosis Chemotherapy Centre, Madras.
    Tubercle, 1968, Volume: 49, Issue:1

    Topics: Antitubercular Agents; Cycloserine; Diet Therapy; Drug Resistance, Microbial; Ethionamide; Home Care

1968
Comparison of various drug regimens in domiciliary chemotherapy.
    The American review of respiratory disease, 1970, Volume: 102, Issue:4

    Topics: Adolescent; Adult; Costs and Cost Analysis; Home Care Services; Humans; Isoniazid; Middle Aged; Myco

1970
[Pulmonary tuberculosis resistant to streptomycin and isoniazid and treated wtih a combination of ethionamide, pyrazinamide, and cycloserine (200 cases)].
    La Tunisie medicale, 1973, Volume: 51, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Aminosalicylic Acids; Child; Cycloserine; Drug Resistance, Mic

1973
[Use of drugs of secondary group in complex therapy of children with chronic tuberculosis].
    Pediatriia akusherstvo i ginekologiia, 1971, Volume: 2

    Topics: Adolescent; Child; Child, Preschool; Chronic Disease; Cycloserine; Ethionamide; Female; Humans; Male

1971
[Therapy of pulmonary tuberculosis in its current aspects].
    Bibliotheca tuberculosea, 1965, Volume: 20

    Topics: Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Ethionamide; Humans

1965
The results of treatment in patients with cultures resistant to streptomycin, isoniazid and PAS: a five-year follow-up.
    Tubercle, 1967, Volume: 48, Issue:1

    Topics: Aminosalicylic Acids; Cycloserine; Drug Resistance, Microbial; Ethionamide; Follow-Up Studies; Human

1967
Treatment of pulmonary tuberculosis.
    The Medical journal of Australia, 1967, Sep-02, Volume: 2, Issue:10

    Topics: Aminosalicylic Acids; Drug Resistance, Microbial; Humans; Isoniazid; Kanamycin; Pyrazinamide; Strept

1967
A continuing study of patients with "open negative" status at Battey State Hospital.
    The American review of respiratory disease, 1968, Volume: 98, Issue:6

    Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Child; Cycloserine; Female; Follow-Up Studies; Georgi

1968
[Preparations of the 2d series in the complex treatment of middle-aged and elderly patients with pulmonary tuberculosis].
    Problemy tuberkuleza, 1967, Volume: 45, Issue:9

    Topics: Aged; Antitubercular Agents; Cycloserine; Ethionamide; Female; Humans; Kanamycin; Male; Middle Aged;

1967
Ethambytol in the retreatment of pulmonary tuberculosis. United States Public Health Service cooperative trial.
    Bulletin of the International Union against Tuberculosis, 1968, Volume: 41

    Topics: Cycloserine; Drug Resistance, Microbial; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Pyra

1968
The treatment of drug resistant chronic pulmonary tuberculosis with new tuberculostatics.
    Bulletin of the International Union against Tuberculosis, 1968, Volume: 41

    Topics: Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethambutol; E

1968
[Treatment of drug resistant chronic pulmonary tuberculosis with a number of tuberculostatics].
    Bulletin of the International Union against Tuberculosis, 1968, Volume: 41

    Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethambutol; Et

1968
The problem of the chronic excretor of tubercle bacilli.
    Scandinavian journal of respiratory diseases, 1968, Volume: 49, Issue:3

    Topics: Adult; Age Factors; Aged; Aminosalicylic Acids; Chronic Disease; Cycloserine; Czechoslovakia; Drug R

1968
[Therapy of pulmonary tuberculosis with reserve drugs in the light of our personal observations].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1970, Jan-01, Volume: 23, Issue:1

    Topics: Adult; Cycloserine; Drug Resistance, Microbial; Ethionamide; Female; Humans; Male; Middle Aged; Pyra

1970
[The course and results of treatment of pulmonary tuberculosis as a function of the dosage of Pyrazinamide].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1970, Volume: 38, Issue:6

    Topics: Cycloserine; Ethionamide; Female; Humans; Male; Pyrazinamide; Tuberculosis, Pulmonary; Viomycin

1970
Ethambutol in the treatment of 26 patients with chronic active pulmonary tuberculosis.
    Tubercle, 1969, Volume: 50

    Topics: Chronic Disease; Cycloserine; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Kanamycin;

1969
Treatment of patients with drug-resistance in economically developed countries.
    Tubercle, 1969, Volume: 50

    Topics: Anti-Bacterial Agents; Antitubercular Agents; Costs and Cost Analysis; Cycloserine; Drug Resistance,

1969
Chemotherapy of tuberculosis.
    Clinical notes on respiratory diseases, 1970,Fall, Volume: 9, Issue:2

    Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide; Humans; Isoniazid

1970
Drug therapy of resistant cases of pulmonary tuberculosis in Indian patients.
    The Indian journal of chest diseases, 1967, Volume: 9, Issue:4

    Topics: Adult; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethionamide; Female; Humans;

1967
[Kanamycin and florimycin in the clinical course of pulmonary tuberculosis].
    Antibiotiki, 1971, Volume: 16, Issue:2

    Topics: Adolescent; Adult; Albuminuria; Aminosalicylic Acids; Antitubercular Agents; Chronic Disease; Cyclos

1971
Treatment of drug-resistant tuberculosis.
    Disease-a-month : DM, 1971

    Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cycloserine; Dr

1971
Hypocalcemia, hypomagnesemia and hypokalemia during chemotherapy of pulmonary tuberculosis.
    Chest, 1972, Volume: 61, Issue:5

    Topics: Alkalosis; Humans; Hypocalcemia; Hypokalemia; Magnesium; Male; Middle Aged; Phosphorus; Pyrazinamide

1972
[Duration of the after-control of the tuberculous patients following the termination of the treatment].
    Wiener medizinische Wochenschrift (1946), 1972, Dec-16, Volume: 122, Issue:51

    Topics: Adolescent; Adult; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide

1972
[Experience in treatment of patients with chronic destructive pulmonary tuberculosis in a suburban tuberculosis hospital].
    Problemy tuberkuleza, 1974, Issue:10

    Topics: Adult; Antitubercular Agents; Chronic Disease; Cycloserine; Drug Evaluation; Ethambutol; Ethionamide

1974
[Centrilobular parenchymal necrosis of the liver. A contribution to the knowledge of drug induced lesions of the liver (author's transl)].
    Zentralblatt fur allgemeine Pathologie u. pathologische Anatomie, 1973, Volume: 117, Issue:3

    Topics: Biopsy; Chemical and Drug Induced Liver Injury; Ethionamide; Humans; Liver; Necrosis; Pyrazinamide;

1973
Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Clinical observations on adverse reactions.
    Scandinavian journal of respiratory diseases. Supplementum, 1973, Volume: 84

    Topics: Acute Kidney Injury; Adolescent; Cycloserine; Drug Therapy, Combination; Dyspnea; Ethambutol; Ethion

1973
Therapeutic effects and side effects of rifampicin administered daily or twice-weekly.
    Scandinavian journal of respiratory diseases. Supplementum, 1973, Volume: 84

    Topics: Adult; Body Weight; Drug Therapy, Combination; Ethambutol; Exanthema; Female; Fever; Follow-Up Studi

1973
Shorter treatment.
    Tubercle, 1972, Volume: 53, Issue:4

    Topics: Animals; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Recurrence; Rifampin; Time Factors; Tub

1972
[Therapeutic effect of rifampicin on re-treatment cases of pulmonary tuberculosis. The second study: a study on the combined therapy of rifampicin with ethambutol and pyrazinamide, especially on intermittent therapy].
    Kekkaku : [Tuberculosis], 1972, Volume: 47, Issue:12

    Topics: Adult; Ethambutol; Female; Humans; Male; Middle Aged; Pyrazinamide; Rifampin; Tuberculosis, Pulmonar

1972
[A controlled comparison of daily and intermittent administration of rifampicin in retreatment of pulmonary tuberculosis].
    Kekkaku : [Tuberculosis], 1972, Volume: 47, Issue:12

    Topics: Adult; Female; Humans; Male; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary

1972
Treatment of pulmonary tuberculosis with ethionamide, cycloserine and pyrazinamide in Hong Kong.
    Bulletin of the International Union against Tuberculosis, 1972, Volume: 47 Suppl 2

    Topics: Adolescent; Adult; Aged; Cycloserine; Ethionamide; Female; Follow-Up Studies; Hong Kong; Humans; Mal

1972
Ethionamide, pyrazinamide and cycloserine in drug resistant cases.
    The Indian journal of chest diseases, 1973, Volume: 15, Issue:1

    Topics: Cycloserine; Drug Resistance, Microbial; Ethionamide; Female; Humans; Male; Pyrazinamide; Tuberculos

1973
Transfer factor therapy in a patient with progressive primary tuberculosis.
    Annals of internal medicine, 1973, Volume: 79, Issue:2

    Topics: Adult; Aminosalicylic Acids; Anemia, Aplastic; Cell Migration Inhibition; Ethambutol; Female; Humans

1973
[Treatment with pyrazinamide given in increased doses twice a week in combination with other drugs].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1973, Volume: 41, Issue:7

    Topics: Adult; Aged; Antitubercular Agents; Chronic Disease; Drug Hypersensitivity; Drug Synergism; Drug Tol

1973
[Megaloblastic anemia caused by pyrazinamide].
    Revista medica de Chile, 1973, Volume: 101, Issue:2

    Topics: Adult; Anemia, Macrocytic; Female; Folic Acid; Humans; Pyrazinamide; Tuberculosis, Pulmonary

1973
Successive manifestations of tuberculosis in a recalcitrant patient.
    The Journal of the Indiana State Medical Association, 1973, Volume: 66, Issue:10

    Topics: Adult; Aminosalicylic Acids; Communicable Disease Control; Hospitalization; Humans; Isoniazid; Male;

1973
[Chronic tuberculous meningitis in a case of known Mycobacterium kansasii infection].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1974, Jun-15, Volume: 29, Issue:12

    Topics: Adult; Burns; Cell Count; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Drug Therapy, Combinati

1974
The management of drug-resistant pulmonary tuberculosis.
    British journal of diseases of the chest, 1968, Volume: 62, Issue:1

    Topics: Aminosalicylic Acids; Antitubercular Agents; Attitude; Bacteriological Techniques; Drug Resistance,

1968
Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues.
    The Journal of experimental medicine, 1966, Mar-01, Volume: 123, Issue:3

    Topics: Animals; Cortisone; Cross Infection; Drug Resistance, Microbial; Isoniazid; Mice; Mycobacterium tube

1966
Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli.
    The Journal of experimental medicine, 1966, Mar-01, Volume: 123, Issue:3

    Topics: Animals; Drug Resistance, Microbial; Isoniazid; Mice; Mycobacterium tuberculosis; Pyrazinamide; Tube

1966
Kanamycin in the therapy of pulmonary tuberculosis in the United States.
    Annals of the New York Academy of Sciences, 1966, Jun-14, Volume: 132, Issue:2

    Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethionamide; Humans; Isoniazid; Kanamycin;

1966
A comparison of various measures of sensitivity of M. tubercolosis to pyrazinamide.
    Tubercle, 1970, Volume: 51, Issue:4

    Topics: Culture Media; Drug Resistance, Microbial; Humans; Hydrochloric Acid; Hydrogen-Ion Concentration; Mi

1970
[Restoration of drug sensitivity in Mycobacterium tuberculosis to streptomycin and isoniazid during treatment with preparations of the 1st series].
    Antibiotiki, 1970, Volume: 15, Issue:4

    Topics: Chronic Disease; Cycloserine; Drug Resistance, Microbial; Ethionamide; Humans; Isoniazid; Mycobacter

1970
[Intermittent chemotherapy of pulmonary tuberculosis].
    Deutsches medizinisches Journal, 1971, Jan-05, Volume: 22, Issue:1

    Topics: Aminosalicylic Acids; Antitubercular Agents; Home Care Services; Hospitals; Humans; Long-Term Care;

1971
[Internal medicine treatment of pulmonary tuberculosis].
    Medizinische Klinik, 1970, Sep-04, Volume: 65, Issue:36

    Topics: Ambulatory Care; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; Cycloserine; Dr

1970
[Refractory tuberculosis: concept and clinical cases].
    Naika. Internal medicine, 1971, Volume: 27, Issue:6

    Topics: Adult; Aged; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; E

1971
A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis.
    Bulletin of the International Union against Tuberculosis, 1969, Volume: 42

    Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Cycloserine; Ethionamide; Gastrointestina

1969
Acute psychotic reaction probably caused by ethionamide.
    Tubercle, 1972, Volume: 53, Issue:2

    Topics: Adult; Ethionamide; Humans; Isoniazid; Male; Prednisolone; Psychoses, Substance-Induced; Pyrazinamid

1972
[Renal function in patients with minor forms of pulmonary tuberculosis in the course of treatment with 2d series drugs].
    Vrachebnoe delo, 1972, Volume: 8

    Topics: Adult; Antitubercular Agents; Ethionamide; Female; Humans; Kidney; Kidney Function Tests; Male; Pyra

1972
Recent developments in the treatment of infectious diseases. V. Management of tuberculosis in the community hospital.
    Missouri medicine, 1971, Volume: 68, Issue:11

    Topics: Aminosalicylic Acids; Cross Infection; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Sanita

1971
[Clinical evaluation of rifampicin in advanced pulmonary tuberculosis resistant to conventional antituberculosis drugs. Combination therapy with rifampicin and pyrazinamide].
    Kekkaku : [Tuberculosis], 1971, Volume: 46, Issue:7

    Topics: Adult; Female; Humans; Male; Middle Aged; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary

1971
Drug resistant pulmonary tuberculosis treated with ethambutol and rifampicin in North East England.
    Tubercle, 1971, Volume: 52, Issue:4

    Topics: Aminosalicylic Acids; Chronic Disease; Cycloserine; Drug Resistance, Microbial; Ethambutol; Ethionam

1971
[Liver toxicity of aetina and pyracinamide and their control by determination of LAP activity in blood serum].
    Zeitschrift fur Erkrankungen der Atmungsorgane mit Folia bronchologica, 1969, Volume: 131, Issue:1

    Topics: Adult; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Chemical and Drug I

1969
[Centrilobular liver necrosis following antimycobacterial treatment].
    Zeitschrift fur Erkrankungen der Atmungsorgane mit Folia bronchologica, 1971, Volume: 135, Issue:1

    Topics: Antitubercular Agents; Biopsy; Chemical and Drug Induced Liver Injury; Ethionamide; Humans; Liver Di

1971
Clinical efficiency of cycloserine in association with other tuberculostatics.
    Scandinavian journal of respiratory diseases. Supplementum, 1970, Volume: 71

    Topics: Adult; Aminosalicylic Acids; Cycloserine; Drug Resistance, Microbial; Ethionamide; Female; Humans; M

1970
The effect of cycloserine in different chemotherapy combinations on chronic pulmonary tuberculosis.
    Scandinavian journal of respiratory diseases. Supplementum, 1970, Volume: 71

    Topics: Chronic Disease; Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis, Pulmonary

1970
A comparison of ethionamide-cycloserine and ethionamide-pyrazinamide regimens in patients resistant to major chemotherapeutics.
    Scandinavian journal of respiratory diseases. Supplementum, 1970, Volume: 71

    Topics: Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis, Pulmonary

1970
General survey of the clinical results of treatment of pulmonary tuberculosis with cycloserine in Turkey.
    Scandinavian journal of respiratory diseases. Supplementum, 1970, Volume: 71

    Topics: Cycloserine; Ethionamide; Humans; Isoniazid; Pyrazinamide; Tuberculosis, Pulmonary

1970
Comparative studies of various antituberculosis drug regimens by means of serum antimycobacterial activity tests in man.
    The Japanese journal of tuberculosis, 1967, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Aminoisobutyric Acids; Antitubercular Agents; Cycloserine; Drug Resistance, Micro

1967
Concentrations of pyrazinamide attained in serum with different doses of the drug.
    Bulletin of the World Health Organization, 1968, Volume: 39, Issue:5

    Topics: Aspartate Aminotransferases; Humans; Pyrazinamide; Tuberculosis, Pulmonary

1968
Toxicity of pyrazinamide, administered once weekly in high dosage, in tuberculous patients.
    Bulletin of the World Health Organization, 1968, Volume: 39, Issue:5

    Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Blood Chemical Analysis; Female

1968
Experience with cycloserine.
    Scandinavian journal of respiratory diseases. Supplementum, 1970, Volume: 71

    Topics: Cycloserine; Depression; Drug Resistance, Microbial; Ethionamide; Humans; Pyrazinamide; Tetany; Tube

1970
[Improved therapy of tuberculosis with a well tolerated INH derivative (INHG)].
    Wiener klinische Wochenschrift, 1969, Nov-04, Volume: 81, Issue:46

    Topics: Cycloserine; Ethambutol; Ethionamide; Glucuronates; Humans; Isoniazid; Middle Aged; Pyrazinamide; St

1969
Chronic tuberculosis in refractory patients--therapeutic aspects.
    Respiration; international review of thoracic diseases, 1969, Volume: 26

    Topics: Aminosalicylic Acids; Antitubercular Agents; Chronic Disease; Cycloserine; Drug Resistance, Microbia

1969
[Triple reserved scheme in the treatment of resistent forms of pulmonary tuberculosis (preliminary results)].
    Revista brasileira de medicina, 1969, Volume: 26, Issue:9

    Topics: Adolescent; Adult; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethionamide; Fema

1969
[Comparative evaluation of several functional tests of the liver in patients with pulmonary tuberculosis with side-reactions to tuberculostatic preparations].
    Terapevticheskii arkhiv, 1969, Volume: 41, Issue:11

    Topics: Adult; Antitubercular Agents; Cycloserine; Ethionamide; Female; Humans; Isoniazid; Kanamycin; Liver;

1969
Four regimens of streptomycin plus pyrazinamide in retreatment: East African-British Medical Research Council investigation.
    Bulletin of the International Union against Tuberculosis, 1970, Volume: 43

    Topics: Drug Resistance, Microbial; Humans; Pyrazinamide; Streptomycin; Tuberculosis, Pulmonary

1970
Ethambutol in the retreatment of chronic pulmonary tuberculosis.
    British journal of diseases of the chest, 1970, Volume: 64, Issue:2

    Topics: Aminosalicylic Acids; Chronic Disease; Cycloserine; Depression, Chemical; Drug Synergism; Ethambutol

1970
Evaluation of the hepatotoxic effect of antituberculous drugs in tuberculosis patients abusing alcohol.
    Polish medical journal, 1970, Volume: 9, Issue:3

    Topics: Acute Disease; Adult; Alcoholism; Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Ind

1970
[Comparative study of specific blood activity in patients with fibrous-cavernous pulmonary tuberculosis during administration of different combinations of antibacterial preparations].
    Antibiotiki, 1970, Volume: 15, Issue:10

    Topics: Blood Bactericidal Activity; Cycloserine; Ethionamide; Humans; Isoniazid; Pyrazinamide; Time Factors

1970
Late results in re-treatment of patients with pulmonary tuberculosis.
    Tubercle, 1970, Volume: 51, Issue:2

    Topics: Cycloserine; Drug Resistance, Microbial; Ethionamide; Follow-Up Studies; Humans; Pyrazinamide; Sputu

1970
Report on the therapeutic results obtained with rifampicin.
    Antibiotica et chemotherapia. Fortschritte. Advances. Progres, 1970, Volume: 16

    Topics: Aminosalicylic Acids; Chronic Disease; Drug Combinations; Ethambutol; Humans; Pyrazinamide; Rifampin

1970
[Effect of pyrazinamide on the blood coagulation system and fibrinolysis].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1970, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Aged; Blood Coagulation; Female; Fibrinolysis; Humans; Liver; Male; Middle Aged;

1970
Clinical experience with Myambutol in the treatment of polyresistant chronic tuberculosis.
    Antibiotica et chemotherapia. Fortschritte. Advances. Progres, 1970, Volume: 16

    Topics: Adult; Cycloserine; Drug Combinations; Ethambutol; Ethionamide; Female; Humans; Isoniazid; Kanamycin

1970
Report on experiences with ethambutol.
    Antibiotica et chemotherapia. Fortschritte. Advances. Progres, 1970, Volume: 16

    Topics: Chronic Disease; Cycloserine; Drug Combinations; Ethambutol; Ethionamide; Humans; Phenylthiourea; Py

1970
International conference.
    Tubercle, 1967, Volume: 48, Issue:4

    Topics: Antitubercular Agents; Child; Cycloserine; Ethionamide; Humans; International Cooperation; Mass Ches

1967
[Toxicity of the primary tuberculostatics].
    Medicinski glasnik, 1967, Volume: 21, Issue:11

    Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Humans; Isoniazid; Pyrazinamide; Streptomy

1967
[Autonomous treatment of pulmonary tuberculosis with delayed-action drugs].
    Revista brasileira de medicina, 1967, Volume: 24, Issue:8

    Topics: Adult; Aged; Antitubercular Agents; Cycloserine; Delayed-Action Preparations; Ethionamide; Female; H

1967
[Immediate results of treatment of tuberculosis patients with drugs of the second series].
    Sovetskaia meditsina, 1967, Volume: 30, Issue:6

    Topics: Adult; Aged; Antitubercular Agents; Cycloserine; Ethionamide; Female; Humans; Male; Middle Aged; Pyr

1967
[Treatment of patients with pulmonary tuberculosis with antibacterial preparations of the second series].
    Vrachebnoe delo, 1967, Volume: 4

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; E

1967
[Tuberculostatic preparations of the 2d series in the clinical treatment of pulmonary tuberculosis].
    Problemy tuberkuleza, 1967, Volume: 45, Issue:5

    Topics: Antitubercular Agents; Chlortetracycline; Cycloserine; Ethionamide; Humans; Kanamycin; Pyrazinamide;

1967
[Cheotherapy of chronic pulmonary tuberculosis with resistant mycobacteria].
    Il Policlinico. Sezione pratica, 1967, Oct-23, Volume: 74, Issue:43

    Topics: Aminosalicylic Acids; Antitubercular Agents; Chronic Disease; Cycloserine; Drug Resistance, Microbia

1967
The use of second line drugs in patients with drug resistance to standard tuberculostatics.
    Diseases of the chest, 1968, Volume: 53, Issue:4

    Topics: Ambulatory Care; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Hypersensitivity; Dr

1968
Multiple drugs in retreatment of chronic pulmonary tuberculosis. Results with capreomycin and ethambutol.
    Diseases of the chest, 1968, Volume: 53, Issue:5

    Topics: Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Chronic Disease; Drug Resistance, Microbi

1968
[Combination of ethambutol with ethionamide, cycloserine and-or pyrazynamide in retreatment of pulmonary tuberculosis].
    Kekkaku : [Tuberculosis], 1968, Volume: 43, Issue:2

    Topics: Cycloserine; Ethambutol; Ethionamide; Humans; Pyrazinamide; Tuberculosis, Pulmonary

1968
[Comparison among single, double and triple drug regimens in retreatment. (the seventh series of the trial, B)].
    Kekkaku : [Tuberculosis], 1968, Volume: 43, Issue:6

    Topics: Cycloserine; Drug Resistance, Microbial; Ethionamide; Humans; Kanamycin; Pyrazinamide; Tuberculosis,

1968
[Functional state of the liver in patients with pulmonary tuberculosis during treatment with chemopreparations of the 2d series].
    Problemy tuberkuleza, 1968, Volume: 46, Issue:8

    Topics: Adolescent; Adult; Aged; Antitubercular Agents; Ethionamide; Female; Humans; Liver; Liver Function T

1968
[Results of treatment of pulmonary tuberculosis in adults with second line drugs].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1968, Volume: 36, Issue:10

    Topics: Adult; Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis, Pulmonary

1968
Results of the second chemotherapy trial of the IUAT. Bacteriological part.
    Bulletin of the International Union against Tuberculosis, 1968, Volume: 41

    Topics: Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethambutol; Humans; Pyrazinamide; Tu

1968
[Certain aspects of new combinations of drugs for the treatment of drug-resistant tuberculosis].
    Bulletin of the International Union against Tuberculosis, 1968, Volume: 41

    Topics: Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Ethionamide; Humans; Isonia

1968
[Treatment of chronic polyresistant pulmonary tuberculosis using ethionamide, pyrazinamide and cycloserine].
    Praxis der Pneumologie, 1968, Volume: 22, Issue:11

    Topics: Adult; Chronic Disease; Cycloserine; Drug Resistance, Microbial; Drug Synergism; Ethionamide; Humans

1968
A note on the relapse rate over a four-year period in patients with quiescent pulmonary tuberculosis following treatment with reserve regimens.
    Tubercle, 1968, Volume: 49, Issue:4

    Topics: Cycloserine; Ethionamide; Follow-Up Studies; Humans; Pyrazinamide; Streptomycin; Tuberculosis, Pulmo

1968
[Late results of treatment of chronic, cavernous pulmonary tuberculosis with reserve drugs].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1968, Volume: 37, Issue:1

    Topics: Chronic Disease; Cycloserine; Ethionamide; Humans; Pyrazinamide; Retrospective Studies; Tuberculosis

1968
[Administration of reserve antitubercular drugs in a single daily dose].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1968, Volume: 37, Issue:1

    Topics: Cycloserine; Ethionamide; Humans; Pyrazinamide; Tuberculosis, Pulmonary

1968
[Liver damage in tuberculosis].
    Zeitschrift fur Tuberkulose und Erkrankungen der Thoraxorgane, 1968, Volume: 128, Issue:1

    Topics: Bile Acids and Salts; Bilirubin; Biopsy; Chemical and Drug Induced Liver Injury; Ethionamide; Fatty

1968
Absorption, metabolism and excretion of pyrazinamide in man.
    Tubercle, 1969, Volume: 50, Issue:2

    Topics: Countercurrent Distribution; Humans; Intestinal Absorption; Pyrazinamide; Statistics as Topic; Time

1969
Observations on human infection with Mycobacterium bovis.
    Tubercle, 1969, Volume: 50, Issue:1

    Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Animals; Cattle; Drug Resistance, Microbial; Humans;

1969
[Metabolism of morphazinamide in patients with pulmonary tuberculosis].
    Minerva medica, 1965, Sep-01, Volume: 56, Issue:70

    Topics: Antitubercular Agents; Humans; Pyrazinamide; Pyrazines; Tuberculosis, Pulmonary

1965
[Comparison of the effect of morphazinamide and pyrazinamide in the treatment of chronic tuberculosis].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1965, Volume: 33, Issue:9

    Topics: Antitubercular Agents; Humans; Pyrazinamide; Pyrazines; Tuberculosis, Pulmonary

1965
[On the metabolism of morphazinamide in the treatment of chronic pulmonary tuberculosis].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1965, Volume: 33, Issue:9

    Topics: Blood Proteins; Humans; Pyrazinamide; Pyrazines; Tuberculosis, Pulmonary

1965
[On the problem of chronic liver damage following drug therapy of tuberculosis].
    Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten, 1965, Volume: 25, Issue:4

    Topics: Adult; Aminosalicylic Acids; Antitubercular Agents; Biopsy; Chemical and Drug Induced Liver Injury;

1965
[On qualitative demonstration of tuberculostatics in the control of taking of drugs].
    Zeitschrift fur Tuberkulose und Erkrankungen der Thoraxorgane, 1965, Volume: 124, Issue:3

    Topics: Aminosalicylic Acids; Cycloserine; Ethionamide; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuber

1965
Late results of treatment of chronic drug-resistant pulmonary tuberculosis.
    British medical journal, 1966, Mar-26, Volume: 1, Issue:5490

    Topics: Cycloserine; Drug Resistance, Microbial; Drug Tolerance; Ethionamide; Humans; Prognosis; Pyrazinamid

1966
Reversible sideroblastic anemia caused by pyrazinoic acid (Pyrazinamide).
    Annals of internal medicine, 1966, Volume: 64, Issue:6

    Topics: Adult; Aminosalicylic Acids; Anemia; Anemia, Sideroblastic; Erythropoiesis; Ethionamide; Female; Fol

1966
[Triple drug regimen with reserve drugs: ETA, PZA and CS in the treatment of chronic pulmonary tuberculosis].
    Gruzlica i choroby pluc; tuberculosis et pneumonologia, 1966, Volume: 34, Issue:3

    Topics: Adult; Cycloserine; Ethionamide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pyrazinamide;

1966